The Diagnosis of Lymphoproliferative Diseases
The Diagnosis of Lymphoproliferative Diseases Kevin C. Gatter Head of D...
70 downloads
1271 Views
104MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
The Diagnosis of Lymphoproliferative Diseases
The Diagnosis of Lymphoproliferative Diseases Kevin C. Gatter Head of Department & Professor of Pathology Nuffield Department of Clinical Laboratory Science Oxford University, Oxford, UK
Georges Delsol Professor of Pathology Laboratory of Pathology, Hôpital Purpan Centre Hôpitalier Universitaire University of Toulouse Toulouse, France
Roger A. Warnke Professor of Pathology Stanford University School of Medicine Stanford, CA, USA
Francesco Pezzella Professor of Pathology Nuffield Department of Clinical Laboratory Science Oxford University, Oxford, UK
S E C O N D E DI T I ON
A John Wiley & Sons, Ltd., Publication
This edition first published 2012, © 2012 by Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing program has been merged with Wiley’s global Scientific, Technical and Medical business to form Wiley-Blackwell. Registered office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030–5774, USA For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought. The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom. Library of Congress Cataloging-in-Publication Data The diagnosis of lymphoproliferative diseases / Kevin C. Gatter ... [et al.]. – 2nd ed. p. ; cm. Rev. ed. of: The diagnosis of lymphoproliferative diseases / Kevin Gatter, Georges Delsol. 2002. Includes bibliographical references and index. ISBN-13: 978-1-4051-7014-7 (hardcover : alk. paper) ISBN-10: 1-4051-7014-X (hardcover : alk. paper) ISBN-13: 978-1-119-97174-0 (ePDF) ISBN-13: 978-1-119-97177-1 (Wiley Online Library) [etc.] 1. Lymphoproliferative disorders–Diagnosis. I. Gatter, Kevin. II. Gatter, Kevin. Diagnosis of lymphoproliferative diseases. [DNLM: 1. Lymphoproliferative Disorders–diagnosis–Atlases. WH 17] RC646.2.D54 2011 616.99'373–dc23 2011015320 ISBN: 978-1-4051-7014-7 A catalogue record for this book is available from the British Library. This book is published in the following electronic formats: ePDF 9781119971740; Wiley Online Library 9781119971771; ePub 9781119971757; Mobi 9781119971764 Set in 9/12pt Meridien by Toppan Best-set Premedia Limited 1
2012
Contents
Preface, vi
18 Adult T-cell Lymphoma/Leukaemia, 169
Abbreviations, vii
19 Extranodal NK/T-cell Lymphomas: Nasal Type, 172 20 Enteropathy-associated T-cell Lymphoma, 178
1 General Introduction, 1
21 Hepatosplenic T-cell Lymphoma, 182
2 Reactive and Infective conditions, 20
22 Subcutaneous Panniculitis-like T-cell Lymphoma and Primary Cutaneous γ/δ T-cell Lymphoma, 185
3 An Introduction to Lymphoma Diagnosis, 59 4 B-cell Lymphoblastic Leukaemia/Lymphoma, 63 5 T-cell Lymphoblastic Lymphoma/Leukaemia, 69 6 B-cell Chronic Lymphocytic Leukaemia, 75 7 Splenic B-cell Marginal Zone Lymphoma, 81 8 Hairy Cell Leukaemia, 86 9 Lymphoplasmacytic Lymphoma, 92 10 Plasmacytoma/Myeloma, 96 11 Marginal Zone B-cell Lymphoma (Extranodal Malt and Nodal Types) and Extranodal Malt Lymphoma, 100 12 Follicular Lymphoma, 108 13 Mantle Cell Lymphoma, 121
23 Mycosis Fungoides/Sézary Syndrome, 189 24 Peripheral T-cell Lymphoma, 194 25 Angioimmunoblastic T-cell Lymphoma, 202 26 Anaplastic Large-cell Lymphoma, 208 27 Hodgkin Lymphoma, 220 28 Immunodeficiency-associated Lymphoproliferative Disorders, 242 29 Histiocytic Sarcoma, 249 30 Follicular Dendritic Cell Proliferations and Related Entities, 255 31 Langerhans Cell Histiocytosis, 261 32 Myeloid Leukaemias (Myeloid Sarcoma), 265
14 Diffuse Large B-cell Lymphoma, 134 15 Burkitt Lymphoma, 155
Index, 268
16 T-cell Prolymphocytic Leukaemia, 161 17 T-cell Large Granular Lymphocytic Leukaemia and Aggressive NK-cell Leukaemia, 164
v
Preface
As was the case for the first edition this the second comes as a companion to the recently revised WHO Classification of Tumours of Haematopoietic and Lymphoid (2008). Once again our aim is to guide pathologists through the practical stages of making an accurate diagnosis. We have updated the text and figures to incorporate all the new entities and to clarify and extend other sections especially the large chapter on reactive conditions. The authorship team has doubled to bring in wider experience and fresh thought. We hope pathologists will find this book helpful and use it side by side with the new WHO classification.
Acknowledgements Again we pay tribute to our departments and colleagues without whom it would have been impossible to gather the cases and find the time to put them together into a cohesive text. Once more our informatics production manager Robin Roberts-Gant has been a sterling assistant in collating text and figures ready for publication. We would also like to thank Wiley- Blackwell for taking on this second edition at a time when medical publishers are cutting back severely and for their high quality help and advice.
vi
Abbreviations
AILT ALCL ALL ALK AML ATLL CHL CLL DLBCL EATL EB/EBV EBER EMA FDC FISH FL HCL HL LP LCA LGL LPL MALT MCL MZL NHL NK NLPHL PCR PLL PTCL PTLD WHO
angioimmunoblastic T-cell lymphoma anaplastic large cell lymphoma acute lymphoblastic lymphoma/leukaemia anaplastic lymphoma kinase acute myeloid leukaemia adult T-cell lymphoma/leukaemia classical Hodgkin lymphoma chronic lymphocytic leukaemia diffuse large B-cell lymphoma enteropathy-associated T-cell lymphoma Epstein–Barr/Epstein–Barr virus Epstein–Barr virus RNA epithelial membrane antigen follicular dendritic cell fluorescence in situ hybridisation follicular lymphoma hairy cell leukaemia Hodgkin lymphoma lymphocyte predominant leucocyte common antigen large granular lymphocytic leukaemia lymphoplasmacytic lymphoma mucosa associated lymphoid tissue mantle cell lymphoma marginal zone lymphoma non-Hodgkin lymphoma natural killer nodular lymphocyte predominant Hodgkin lymphoma polymerase chain reaction prolymphocytic lymphoma peripheral T-cell lymphomas post-transplant lymphoproliferative disorder World Health Organization
vii
1
General Introduction
The biopsy The decision on whether or not to biopsy a lymph node or other tissue for a suspected haematological disease is taken by the clinician. In a good haematological oncology unit the pathologist will be involved in this decision, if only to provide technical advice. The correct biopsy optimally handled is very much in everyone’s best interests and is often crucial in reaching an accurate diagnosis. The old military adage of the six Ps (proper preparation prevents p*** poor performance) was never more apt. Clinical details of who, when and what are better placed in clinical books but a few practical comments may be appreciated.
Sutton’s law If a patient has significant lymphadenopathy associated with other signs and symptoms, do not mess about with skin, bone marrow smears or cytological preparations in the hope that it will save a biopsy. If patients are sick they need a diagnosis and the money is in the lymph node.
Can we manage with a needle biopsy – skinny or cutting? In the first edition of this work we said no. These techniques are marvellous in their place but no substitute for a lymph node biopsy when it can reasonably be obtained. It has become increasingly obvious as costs and clinical workloads soar worldwide that we are going to have to cope with needle biopsies more and more whether we like it or not. This means that we will need to rely increasingly on ancillary techniques to make diagnoses. We should, however, never forget that these are suboptimal specimens and be aware that we may have missed the true lesion.
Must we take out the whole node? Can’t you make do with a slice? Yes and no (well perhaps). Lymphoid diseases are often focal and surrounded by reactive changes and so easy to miss on smaller samples. Slices get crushed with resultant misleading artefacts. Go for the biggest node accessible. Cervical nodes are best and inguinal worst (due to the inevitable reactive changes). Take out the whole node and send to an alerted pathologist or experienced laboratory. It is much better to send a fresh node so that it can be dealt with promptly and optimally. This also allows material to be used for techniques that can be suboptimal on fixed material such as some molecular investigations. It also enables material to be taken for biobanking, which is becoming increasingly important with the current renewed interest in translational medical research. If the biopsy cannot be sent or processed that day, get the surgeon or lab technician to slice it like a boiled egg into fixative (plenty of). There is no better way that we know of ruining a lymph node than to ram it whole into a small pot. The capsule is immensely impervious to fixative, leaving the innards to rot rapidly. Take representative blocks, one per centimetre should easily suffice, send a piece to microbiology if infection is queried and freeze a piece in liquid nitrogen (it can be stored at −70°C later). The rest of the slices can be left in fixative while a diagnosis is being sought. Most hospitals keep this material for a month or so, allowing plenty of time to go back for more blocks if necessary.
Which fixative? Theses have been written on this and largely ignored. Ninety-nine per cent of the world uses formalin and shows
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
1
CHAPTER 1
General Introduction
little evidence of changing. And if the steps above are taken, it is a good all-round reagent that is hard to better. All the other fixatives suggested to date (e.g. Bouin’s, B5, Duboscq– Brasil) are good in experienced hands but may compromise certain antibody stains and most molecular studies.
Immunocytochemistry If you are doing serious haematopathological diagnoses you will be using a lot of antibodies. So you might as well invest in an immunostaining machine (or two). Once done you will wonder how you coped without it. It is just like having a dishwasher at home. All the machines currently on the market work well. They differ in the degree to whether they are open or closed systems, as well as whether antigen retrieval is available on the machines, or whether it must be performed manually (see below). Closed systems are fine when the finances for immunostaining are no problem because all the reagents can be bought pre-packed from the manufacturer and used straight off the shelf. If every penny (cent or euro) counts (as in the cash-starved NHS in the UK), then completely open systems are best where individual reagents, including the detection reagents, can be bought at good prices or begged and borrowed and used according to local recipes. To our knowledge all machines are capable of following most techniques but, as with the fixatives above, most of the world has settled on one or other variation of immunoperoxidase staining. This gives excellent reliable results, and full details and technical back-up are available from a range of antibody companies. Recently introduced antigen retrieval techniques have been a revolution, so every laboratory needs a microwave and/or pressure cooker for manual methods as well as for certain staining platforms. Again all the reagents and advice necessary are available from the relevant commercial companies.
Which antibodies? In the early days of immunocytochemistry considerations of cost and labour led most pathologists to select reagents singly, according to the details of each case. Now that immunostaining is an accepted diagnostic technique and automated machines are available, there is little reason any longer to remain parsimonious. Link this with the current epidemic of medicolegal claims, and comprehensive panels of antibodies start to seem common sense. Ask yourself if you could justify in court missing a mantle cell lymphoma or a reactive node just because you thought a cyclin D1 or a bcl-2 immunostain was not warranted. Specific details of individual antibodies and how they are used and interpreted are discussed under the individual entities. Here, for reference purposes, are the antibodies that we use routinely. All refer to use on paraffin-embedded fixed
2
material. The clone numbers given are those known to us as working antibodies. New and better reagents appear regularly and may be available from more than one producer, so it is worth looking around. Pre-treatments for optimal staining are constantly being updated. They differ from place to place, and change as new techniques are described and new reagents produced. It is worth each laboratory testing out a number of these for themselves for each new antibody introduced. Table 1.1 gives a differential diagnosis between lymphoma and non-haematopoietic tumours.
Monoclonal antibodies of diagnostic value in paraffin sections in the diagnosis of haematopoietic neoplasms The antibodies used for different antigens can be organised into panels for specific purposes or divided into those for first and subsequent runs of immunostaining according to personal preference. The importance of the panel approach is to ensure that an important diagnosis is not overlooked. Table 1.2, for example, gives some panels that we use in routinely diagnosing and classifying lymphomas.
Low-grade B-cell lymphoma CD20, CD79a, CD3, CD10, bcl-2 protein, κ and λ, cyclin D1, CD5, CD23, proliferation marker (Ki67 or equivalent). When a marginal zone lymphoma (MZL) of MALT (mucosaassociated lymphoid tissue) type, add a pancytokeratin.
High-grade B-cell lymphoma CD20, CD79a, CD3, CD10, cyclin D1, CD5, CD30, proliferation marker (Ki67 or equivalent) and bcl-2 protein.
T-cell lymphomas CD3, CD4, CD8, CD30, proliferation marker (Ki67 or equivalent) as well as CD20 and antibodies against follicular dendritic cells (FDCs: CD21, CD23, CD35 or CNA.42). Antibodies reacting against CD2, CD5 and CD7 antigens can be useful for demonstrating loss of one or more T-cell-associated antigens.
Hodgkin lymphoma CD15, CD30, CD20, CD3, MUM1, EMA, LMP-1 and proliferation marker (Ki67 or equivalent).
Important additional markers for haematopathology ALK-1, EMA, CD21 and other FDC markers, CDw76 (DBA.44) and annexin A1, plasma cell marker (VS38 or CD138-syndecan), CD68 and CD163, and CD1a and langerin. A range of markers for non-haematopoietic and myeloid proliferations also needs to be available.
CHAPTER 1
General Introduction
Table 1.1 Differential diagnosis between lymphoma and non-haematopoietic tumours (i.e. undifferentiated carcinoma and malignant melanoma) Antibodies/Clones
Major reactivities
Unexpected reactivities: remarks
CD45
Leukocyte common antigen (LCA) expressed by 90% of B- or T-cell lymphomas Some large-cell lymphomas, in particular anaplastic large-cell lymphoma and lymphoblastic lymphoma, are weakly positive or even negative for LCA Erythroblasts and megakaryocytes are negative Reed–Sternberg cells are usually negative
Exceedingly rare
LSP1 Clone: LSP1
Most lymphomas and myeloproliferative disorders
No cross-reactivity has been reported
EMA Clone E29
Epithelial membrane antigen expressed by most carcinomas Various benign or malignant tumours of diverse origin >80% of anaplastic large cell lymphomas
Expressed by : L&H cells (>80%) in lymphocyte predominance Hodgkin disease; 10% of large B- or T-cell lymphomas; erythroblasts
Cytokeratin clones: 1. KL1 2. MNF116 3. CAM 5.2 4. AE1/3
Most carcinomas are positive Numerous non-epithelial neoplasms may be positive: sarcoma, melanomas, etc.
Occasional lymphoma and plasma cell tumours may show a cytoplasmic dot-like staining
HMB45 Clone HMB45
Melanocytic proliferation; malignant melanoma
Reacts with angiomyolipoma of the kidney and clear cell sarcoma
PNL2 Clone PNL2
Melanocytic proliferation; malignant melanoma
Reacts with angiomyolipoma of the kidney and clear cell sarcoma; granulocytes
S100 Polyclonal
Reacts with S100 A and B Most malignant melanomas are positive
Reacts with a wide variety of normal cells and tumours
Two clones 2B11 and PD7/26
Pitfalls in immunohistochemistry Although immunohistochemistry allows the diagnosis of most lymphoid tumours, there are some that remain difficult to identify. Several factors are responsible for diagnostic difficulties and pitfalls in immunohistochemistry, and quality control has often been raised as a critical issue. False-negative staining is more common than false-positive staining (with the notable exception of false-positive staining due to passive absorption of extracellular Ig) and fixation is the most common culprit. The following discussion is restricted to the labelling of paraffin-embedded biopsy specimens
False-negative staining False-negative staining may be due to denaturation of either antigen or antibody. As far as the denaturation of the antigen is concerned, one must bear in mind that the gold standard in immunohistochemistry is the labelling on frozen sections which preserves all antigens. However, antigens surviving fixative or that can be retrieved using a number of procedures such as microwave oven heating [1] are now well known. Nevertheless, in some tissue specimens, even after
Occasional seminomas or primitive sarcomas positive for CD45 have been reported Exceptional carcinomas may show strong CD45 cytoplasmic staining though this is generally a misinterpretation of macrophages within the tumour
using the latter procedure, some antigens cannot be retrieved, mainly because of the length of the fixation or the nature of the fixative or for other unknown reasons. We have noted that, in a given tissue specimen, some antigens are better preserved than others. Fortunately, in most cases, there is an internal control (i.e. normal B lymphocytes for B-cell antigens, plasma cells for Ig or epithelial membrane antigen [EMA] staining) which, if absent, may indicate that we are dealing with a false-negative staining. Of course, the lack of internal controls may also be related to technical problems involving one or several steps of the staining protocol. Sections stained in the same batch are usually good external controls to rule out such a pitfall. A number of laboratories use positive and negative tissue specimens such as tonsil for B, T and cytokeratin stainings that are subjected to the same immunohistochemical procedure as the samples stained for diagnostic purpose. Sometimes these are mounted on the same slides as the diagnostic sections. This is convenient provided that one is aware of this and does not score the control staining instead of the diagnostic specimen. It is worth noting that a positive staining
3
CHAPTER 1
General Introduction
Table 1.2 Monoclonal antibodies of diagnostic value T-cell markers
4
Antibodies/Clones
Major reactivities
Unexpected reactivities: remarks
CD1a Clone: O10
Reacts with cortical thymocytes, Langerhans cells and interdigitating dendritic cells Of diagnostic value in Langerhans cell histiocytosis Some precursor T-cell lymphomas are also positive
No reported cross-reactivity
CD2 Clone: AB75
Reacts with most T cells Most T-cell lymphomas are positive
<5% of examples of classic Hodgkin lymphoma (CHL) show reactivity in Reed–Sternberg (RS) cells
CD3 (polyclonal) CD3: monoclonal
Intracytoplasmic domain of CD3 ε-chain Reacts with most T-cell lymphomas (>75%) Reacts with cytoplasmic CD3 in about 50% of natural killer (NK) cell lymphomas Frequently negative or weakly positive in anaplastic large cell lymphoma
Exceptional cases of malignant lymphoma express CD3 and CD20 The RS cells in <5% of examples of CHL show a dot-like staining in the Golgi area Some (<10%) cases of acute myeloid leukaemia (AML) are CD3+ Megakaryocytes may show a weak non-specific cytoplasmic staining
CD4 Clone: 1F6 MT310
Reacts with transmembrane glycoprotein found on helper/inducer T cells Good marker for CD4+ T-cell lymphomas
Macrophages are positive for CD4 True histiocytic tumours and Langerhans cell histiocytosis are CD4 + <5% of examples of CHL show reactivity in RS cells
CD5 Clone: 5C7
Reacts with thymocytes and T cells in lymph nodes A small subpopulation of B cells in lymph nodes is CD5+ Most T-cell lymphomas and leukaemias are positive
Antibody of diagnostic value (together with other antibodies for the diagnosis of chronic lymphocytic leukaemia (CLL) (CD5+ in 95% of cases] and mantle cell lymphoma (CD5+ in 90% of cases] Some thymic carcinomas are CD5+
CD7 Clone: CBC37
Expressed by thymocytes and T cells in lymph nodes and spleen Most nodal T-cell lymphomas positive This antigen is frequently absent in cutaneous T cell and some other peripheral T-cell lymphomas
Some myeloid leukaemias are positive
CD8 Clone: C8/144B
Expressed by cytotoxic/suppressor T cells
Useful antibody for labelling lymphomas and leukaemias derived from cytotoxic/suppressor T cells
CD43 Clones: MT1, DF1, Leu-22
Detects sialophorin expressed on the cell membrane of myeloid cells, T cells and some histiocytes and plasma cells Most T-cell lymphomas are positive Most anaplastic large cell lymphomas (CD3−) are positive for CD43 Langerhans cell histiocytosis and true histiocytic neoplasms are positive RS cells in Hodgkin lymphoma are negative
Useful antibody for the diagnosis of mantle cell lymphoma (>50% positive) and marginal zone lymphoma (>25% positive) as well as CLL/small lymphocytic lymphoma (SLL) (80% positive) Precursor lymphoblastic B-cell lymphomas are often positive (60% of cases) Epstein–Barr virus (EBV)-positive large cell lymphomas are often positive
CD45RO Clone: UCHL1
Subpopulation of T cells (memory) and macrophages Most peripheral T-cell lymphomas In autoimmune lymphoproliferative syndrome (ALPS) the CD45RO+ memory T cells are decreased and the CD45RA+ naïve T cells are increased
Some B-cell lymphoma and plasma cells neoplasms are positive Reacts with myelomonocytic cells and granulocytes
CHAPTER 1
General Introduction
Table 1.2 (continued) T-cell markers Antibodies/Clones
Major reactivities
Unexpected reactivities: remarks
βF1 TCR β chain Clone: 8A3
Reacts with a non-polymorphic determinant of the β chain of the T-cell antigen receptor (TCR) Most T-cell lymphomas expressing αβ receptors are positive for βF1. However, on paraffin sections the staining is strongly dependent on the fixative and length of fixation
RS cells in Hodgkin lymphoma may show a focal paranuclear staining in 10% of cases
TCR γ chain Clone: γ3.20
Recognises γδ T cells in normal and neoplastic conditions
Useful in identifying rare cases of γδ T-cell lymphoma No reported cross-reactions
B-cell markers Antibodies/Clones
Major reactivities
Unexpected reactivities: remarks
CD20 Clone L26
Phosphoprotein expressed by more than 90% of B-cell lymphomas: Precursor B-lymphoblastic and diffuse large B cell with plasmacytic differentiation may be negative L&H (lymphocytic and histiocytic) cells of LP Hodgkin lymphoma RS cells in classic Hodgkin lymphoma are positive in 30% of cases but staining varies from cell to cell
Occasional T-cell lymphomas are positive Non-specific granular cytoplasmic staining can be found in some macrophages Non-specific nucleolar staining may be observed in a variety of haematopoietic and non-haematopoietic tumours (e.g. in RS cells or in carcinomas) Epithelial cells in thymoma may be CD20+ Rare cases (<5%) of AML are CD20+
CD23 Clone: MHM6, 1B12
Reacts with follicular dendritic cells and a variable proportion of mantle zone lymphocytes Expressed by 90% of B-CLL cases Other neoplasms are usually negative
About 70% of mediastinal large B-cell lymphomas are positive Subset of B-cell lymphomas positive (25% of follicular, 10% of marginal zone, <10% of non-mediastinal large B-cell, 5% of mantle cell)
CD45RA Clone: DBB42
Reacts with B cells in lymph nodes and spleen A subset of T cells (large granular lymphocytes or LGLs) and naïve T cells as well as histiocytes/ macrophages express this antigen Most B-cell lymphomas are positive Naïve T-cells increased in autoimmune lymphoproliferative syndrome
Large granular lymphocytic leukaemias and approximately 20% of other T-cell lymphomas are positive
CD76-like Clone: DBA-44
Reacts with mantle zone lymphocytes and scattered immunoblasts in lymph node pulp Of diagnostic value in hairy cell leukaemia, in particular for detecting minimal or residual bone marrow involvement in patients after treatment diffuse large B-cell lymphomas are frequently positive.
Endothelial cells are weakly positive Erythroblasts may be positive
CD79a Clone JCB 117
Detects mb1 protein associated with surface immunoglobulin (SIg) In contrast to CD20 the staining is mainly cytoplasmic Reacts with virtually all B-cell lymphoma including those with plasma cell differentiation
50% of lymphoblastic T-cell lymphomas are positive Rare cases of other T-cell lymphomas including extranodal NK T-cell lymphoma are positive for CD3 and CD79a Some smooth muscle cells show a cytoplasmic staining
Anti-Ig heavy and light chains
On paraffin sections only cytoplasmic Ig routinely detectable
False-positive staining may be observed on a variety of cells (i.e. RS cells) and tumours because of passive absorption of extracellular Ig (continued)
5
CHAPTER 1
General Introduction
Table 1.2 (continued) B-cell markers Antibodies/Clones
Major reactivities
Unexpected reactivities: remarks
PAX5 Clone: NCL-L-PAX5
Pax5 encodes for a B-cell-specific transcription factor that is expressed in pro-B cells and subsequently in all stages of B-cell development until the plasma cell stage in which it is downregulated
Also positive on most RS cells which can be useful in the distinction of CHL from anaplastic large-cell lymphoma (ALCL)
IgD Clone: IgD26
Reacts on paraffin sections with SIgD of small B lymphocytes of mantle zone CLL and mantle cell lymphomas are usually positive
None reported
CD138/Syndecan 1
Reacts with reactive and neoplastic plasma cells Large B-cell lymphomas with plasma cell differentiation are positive
Reacts with a variety of non-haematopoietic neoplasms, in particular squamous cell carcinoma
OCT2 and BOB1 Clones: PT1, sc955
These are two B-cell transcription factors that are generally used together to help distinguish CHL (usually negative) from B-cell lymphomas and nodular lymphocyte-predominant Hodgkin lymphoma (positive)
VS38 Clone: VS38
Recognises the p63 antigen on ribosomes Reacts strongly with most reactive and neoplastic plasma cells Large B-cell lymphomas with plasma cell differentiation are positive
Reacts with a variety of non-haematopoietic neoplasms, especially endocrine tumours
BCL6
In normal lymphoid tissue BCL-6 is preferentially expressed by germinal centre cells but not by immature B-cell precursors or plasma cells Most diffuse large B-cell lymphomas are BCL-6+ L&H cells in lymphocyte predominance Hodgkin lymphoma are usually positive whereas in only 50% of classic Hodgkin lymphoma RS cells are BCL-6+
BCL-6 is found in CD4+ cells within germinal centres and in scattered T cells in the perifollicular areas Cortical thymocytes and T-cell lymphoblastic lymphomas are often BCL-6+
Annexin A1 Clone: 29
37-kDa calcium and phospholipids-binding protein is a strong inhibitor of glucocorticoid-induced eicosanoid synthesis and phospholipase A2 Positive on virtually all cases of hairy cell leukaemia but not on any other B-cell lymphomas
Neutrophils, monocytes, macrophages, subset of CD4+ T cells Many carcinomas are positive
Histiocytic markers
6
Antibodies
Major reactivities
Unexpected reactivities: remarks
CD68 Clone: KP1
Stains macrophages in a wide variety of human tissues and plasmacytoid dendritic cells in lymph nodes Reacts with all true histiocytic tumours Reacts with myeloid precursors and granulocytes Most AMLs show strong cytoplasmic staining
Some B-cell lymphoma leukaemias such as CLL and hairy cell leukaemia may show a weak granular cytoplasmic staining Some ALCLs are positive Reacts with melanomas
CHAPTER 1
General Introduction
Table 1.2 (continued) Histiocytic markers Antibodies
Major reactivities
Unexpected reactivities: remarks
CD68 Clone: PGM1
Stains macrophages in a wide variety of human tissues and plasmacytoid dendritic cells in lymph nodes Reacts with all true histiocytic tumours but only M4 and M5 AMLs are positive
in contrast to KP1 this antibody does not cross-react with myeloid cells acute myeloid leukaemias M1, M2, M3, M6 and M7 types are negative
CD163 Clone: NCL-CD163
CD163 antigen is restricted in its expression to the monocytic/macrophage lineage. It is present on all circulating monocytes and most tissue macrophages
Exceptions are macrophages found in the mantle zone and germinal centres of lymphoid follicles. It does not stain interdigitating reticulum cells or Langerhans cells
Lysozyme
Stains macrophages in a wide variety of human tissues Reacts with all true histiocytic tumours Acute and chronic myeloid leukaemias
Frequent background staining
S100 protein
Stains Langerhans cells and interdigitating reticulum cells Virtually all cases of Langerhans cell histiocytosis are positive
Many non-haematopoietic neoplasms express this antigen, especially melanoma
CD207 Langerin Clone: 12D6
Langerin (CD207) is a type II membraneassociated C-type lectin known to be expressed exclusively by Langerhans cells. Langerin recognises mannose residues via its single carbohydrate recognition domain (CRD)
Occasional focal staining in non-Langerhans cell histiocytic sarcomas
Activation and proliferation markers Antibodies
Major reactivities
Unexpected reactivities: remarks
CD30 Clone: Ber-H2 or JCM182
Glycoprotein of the tumour necrosis factor/nerve growth factor (TNF/NGF) receptor family Activated B or T cells RS cells in classic Hodgkin lymphoma show membranous and paranuclear cytoplasmic staining. Positivity restricted to the paranuclear area is seen in some cases which may be related to fixation Anaplastic large-cell lymphomas Some large T- or B-cell lymphomas
Embryonal carcinoma With some fixatives plasma cells (BerH2) or granulocytes ( JCM182) may show cytoplasmic staining Rare undifferentiated squamous carcinomas are positive Mastocytosis is positive About 70% of mediastinal large B-cell lymphomas are positive
Ki-67/MIB1
Reacts with a nuclear antigen expressed in G1, S, G2 and M phases of the cell cycles Useful antibody to assess the growth fraction rate in lymphoproliferative disorder; In some overfixed specimens the staining may be restricted to nucleoli or mitotic figures
None reported consistently
(continued)
7
CHAPTER 1
General Introduction
Table 1.2 (continued) Myeloid, erythroblast and megakaryocyte markers Antibodies
Major reactivities
Unexpected reactivities: remarks
CD15 Various clones
Detects the X hapten, a late differentiation marker of myeloid cells, also expressed by some monocytes and epithelioid cells Membranous and paranuclear cytoplasmic staining. Positivity restricted to the paranuclear area is seen in some cases which may be related to fixation Useful in the diagnosis of Hodgkin lymphoma: 80% of cases are positive Some T-cell lymphomas and occasional B-cell lymphomas are positive About 5% of anaplastic large-cell lymphoma are positive but the staining is weaker than that of RS cells
This antigen is expressed by many normal and malignant epithelial cells. Cytomegalovirus (CMV)-infected cells label for CD15
CD31 Clone: JC70
Endothelial cells, platelets and megakaryocytes Some reactive and neoplastic plasma cells and histiocytes are labelled
Vascular tumours
Myeloperoxidase
Granulocytes and their precursors Useful markers for the diagnosis of extramedullary myeloblastic proliferations AMLs are positive
Systemic and skin mast cell proliferations are positive Some macrophages, e.g. in Kikuchi disease, are also positive
Anti-von Willebrand factor Clone: F8/86
Reacts with von Willebrand factor in megakaryocytes (cytoplasmic staining) Megakaryoblastic leukaemia (M7)
Endothelial cells
CD61 GpIIIa
Megakaryocytes and platelets Megakaryoblastic leukaemia
Reacts with endothelial cells and osteoclasts
Elastase Clone: NP57
Reacts with neutral protease of granulocytes and their precursors Most AMLs are labelled
A few monocytes are weakly labelled
Follicular dendritic cells (FDCs)
8
Antibodies/Clones
Major reactivities
Unexpected reactivities: remarks
CD21 Clones: IF8, 2G9, DR53
Reacts with C3d complement receptor Stains the FDC network in normal and neoplastic lymphoid tissue
Also positive on a small number of B-cell lymphomas of all types and some cases of T-cell lymphoblastic Positive in many littoral cell angiomas
CD35 Clones: Ber-MacDRC, C3br, TO5
Reacts on paraffin sections with the C3b receptor of complement (CR1) Stains the FDC network but the reactivity is strongly dependent on the type and length of fixation
Reacts with epithelial cells of renal glomeruli Positive on epithelial cells in inflammatory conditions and many carcinomas
CD23 Clones: MHM6, 1B12
Reacts with follicular dendritic cells and a variable proportion of mantle zone lymphocytes
Expressed by B-CLL and some follicular, marginal zone and infrequent mantle cell lymphomas About 70% of mediastinal large B-cell lymphomas are positive Other neoplasms are usually negative
CHAPTER 1
General Introduction
Table 1.2 (continued) Follicular dendritic cells (FDCs) Antibodies/Clones
Major reactivities
Unexpected reactivities: remarks
CNA-42 (NC) Clone: CNA.42
Reacts with FDCs and scattered mononuclear cells in the lymph node pulp Some cortical thymocytes are positive useful for demonstrating FDC meshworks in follicular lymphoma and some T-cell lymphomas FDC sarcomas are positive as well as some inflammatory pseudotumours of FDC origin
Mast cells, endothelial cells and a subpopulation of plasma cells are labelled Anaplastic large-cell lymphomas are positive (60%) 40% of T-cell lymphomas are positive weak-to-moderate cytoplasmic staining is found in 20% of cases of Hodgkin lymphoma rare cases of large B-cell lymphoma (5%) are positive
Miscellaneous Antibodies
Major reactivities
Unexpected reactivities: remarks
BCL-2 Clones: 124, 3.1
Protein able to suppress cell death by apoptosis B and T small lymphocytes are positive but germinal centre cells in reactive lymph nodes are negative Very helpful in the diagnosis of follicular lymphoma (85% +) versus follicular hyperplasia; Most B- or T-cell lymphoma are positive RS cells in Hodgkin lymphoma are frequently positive (60% of cases)
Most AMLs and chronic myeloid leukaemia (CML) in blast crisis are positive Blasts in refractory anaemia with excess of blasts are positive Many normal and malignant epithelial cells are positive
Cyclin D1
Reacts with cyclin D1 antigen Nuclear staining very helpful in diagnosing mantle cell lymphoma
Hairy cell leukaemias and many cases of myeloma are positive Cytoplasmic staining is not considered to be specific
ALK Clone: ALK1
Highly specific for the NPM/ALK protein associated with the t(2;5) and full-length ALK protein Reacts with 85% of anaplastic large cells lymphoma of T or null phenotype Cytoplasmic, nuclear and nucleolar staining is highly indicative of the t(2;5) (90% of cases) 20% cases show a staining restricted to the cytoplasm. These cases are associated with ALK variant translocations (TPM3-ALK, TFG-ALK, ATIC-ALK, etc.)
Rare cases of large B-cell lymphoma (CD30−, EMA+, IgA+) show ALK-positive staining restricted to the cytoplasm of malignant cells Some inflammatory myofibroblastic tumours associated with TPM3-ALK, TPM4-ALK, CLTC-ALK or RanBP2-ALK protein show ALK-positive staining restricted to the cytoplasm of neoplastic cells
TIA1
Granule-associated cytotoxic protein of cytotoxic T cells, NK cells and granulocytes Granular cytoplasmic staining is seen in some peripheral T-cell lymphomas, in particular in anaplastic large-cell lymphoma
Occasional cases of classic Hodgkin lymphoma show positive RS cells As a result of granulocytes labelling in bone marrows, another marker for cytotoxic granules such as granzyme B may be preferred in this setting
MUM1 Clone: MUM1p
Labels MUM1 protein in a subset of light zone germinal centre (GC) B cells (probably centrocytes and their progeny), plasma cells, activated T cells and a wide spectrum of haematolymphoid neoplasms derived from these cells; MUM1 protein is a useful tool for identifying RS cells in classic Hodgkin lymphoma as virtually all are positive
Of non-haematolymphoid neoplasms, only a proportion of melanomas are labelled
(continued)
9
CHAPTER 1
General Introduction
Table 1.2 (continued) Miscellaneous Antibodies
Major reactivities
Unexpected reactivities: remarks
Perforin
Granule-associated cytotoxic protein of cytotoxic T cells Granular cytoplasmic staining is seen in some peripheral T-cell lymphomas in particular in anaplastic large-cell lymphoma
Useful antibody in the differential diagnosis between neoplastic cell-rich Hodgkin lymphoma (perforin negative) and anaplastic large cell lymphoma (frequently positive)
Granzyme B
Granule-associated cytotoxic protein of cytotoxic T cells Granular cytoplasmic staining is seen in some peripheral T-cell lymphomas
TdT Rabbit anti-TdT
Reacts with terminal deoxynucleotidyl transferase Most cortical thymocytes are positive (nuclear staining) Small population (<1%) of bone marrow lymphoid cells Most precursor B- and T-lymphoblastic leukaemia/ lymphoma is TdT+
Exceptionally found in a few cells in reactive lymph nodes, tonsils and spleens Cytoplasmic staining is considered to be non-specific Some cases of AML are positive
CD10
Positive on most B lymphoblastic lymphoma/ leukaemias and some T lymphoblastics Most germinal centre cells are positive as are about 80% of follicular lymphomas Some large B-cell lymphomas are positive
Stromal cells in a variety of tissues are positive, making a useful internal control Angioimmunoblastic T-cell lymphomas are often labelled for CD10 but newer markers such as BCL6, CXCL13 and PD1 more often label these follicular helper T cells
CD34 Clone: QBEN10
Glycoprotein expressed by lymphohaematopoietic stem and progenitor cells Reacts with precursor B- or T-lymphoblastic lymphoma/leukaemia AMLs are also labelled
Endothelial cells Vascular tumours Some sarcomas
CD56
reacts with neural cellular adhesion molecule (NCAM) NK neoplasms in particular T/NK cell nasal lymphoma
CD56 is expressed by 20% of AML and in myeloblasts of high-grade myelodysplastic syndromes
CD57 Clones: IOT10 anti-Leu7
Carbohydrate antigen expressed on mononuclear cells with NK activity Some T-lymphoblastic lymphomas and NK tumours are positive Occasional large B-cell lymphomas are positive Lymphocytes forming rosettes around lymphocytepredominant (LP) cells in LP Hodgkin lymphoma are often CD57+
Reacts with a variety on non-haematopoietic neoplasms such as prostatic carcinoma and neuroendocrine tumours
Anti-HLA-DR Clone: DK22
Expressed by most B-cell lymphomas Occasional T-cell lymphomas developed from activated T cells are positive Langerhans cell histiocytosis is positive Histiocytic tumours are usually positive
Various non-lymphoid tumours are positive for HLA-DR
c-kit (CD117)
Mast cells and mastocytosis are strongly positive Many cases of AML and blast cells in myelodysplasia are positive
Various lymphoid and non-lymphoid tumours (e.g. gastrointestinal stromal tumours or GISTs) are positive for c-kit
10
CHAPTER 1
General Introduction
Table 1.2 (continued) Miscellaneous Antibodies
Major reactivities
Unexpected reactivities: remarks
Vimentin Clone V9
Occasional B- or T-cell lymphomas are positive RS cells in Hodgkin lymphoma are usually positive
Expressed by a wide variety of benign and malignant cells
Fascin Clone: K-2
Reacts with actin-bundling protein expressed by dendritic cells Stains dendritic cells (interdigitating reticulum cells) in lymph nodes RS cells in classic Hodgkin’s disease are usually positive (L&H cells are negative) Langerhans cell histiocytosis is positive
FDCs are weakly to moderately positive Endothelial cells are strongly positive Occasional B- or T-cell neoplasms are positive
Infectious agents Antibodies
Major reactivities
Unexpected reactivities: remarks
p24 Clone: Kal-1
HIV type 1 capsid protein Reacts with the p24 protein in FDCs infected by HIV
Background staining may be responsible for false positive staining
CMV Clones: 2A2, E13
Reacts with early antigen (EA) detected during the CMV infection
LMP1 Clone: CS1-4
Reacts with EBV latent membrane protein in latently infected cells Immunoblasts in infectious mononucleosis are LMP1+ Many cases of classic Hodgkin lymphoma are positive Most large B-cell lymphomas in HIV-positive patients and post-transplantation B-cell lymphomas are positive Scattered non-neoplastic B-cell immunoblasts are found in some peripheral T-cell lymphomas T/NK cell lymphoma latently infected by EBV (i.e. nasal-type lymphomas) are usually negative (but positive for EBV RNA or EBER)
Reactive plasma cells may show a non-specific cytoplasmic staining In some bone marrow biopsies megakaryocytes may show a strong cytoplasmic staining Extensive non-specific labelling may be observed in B-5-fixed sections
EBNA2 Clone: PE2
EBV nuclear antigen expressed in latently infected cells EBV-positive, large B-cell lymphomas express this antigen EBV-positive RS cells are negative for EBNA2
On paraffin section the staining is usually weak
HHV8 Clone: LN53
This antibody reacts with the latent nuclear antigen (LNA-1) of human herpesvirus 8 (HHV8) Kaposi sarcoma and lymphoid cells in multicentric Castleman disease are positive
Positive in primary effusion lymphomas as well as the large B-cell lymphomas that arise in HHV8+ multicentric Castleman disease
11
CHAPTER 1
General Introduction
of the control samples and a negative staining of the tested sample do not exclude the possibility of false staining because the various steps in the preparation of the tissue sample (including length of fixation and type of fixative) may be different. In addition, control tissue on the same slide may be falsely negative on some staining platforms if control tissue is not placed close enough to the target tissue because reagents may not cover the entire slide. Once again, the presence of an internal positive control is the most reliable criterion to decide whether neoplastic cells in a given biopsy specimen are negative or not. Finally, false-negative staining may be due to antibodies that are not suitable for immunohistochemistry even though they are perfectly good reagents for other techniques such as western blotting.
False-positive staining If one excludes background staining, non-specific labelling may be related to contaminating antibodies in the primary serum (i.e. anti-IgG reactivity in an anti-IgM antiserum). Such non-specific staining may be decreased by increasing the dilution of the primary antibody. The most common false-positive staining in lymphoid pathology is due to passive absorption of extracellular proteins (i.e. Ig and other serum proteins) by neoplastic cells [2]. In some malignant lymphoid proliferations this phenomenon may be responsible for an erroneous diagnosis of a reactive disorder on the basis of a false polytypic staining (i.e. lymphoma cells positive for Igκ and Igλ) because neoplastic cells have passively absorbed IgGκ and IgGλ, which are in large amounts in the serum and thus in the extracellular milieu. For unknown reasons, large cells in diffuse large B-cell lymphoma and Reed–Sternberg cells or even histiocytes have a great tendency to absorb passively extracellular proteins. Some signs may allow the recognition of false-positive staining due to passive absorption: • The staining is diffuse rather than granular and the nucleus is often stained. • Positive cells are scattered among a majority of negative cells. • The artefactual staining is proportional to the concentration of proteins in the serum (IgG > IgM). • Double staining for κ and λ reveals mixed staining • J-chain staining may be helpful for differentiating positive Ig-secreting cells (J chain positive) from cells having passively absorbed extracellular Ig (J chain negative). Unfortunately there is not at present a good commercially available anti-J chain antibody for use on routine specimens.
Unexpected reactivity of monoclonal antibodies Some antibodies, which are very useful in routine immunohistochemistry, may show a very confusing, unexpected reactivity with some normal or neoplastic cells. One of the
12
best examples of this phenomenon is represented by the reactivity of anti-EMA antibodies.
Anti-EMA antibodies Anti-EMA usually refers to the commercially available antiEMA/E29 antibody, although there are other antibodies reacting with epithelial membrane antigen. Positive staining of a subset of plasma cells was recognised early in the history of EMA and now constitutes an acceptable internal control in haematolymphoid tissues [3]. The staining is mainly membrane associated. The most consistent reactivity of EMA within B-cell neoplasms is found in multiple myeloma and plasmacytoma [4]. In hyperplastic bone marrow showing increased numbers of immature cells, some erythroblasts may react with anti-EMA antibody. However, the membrane staining is usually weak, and sometimes the staining is restricted to the Golgi area (dot-like staining). Caution is therefore required when using anti-EMA antibodies for detecting marrow involvement in epithelial malignancies or in patients with anaplastic large-cell lymphoma (see below). Blastic cells in erythroleukaemia and megakaryoblastic leukaemia may also express EMA. The most frequent non-epithelial expression of EMA is recorded in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma and the cumulative experience of the reactivity of LP cells with anti-EMA approaches 80% of cases [5–7]. In cases with apparently negative atypical cells, comparison with the staining intensity of plasma cells as the internal control is critical. Many cases of transformation of nodular lymphocyte-predominance Hodgkin lymphoma to large B-cell lymphoma have been shown to conserve EMA expression [6]. The situation is quite different in classic Hodgkin lymphoma of nodular sclerosis and mixed cellularity subtypes. The reactivity of anti-EMA with Hodgkin and Reed–Sternberg cells and variants is exceedingly rare at less than 5% [4]. The percentage of cases with EMA+ Reed–Sternberg cells is even lower if only the larger reported series are taken into account which suggests that the finding of EMA+ Reed–Sternberg cells and variants should lead to a reassessment of a diagnosis of classic Hodgkin lymphoma. The series of Filippa et al. [8] of 128 cases of nodular sclerosis and mixed cellularity subtypes without EMA expression is notable, and the authors attached clinical significance to the non-expression of EMA in classic Hodgkin lymphoma. Nevertheless, there are probably rare cases where the diagnosis of classic Hodgkin lymphoma is sustainable by morphology and other antibodies (CD15+, CD30+, MUM1+, null cell phenotype) despite the expression of EMA. Within the lymph node-based, low- and high-grade, B-cell lymphomas, reactivity of EMA is of the order of 5% in major series. EMA is mainly expressed by T-cell-rich B-cell lymphomas and by diffuse large B-cell lymphomas. A distinct subtype of large B-cell lymphoma expressing EMA strongly
CHAPTER 1
together with the tyrosine kinase receptor ALK has been recognised [9]. The presence of EMA on T-cell lymphomas is of the order of 10–20% in larger series [3]. Most cases of enteropathyassociated T-cell lymphoma and anaplastic large-cell lymphoma express EMA [10]. EMA expression in CD30+ primary cutaneous lymphoproliferative disorders is still the subject of controversy. In our experience EMA is expressed by most CD30+ tumours and is not of diagnostic value for differentiating secondary from primary CD30+ cutaneous lymphomas.
Anti-CD30/Ber-H2 antibody The reactivity of this antibody was first reported in reactive B and T immunoblasts, Reed–Sternberg cells, and is now the defining marker of anaplastic large cell lymphoma [11]. A subpopulation of plasma cells is reactive for CD30/Ber-H2 antibody in formalin-fixed tissue, although this is not seen when heat-associated antigen retrieval methods are used [11]. However, the range of neoplastic cells expressing the CD30 antigen is wider than initially thought [12]. Mastocytosis is commonly positive for CD30 and the authors have observed that occasional cases of true histiocytic tumours and erythroleukaemia are also positive for this antigen. Some non-haematopoietic cells are positive for CD30/ Ber-H2. In addition to the well-known reactivity of embryonal carcinoma, various carcinomas and occasional melanomas may show a reactivity for CD30/Ber-H2(12). A new clone, JCM182, specifically produced to improve the recognition of CD30 on paraffin sections has recently become available. It too has a few unexpected reactions such as identifying granulocytes especially in bone marrow specimens.
Miscellaneous unexpected reactivities Some of these reactivities are commonly seen in routine practice and are not really a source of error:
General Introduction
the expression of CD79a, lymphoblastic lymphomas that are positive for CD3 and CD79a are of T-cell lineage [16]. Occasional cases of extranodal NK/T-cell and peripheral T-cell lymphoma may express CD79a antigen [17,18]. The reported positivity of acute promyelocytic leukaemia occurs only with the clone HM57 and not with the more commonly used reagent JCB 117 [19].
CD3 In various lesions, macrophages may show a spurious globular cytoplasmic staining. The authors have observed exceptional cases of B-cell lymphoma with clonal Ig gene rearrangement positive for CD3. Acute myeloid leukaemias express CD3 (as well as other T-cell-associated antigens) in less than 10% of cases.
CD5 This pan-T-cell antigen is expressed by a wide variety of B-cell lymphomas including small lymphocytic lymphoma/ leukaemia, mantle cell lymphoma and occasional cases of diffuse large B-cell lymphomas. CD5 is also found in thymic carcinomas and other non-lymphoid neoplasms [20].
CD10 CD10 antibodies recognize a 100-kDa cell surface glycoprotein that is present in a variety of cell types. Originally this antigen was referred to as ‘common acute lymphoblastic leukaemia antigen’ or CALLA, because it was found to be expressed on the cell surface of most cases of acute lymphoblastic leukaemia (ALL) and thought to be specific for this lymphoproliferative disorder. CD10 antigen can be demonstrated not only on precursor B-cell or T-cell lymphoblastic lymphomas/leukaemias but also on follicular lymphomas, most Burkitt lymphomas and diffuse large B-cell lymphomas (30% of cases). CD10 is also expressed in a wide variety of non-neoplastic human cells, including haematopoietic (germinal centre cells and mature granulocytes), epithelial (renal proximal tubules, bile canaliculi) and stromal cells (fibroblasts).
CD20/L26 The nucleolar staining of large number of cells of many different tissue types with CD20/L26 is commonly observed and does not indicate a B-cell origin of these cells. Only membrane-associated staining should be taken into consideration. Rare cases of CD20+ T-cell lymphoma have been reported [13]. CD20 antigen has been reported in occasional cases (<5% of cases) of acute myeloid leukaemia and in epithelial cells of thymoma [14]. Some follicular dendritic cells are also reactive for CD20.
CD79a/JCB117 Unexpectedly, approximately 40% of lymphoblastic T-cell lymphomas are positive for CD79a [15]. However, despite
CD23 The CD23 molecule is a low-affinity IgE receptor found on B cells. It is a membrane glycoprotein of 45 kDa and is reported to be found on a subpopulation of peripheral blood cells, B lymphocytes and Epstein–Barr virus (EBV)transformed B-lymphoblastoid cell lines. Expression of CD23 antigen has been reported on monocytes and dendritic cells and is generally positive on most cases of B-CLL (B-cell chronic lymphocytic leukaemia). Although originally considered to be negative it has become clear that approximately 20–30% of follicular lymphomas are positive and increasingly positive cases of other subtypes of B-cell lymphoma are being recognised [21].
13
CHAPTER 1
General Introduction Most malignant lymphomas expressed the leukocyte common antigen CD45 and are negative for epithelial markers. There are, however, exceptions that are responsible for diagnostic difficulties in immunohistochemistry. According to the largest series in the literature, 10% of diffuse large cell lymphomas, 20% of lymphoblastic T-cell lymphomas and most plasmocytomas/myelomas are negative for CD45 [25–27]. Note that more than a third of anaplastic large-cell lymphomas are negative for CD45, the highest rate of negativity among non-Hodgkin lymphomas. Generally speaking, the larger the cells the weaker the expression of the leukocyte common antigen and in some cases this antigen is detected only on frozen sections. It is worth noting that some of these tumours are usually positive for EMA which may lead to an erroneous diagnosis of undifferentiated carcinoma. Additional markers of B- or T-cell lineage along with CD30 should enable a correct identification of the lymphoid nature of these tumours.
Anti-TdT antibody This antibody is very useful for diagnosing lymphoblastic lymphomas from B- or T-cell origin. However, approximately 10% of myeloblastic leukaemias are also positive for TdT. Furthermore cortical thymocytes are strongly positive so a diagnosis of T-lymphoblastic leukaemia in the thymus needs to be made on more than TdT positivity. In addition, there are increased numbers of TdT+ precursors in regenerating bone marrows, so TdT needs to be used with great caution when monitoring the bone marrow of ALL patients for evidence of minimal relapse.
CD68 antibodies The two anti-CD68 antibodies, PGM1 and KP1, do not have the same reactivity despite being in the same cluster. Thus, CD68/KP1 reacts with immature myeloid cells whereas CD68/PGM1 has a restricted reactivity with monocytes/ macrophages. A significant number of lymphocytic and diffuse large B-cell lymphomas are positive for KP1 [22] as are most melanomas [23,24] whereas PGM1 is unreactive with these tumours.
Loss of B- or T-cell-associated antigens In B-cell lymphoma the loss of both CD20 and CD79a antigens has been reported in rare cases of ALK (anaplastic lymphoma kinase)-positive large B-cell lymphoma secreting IgA [9]. Cases of CD20-positive B-cell lymphomas that became CD20 negative at relapse have been reported after rituximab therapy [17] (Fig 1.1).
Loss of leukocyte common antigen Malignant cells may lose one or more antigens usually found on normal cells of their origin. The best example is provided by malignant lymphomas negative for the leukocyte common antigen CD45.
HE
HE
Proliferation (mib1)
CD20
CD20
CD79a
Fig 1.1 Example of a follicular lymphoma that was CD20+ on diagnosis, but at relapse after rituximab therapy is virtually negative apart from a few dots of cytoplasmic staining. The lymphoma remains B cell, being CD79a+, and has the typical cytology and proliferation rate and pattern of a follicular lymphoma.
14
CHAPTER 1
In T-cell lymphomas the loss of one or more pan-T-cell antigens (CD3, CD5, CD2 or CD7) is seen in most cases (75% of cases), CD7 being the most frequent, particularly in cutaneous T-cell lymphomas [28–30]. Pan-T-cell antigens are commonly missing in anaplastic large-cell lymphomas with CD3 staining being observed in only a third of cases.
Acquisition of antigens Some malignant cells may express one or several antigens that are normally restricted to another cell lineage. The best example is provided by some lymphomas being positive for cytokeratin or some carcinomas reacting with anti-leukocyte antibodies.
Malignant lymphoma positive for keratin A number of reports have emphasised the existence of myelomas or large-cell lymphomas positive for cytokeratin
General Introduction
[26,31–35]. It is worth noting that, in these cases, the staining for cytokeratin is usually focal and restricted to the paranuclear Golgi area. Of note is that most of these tumours are negative for leukocyte common antigen which may increase the diagnostic difficulty. The diagnosis of lymphoma in these cases relies heavily on the reactivity with anti-T or anti-B antibodies. The authors have also observed rare cases of acute myeloblastic leukaemia positive for cytokeratin.
Other unexpected reactivities Some other unexpected reactivities have been reported such as B-cell lymphomas reactive for HMB45, the melanoma marker [36], and positivity for S100 protein, actin [37] and vimentin [38]. Unexpectedly, some cases of mediastinal B-cell lymphomas are positive for β human chorionic gonadotrophin (βhCG) [39]. In fact, these aberrant reactivities are rarely encountered in routine practice.
Capsule
Primary follicle
Paracortex Secondary follicle Sinuses
Fig 1.2 Principal structures in a normal lymph node. Normal lymph node structures are indicated. An abundance of primary follicles denotes a lymph node little affected as yet by antigenic stimulation.
Bcell (CD20)
Tcell (CD3)
15
CHAPTER 1
General Introduction
The normal lymph node
Primary follicles
Secondary follicles
Proliferation (Ki67)
Non-lymphoid tumors positive for the leukocyte common antigen
Squamous epithelium
Paracortex
Follicles Fig 1.4 Tonsil differs from lymph node principally by being covered by oral-type non-keratinising squamous epithelium. The sinus meshwork is also poorly developed and difficult to identify.
16
Fig 1.3 When follicles undergo secondary change on antigenic stimulation there is a greatly increased level of proliferation in the developing germinal centre which is predominantly in one area, the so-called ‘dark zone’ where the centroblasts are most numerous.
A more confusing aberrant phenotype is provided by some non-lymphoid tumours positive for the leukocyte common antigen (LCA). Warnke and Rouse [40] reported two cases, one an aggressive pituitary adenoma and the other a seminoma positive for LCA. Such reactivity has also been reported in non-malignant breast lesions [41]. We have observed two cases of breast carcinoma positive for LCA but in these cases the staining was mainly cytoplasmic and not membrane associated as in lymphoid tumours. However, a clear CD45 membrane staining has been reported in undifferentiated and neuroendocrine carcinoma [42]. It should be emphasised that these are exceptionally rare events in diagnostic practice. By far the most common reason for pathologists thinking that a carcinoma is CD45+ is by mistaking a heavy macrophage infiltration for malignant epithelial cells. This can be easily resolved by staining for CD68.
I’ve only got one H&E – help! No problem, except you can only do one immunostain so choose carefully. Just immerse the slide in toluene for 12– 72 h to remove the coverslip and then place in successive baths of absolute alcohol, distilled water and phosphatebuffered saline. This treatment removes the eosin staining
CHAPTER 1
General Introduction
White pulp
Red pulp
CD20
CD3
Fig 1.5 In the spleen the lymphoid tissue resides in the white pulp, which similar to lymph node contains well-circumscribed B- and T-cell areas.
of the cytoplasm, but does not affect the nuclear staining. Immunohistochemical staining is then performed as for unstained sections.
Conclusion This brief description of some pitfalls in immunohistochemistry stresses that the immunophenotypic diagnosis and the cellular origin of a tumour cannot rely on a single immunological marker. Aberrant stainings, such as positive staining
for cytokeratin in malignant lymphomas, or lymphomas negative for the LCA (CD45) do not diminish the diagnostic utility of immunohistochemistry, which allows the accurate classification of most if not all haematopoietic neoplasms. However, these unusual stainings emphasise the need to interpret immunohistochemical results with morphology and clinical data.
Molecular techniques ‘Molecular studies have revolutionized hematopathologic diagnosis’ writes an eminent author of a recent excellent
17
CHAPTER 1
General Introduction
lymph node textbook [43]. But have they? A positive rearrangement or translocation might be supportive but who feels confident enough to diagnose malignancy when only a band on a polymerase chain reaction (PCR) gel says so? Although these techniques remain expensive they have now become much more reliable in routine service. We continue to use PCR or fluorescent in situ hybridisation (FISH) methods as supportive in difficult cases, but do not rely on them for a diagnosis. So, for example, a B- or T-cell clonal rearrangement is helpful in a case with a strong suspicion of B- or T-cell malignancy as is an appropriate FISH translocation for suspected Burkitt lymphoma or mantle cell lymphoma. By themselves they are still insufficiently robust to deliver a diagnosis, although surely similar to telepathology their day will come (though for the moment we continue to wait patiently).
Normal lymphoid structures The key to virtually all pathological diagnoses is knowing and understanding the normal. It is difficult to define what a normal lymph node is because it is a structure that is changing and adapting daily. Figures 1.2 and 1.3 outline the basic structure of a lymph node, Fig 1.4 the tonsil and Fig 1.5 the spleen, and contrast the difference between an unstimulated node with its primary follicles and one that has been stimulated to produce secondary follicles with germinal centres.
9.
10.
11.
12. 13.
14. 15.
16.
17. 18.
19.
References 20. 1. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741–8. 2. Mason DY, Biberfeld P. Technical aspects of lymphoma immunohistology. J Histochem Cytochem 1980;28:731–45. 3. Delsol G, Gatter KC, Stein H, et al. Human lymphoid cells express epithelial membrane antigen. Implications for diagnosis of human neoplasms. Lancet 1984;ii:1124–9. 4. Chittal SM, Al Saati T, Delsol G. Epithelial membrane antigen in hematolymphoid neoplasms. A review. Appl Immunohistochem 1997;5:203–15. 5. Chittal S, Caveriviere P, Schwarting R, et al. Monoclonal antibodies in the diagnosis of Hodgkin’s disease. The search for a rational panel. Am J Surg Pathol 1988;12:9–21. 6. Chittal SM, Alard C, Rossi JF, et al. Further phenotypic evidence that nodular, lymphocyte-predominant Hodgkin’s disease is a large B-cell lymphoma in evolution. Am J Surg Pathol 1990; 14:1024–35. 7. Mason D, Banks P, Chan J, et al. Nodular lymphocyte predominance Hodgkin’s disease: a distinct clinico-pathological entity. Am J Surg Pathol 1994;18:528–30. 8. Filippa DA, Ladanyi M, Wollner N, et al. CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic,
18
21.
22.
23. 24. 25.
26. 27. 28.
and genetic characteristics and differences with Hodgkin’s disease. Blood 1996;87:2905–17. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997;89:1483–90. Delsol G, Al Saati T, Gatter K, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas: diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988;130:59–70. Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989;74:1678–89. Pallesen G. The diagnostic significance of the CD30 (Ki-1) antigen. Histopathology 1990;16:409–13. Algino KM, Thomason RW, King DE, Montiel MM, Craig FE. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am J Clin Pathol 1996;106:78–81. Chang KL, Arber DA, Weiss LM. CD20: A review. Appl Immunohistochem 1996;4:1–15. Pilozzi E, Pulford K, Jones M, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol 1998; 186:140–3. Pilozzi E, Muller-Hermelink HK, Falini B, et al. Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 1999; 188:267–70. Chu PG, Arber DA. CD79: a review. Appl Immunohistochem Mol Morphol 2001;9:97–106. Yao X, Teruya-Feldstein J, Raffeld M, Lynn Sorbara L, Jaffe ES. Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: A diagnostic pitfall. Mod Pathol 2001;14:105–10. Arber DA, Jenkins KA, Slovak ML. CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia. Am J Pathol 1996;149:1105–10. Kornstein MJ, Rosai J. CD5 labeling of thymic carcinomas and other nonlymphoid neoplasms. Am J Clin Pathol 1998;109: 722–6. Thorns C, Kalies K, Fischer, et al. Significant high expression of CD23 in follicular lymphoma of the inguinal region. Histopathology 2007;50:716–19. Carbone A, Gloghini A, Volpe R, Pinto A. KP1 (CD68)-positive large cell lymphomas: a histopathologic and immunophenotypic characterization of 12 cases. Hum Pathol 1993;24:886–96. Facchetti F, Bertalot G, Grigolato PG. KP1 (CD 68) staining of malignant melanomas. Histopathology 1991;19:141–5. McHugh M, Miettinen M. KP1 (CD68). Its limited specificity for histiocytic tumors. Appl Immunohistochem 1994;2:186–90. Van Eyken P, De Wolf-Peeters C, Van den Oord J, Tricot G, Desmet V. Expression of leukocyte common antigen in lymphoblastic lymphoma and small noncleaved undifferentiated non-Burkitt’s lymphoma: an immunohistochemical study. J Pathol 1987;151:257–61. Wotherspoon AC, Norton AJ, Isaacson PG. Immunoreactive cytokeratins in plasmacytomas. Histopathology 1989;14:141–50. Weiss LM, Arber DA, Chang KL. CD45. A review. Appl Immunohistochem 1993;1:166–81. Picker L, Weiss L, Medeiros L, Wood G, Warnke R. Immunophenotypic criteria for the diagnosis of non-Hodgkin’s lymphoma. Am J Pathol 1987;128:181–201.
CHAPTER 1
29. Warnke RA, Weiss LM. Practical approach to the immunodiagnosis of lymphomas emphasizing differential diagnosis. Cancer Surv 1985;4:349–58. 30. Wood KM, Pallesen G, Ralfkiaer E, Warnke R, Gatter K, Mason DY. Heterogeneity of CD3 antigen expression in T-cell lymphoma. Histopathology 1993;22:311–7. 31. de Mascarel A, Merlio JP, Coindre JM, Goussot JF, Broustet A. Gastric large cell lymphoma expressing cytokeratin but no leukocyte common antigen. A diagnostic dilemma. Am J Clin Pathol 1989;91:478–81. 32. Frierson HF Jr, Bellafiore FJ, Gaffey MJ, McCary WS, Innes DJ Jr, Williams ME. Cytokeratin in anaplastic large cell lymphoma. Mod Pathol 1994;7:317–21. 33. Lasota J, Hyjek E, Koo CH, Blonski J, Miettinen M. Cytokeratinpositive large-cell lymphomas of B-cell lineage. A study of five phenotypically unusual cases verified by polymerase chain reaction. Am J Surg Pathol 1996;20:346–54. 34. McCluggage WG, el-Agnaff M, O’Hara MD. Cytokeratin positive T cell malignant lymphoma. J Clin Pathol 1998;51: 404–6. 35. Menestrina F, Lestani M, Scarpa A, et al. Common acute lymphoblastic leukaemia–lymphoma expressing cytokeratin: a case report. Virchows Arch 1994;425:83–7.
General Introduction
36. Friedman HD, Tatum AH. HMB-45-positive malignant lymphoma. A case report with literature review of aberrant HMB45 reactivity. Arch Pathol Lab Med 1991;115:826–30. 37. Fung CH, Antar S, Yonan T, Lo JW. Actin-positive spindle cell lymphoma. Arch Pathol Lab Med 1993;117:1053–5. 38. Lertprasertsuke N, Tsutsumi Y, Maruyama T. B-cell lymphoma with vimentin-positive cytoplasmic inclusions. Acta Pathol Jpn 1991;41:473–9. 39. Fraternali-Orcioni G, Falini B, Quaini F, et al. Beta-HCG aberrant expression in primary mediastinal large B-cell lymphoma. Am J Surg Pathol 1999;23:717–21. 40. Warnke RA, Rouse RV. Limitations encountered in the application of tissue section immunodiagnosis to the study of lymphomas and related disorders. Hum Pathol 1985;16:326–31. 41. Herman GE, Elfont E. Aberrant CD45 (Leucocyte common antigen) staining of non-malignant breast lesions in zinc formalin fixed tissue. J Histotechnol 1993;16:151–3. 42. Nandedkar MA, Palazzo J, Abbondanzo SL, Lasota J, Miettinen M. CD45 (leukocyte common antigen) immunoreactivity in metastatic undifferentiated and neuroendocrine carcinoma: a potential diagnostic pitfall. Mod Pathol 1998;11:1204–10. 43. Strauchen J. Diagnostic Histopathology of the Lymph Node. New York: Oxford University Press, 1998.
19
2
Reactive and Infective Conditions
Reactive lymph node changes are typically classified either by the predominant site in the node which is expanded or by the aetiology of the change. Table 2.1 attempts to summarise these changes using both features. It is important to understand that lymph nodes react as organic structures and that none of these changes should be considered in isolation. In other words, all the structures frequently undergo changes and the suggested categorisation refers only to the predominant changes.
Follicular hyperplasia Non-specific In most cases follicular hyperplasia is characterised by a lymph node that has gradually enlarged over weeks or months and for which there is usually no obvious clinical diagnosis. The lymph node is hence biopsied more than anything to eliminate a diagnosis of malignancy [1]. Follicular hyperplasia (Fig 2.1) is characterised by an increase in the number and size of follicles, so it is a hypertrophic as well as a hyperplastic event. The structure of the node is maintained and the capsule is usually intact. The germinal centres are the main site of this change with increased numbers of mitoses and ‘tingible body’ macrophages (these are large macrophages phagocytosing apoptotic nuclear debris). Typically the mantle zones remain intact and follicles are separated by at least a small sliver of paracortex. The size of the follicles may be quite variable and, although they are typically round, a number of odd shapes including dumb-bells and balloons may be seen. Note that some follicles can be seen in the pericapsular adipose tissue. The main differential diagnosis is with follicular lymphoma. Reactive follicles are polyclonal, have a high proliferation rate and are bcl-2 protein negative. Further practical details of this distinction are in Chapter 12.
Toxoplasmosis Lymphadenitis may occur after primary infection with the protozoan Toxoplasma gondii, caught apparently from domestic cat faeces or eating infected meat. The clinical features are highly variable, ranging from solitary lymphadenopathy with no symptoms through a self-limiting infectious mononucleosis-like condition to a life-threatening systemic disease with encephalitis and myocarditis. The latter is more likely to arise in an immunodeficient host. Histologically toxoplasmosis is characterised by three features [2,3]. These are prominent follicular hyperplasia, epithelioid histiocytes in small collections (‘epithelioid congeries’), often hanging on to the mantle zones like limpets, and sinuses packed with monocyte-like cells (monocytoid B lymphocytes) (Fig 2.2). Monocytoid B cells are often accompanied by small numbers of neutrophils. These cells were initially designated as immature sinus histiocytes but immunostaining studies have identified them as mature B cells. Although these are characteristic if not diagnostic of toxoplasmosis, monocytoid B lymphocytes filling the sinuses can be observed in lymphadenitis of other aetiologies, e.g. cytomegalovirus (CMV). The parasite is rarely found in lymph nodes even by the polymerase chain reaction (PCR) so that the diagnosis requires serological antibody studies to be confirmed [4].
Leishmaniasis Visceral or systemic leishmaniaisis, also known as kala-azar, is rare in the west. Biopsies of infected organs may include the spleen, lymph node, liver and bone marrow. Usually there is an extensive population of macrophages full of the typical ‘safety pin-like’ amastigotes. Regional lymph node involvement in cutaneous leishmaniasis may be more subtle, with changes very similar to toxoplasmosis although usually the granulomas are bigger and careful inspection reveals the presence of amastigotes (Fig 2.3).
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
20
CHAPTER 2
Table 2.1 Reactive and infective conditions Follicular hyperplasia Non-specific Toxoplasmosis Castleman disease Rheumatoid arthritis Syphilis Kimura disease Measles Progressive transformation of germinal centres HIV Paracortical expansion Most viral lymphadenopathy especially Epstein–Barr virus Kikuchi disease Lupus Typhoid Dermatopathic Drug induced Sinus hyperplasia: Sinus histiocytosis Rosai–Dorfman disease Lymphangiography effect and silicon deposition Granulomatous conditions: Tuberculosis and leprosy Sarcoidosis Cat-scratch fever and lymphogranuloma venereum Fungal Lipidoses and other depositions
Castleman disease This is an unusual follicular hyperplasia of unknown aetiology [5]. It is usually divided into two categories – hyaline– vascular type and plasma cell variant – although there is overlap between them, with some authorities describing mixed or transitional forms.
Hyaline–vascular type This usually occurs as a solitary enlarged lymph node commonly in the mediastinum (where it was originally described [6]) in young patients with no other symptoms. It may occur in extranodal sites including lung and soft tissues. It is worth checking for the presence of follicular dendritic cell sarcoma because a few cases have been associated with the features of Castleman disease. Excision of the lymph node is usually curative. The histology is characterised by increased numbers of small follicles (Fig 2.4). Closer inspection shows that most of these have the germinal centre replaced by a thick-walled blood vessel, around which are clustered a few B cells and follicular dendritic reticulum cells, sometimes showing a concentric arrange-
Reactive and Infective Conditions
ment mimicking Hassall’s bodies. Some atypical large cells with bizarre nuclei corresponding to FDCs are commonly observed, and some of these may be quite large with bizarre nuclei and have been confused with the tumour giant cells of Hodgkin lymphoma (Fig 2.5). The interfollicular area shows increased numbers of thickwalled, high endothelial venules surrounded by a mixture of plasma cells (but not in sheets) and lymphocytes, sometimes accompanied by small clusters of plasmacytoid dendritic cells (Fig 2.6). Immunostaining can be helpful in identifying the abnormal FDCs (CD21, CNA-42) or the plasmacytoid dendritic cells (CD68 or CD123), both of which can occasionally give rise to diagnostic concern. However, these dysplastic FDCs may label poorly with the usual FDC markers. More recent studies of plasmacytoid monocytes have suggested they are differentiating more towards dendritic cells than mature macrophages. This is based on their positivity for recently described markers such as bcl11a, CD123 and CD2AP [7]. These are more commonly associated with dendritic cells than macrophages. Plasmacytoid monocytes/ dendritic cells are frequently seen in other specific reactive conditions, including Kikuchi disease and lupus lymphadenitis, but do occur occasionally in many other reactive conditions, including in nodes draining tumours where care needs to be taken not to mistake them for metastases (Fig 2.7).
Plasma cell variant This variant occurs in two forms: localised disease and multicentric or systemic Castleman disease. The localised form usually occurs in younger adults, particularly in mediastinal or abdominal lymph nodes. In contrast to the hyaline vascular variant, these patients usually present with symptoms such as fever, anaemia and hypergammaglobulinaemia. However, similar to hyaline vascular Castleman disease excision is often curative. The histology of the plasma cell variant is characterised by confluent sheets of either monoclonal (usually λ) or polyclonal plasma cells in the interfollicular areas [8–10]. Follicular hyperplasia is prominent but, unlike hyaline vascular Castleman disease, many if not all of the follicles are quite ordinary with typical germinal centres rather than all showing hyaline vascular change (Fig 2.8).
Multicentric or systemic Castleman disease This disorder affects older patients. They present with widespread lymphadenopathy, often with accompanying hepatosplenomegaly. They are usually quite ill with a variety of severe systemic symptoms. In particular some have a characteristic constellation of features known as the POEMS syndrome. This acronym stands for polyneuropathy, organomegaly, endocrine abnormalities, monoclonal gammopathy and skin rashes). These patients are immunodeficient
21
CHAPTER 2
Reactive and Infective Conditions
H&Es
CD20
CD10
Proliferation
FDCs
DBA-44
bcl-2
Fig 2.1 Reactive follicular hyperplasia contains typical germinal centres composed of centroblasts and centrocytes with admixed tingible body macrophages being prominent. They are well circumscribed, a feature often best seen by immunostaining for B cell antigens such as CD20. Germinal centres have a high proliferation rate (Ki67 antigen) which is often zoned reflecting the light and dark zones seen on the H&E stain. The follicular dendritic cell meshwork (FDCs) is regular (CD21 positive) and follicles are often CD10 positive but bcl-2 protein negative. Mantle zones have a different phenotype from the germinal centre and can be highlighted with markers such as IgD or DBA.44.
22
CHAPTER 2
Reactive and Infective Conditions
CD20
CD68
Fig 2.2 The major features of toxoplasmosis are illustrated using haematoxylin and eosin (H&E) and by immunostaining. The ‘monocytoid B cells in the sinuses’ are indicated with white arrows and shown at high power (bottom left), whereas the epithelioid congeries or microgranulomas in their typical parafollicular (and occasionally germinal centre) positions are shown by black arrows. *Germinal centres.
CD20
CD68
23
CHAPTER 2
Reactive and Infective Conditions
Fig 2.3 Lymph nodes in leishmaniasis, especially the cutaneous variety, may show follicular hyperplasia with surrounding granulomatous lesions. Within these amastigotes can usually be found in the epithelioid macrophages.
CD20
Castleman disease: hyaline vascular type CD21
Fig 2.4 The hyaline–vascular subtype of Castleman disease is composed of atrophic B-cell follicles in which the germinal centres have become progressively vascularised. This change in the germinal centre is often best highlighted by immunostaining for follicular dendritic cells (FDCs), e.g. with CD21. The dendritic cell processes may also form rings that probably account for the onion skin appearance of mantle lymphocytes around some of the follicles. These vascularised follicles are surrounded by a hyalinised or highly vascular paracortex.
24
CHAPTER 2
and prone to severe infections and have a raised incidence of developing lymphoma or Kaposi sarcoma. The 5-year survival rate is less than 50%. Many cases of multicentric Castleman disease occur in HIV-positive patients and all of these are also positive for human herpesvirus 8 (HHV8) [11–13]. In HIV-negative
Reactive and Infective Conditions
Castleman disease of whatever type, a varying proportion of cases has been reported to express HHV8 preferentially in subcapsular spindle cells [14]. A number of these cases of HHV8 multicentric Castleman disease go on to develop a characteristic plasmablastic large-cell lymphoma, which has recently been recognised by the World Health Organization (WHO) as a separate subentity of diffuse large B-cell lymphoma (Fig 2.9).
Rheumatoid arthritis Most patients with rheumatoid arthritis develop lymphadenopathy at some stage in their disease. This may be either localised or systemic. The latter is particularly common with Still disease or juvenile rheumatoid arthritis. Patients with rheumatoid arthritis have an increased risk of developing lymphomas, especially follicular lymphoma. Even so the incidence is quite low and should not be overdramatised [15]. Although about 25% of patients with T-cell large granular lymphocyte leukaemia have rheumatoid arthritis, this lymphoma is rare. Controversy continues over whether it is rheumatoid arthritis itself that is the risk factor for lymphoma or the treatments meted out to these patients, including drugs such as methotrexate and gold [16]. The histology is one of florid follicular hyperplasia [17] and indeed the nodes can be enormous. Often there is a marked polyclonal plasmacytosis in the paracortical regions (Fig 2.10). Clusters of neutrophils may also be prominent, particularly in nodes that are in the region of active joint inflammation. The pathology can be complicated by the development of amyloidosis in longstanding sufferers.
Syphilis
Fig 2.5 Examples of the pleomorphic morphology of FDCs (black arrows) that may be seen in and around the nodules of hyaline–vascular subtype of Castleman disease.
Lymphadenopathy arising from Treponema pallidum infection is often also rather quaintly referred to as luetic lymphadenitis. Enlarged lymph nodes are really only a feature of the primary and secondary stages. Most patients are now diagnosed clinically so that lymph node biopsies for syphilis
CD68 Fig 2.6 Plasmacytoid monocytes are a typical feature of Castleman disease of hyaline vascular subtype. They consist, as shown, of clusters of small cells (arrowed) with abundant cytoplasm and a lymphoid nuclear morphology. Originally thought to be a T-cell variant, histiocytic immunostains such as CD68 clearly identify them as being of monocytic lineage derived from plasmacytoid dendritic cells.
25
CHAPTER 2
Reactive and Infective Conditions
Fig 2.7 Typical example of plasmacytoid monocytes/dendritic cells seen in a reactive node draining a breast cancer. Any doubts as to their nature can be resolved by showing their positivity for CD68 (KP1 or PGM1 (middle left and centre) and their negativity for myeloperoxidase (middle right), CD3, CD20 and CD21 (bottom left to right).
26
CHAPTER 2
Reactive and Infective Conditions
VS38
CD34
κ
CD79a
λ Fig 2.8 In the plasma cell variant of Castleman disease only a proportion of the follicles (example shown with antibody CD34 in insert) show the vascularised morphology seen in the hyaline vascular variant. A variety of different follicles is illustrated here with both H&E and the B-cell marker CD79a. Plasma cells are prominent in the interfollicular area (highlighted by antibody VS38) and may be polyclonal (as shown here) or monoclonal (usually λ).
27
CHAPTER 2
Reactive and Infective Conditions
CD34
HHV8
CD34 + HHV8
Fig 2.9 Immunostains for CD34 and human herpesvirus 8 (HHV8) show that a proportion of cells surrounding the follicles are HHV8+. Double staining indicates that these are not of vascular origin.
chetes can be detected by silver staining though most patients are in fact diagnosed serologically.
Kimura disease
Fig 2.10 Florid follicular hyperplasia as seen in rheumatoid arthritis.
would be taken these days only by mistake. The disease is also not as common as it was so most currently practising haematopathologists will have seen few, if any, examples. There are two main patterns described [18]. One is florid follicular hyperplasia with sheets of interfollicular polyclonal plasma cells, which makes the plasma cell variant of Castleman disease the most likely differential diagnosis. The second is marked paracortical expansion with immunoblasts and plasma cells as seen in many viral infections. Associated changes are many and varied including endarteritis, granulomatous inflammation and necrosis. If suspected the spiro-
28
This is a rare inflammatory disorder typically affecting lymph nodes and soft tissues of the head and neck in young males. There is a great predominance of cases in Asian and Oriental populations [19]. Histologically the lymph nodes are characterised by follicular hyperplasia with an associated paracortical hyperplasia. It is this that is diagnostic, being composed of a proliferation of thin-walled blood vessels surrounded by masses of eosinophils (Fig 2.11). Many cases of Kimura disease will also show masses of eosinophils in germinal centres accompanied by necrosis, ‘eosinophilic folliculolysis’. It is often emphasised that Kimura disease should not be confused with angiolymphoid hyperplasia with eosinophilia [20,21]. This is not always as easy as some authorities make out. In general angiolymphoid hyperplasia is a haemangiomatous reaction in the subcutaneous tissues of the head and neck. It is characterised by thick-walled masses of vessels which, although accompanied by eosinophils, are not massed in clusters as with Kimura disease (Fig 2.12). Involvement of lymph nodes is rare but when present makes the differential from Kimura disease more difficult. Furthermore, angiolymphoid hyperplasia occurs as commonly in western as in Oriental populations and is, if anything, more common in women than in men. The aetiology of this condition is unknown.
CHAPTER 2
Reactive and Infective Conditions
CD15
Fig 2.11 Kimura disease is characterised by reactive follicles separated by an angiolymphoid proliferation with many clustered eosinophils. These are highlighted by the CD15 immunostain.
Measles
Progressive transformation of germinal centres
Lymphadenopathy is common in measles infections but is rarely biopsied because the disease is diagnosed clinically. Dr Strauchan, in his excellent account of reactive viral lymphadenitis, says: ‘Lymph node biopsy during the prodromal phase may permit the pathologist to make a diagnosis of probable measles before the appearance of the characteristic exanthem, thereby gaining great credit amongst his clinical colleagues!’ [22]. Alas for the current authors because we have signally failed to achieve this, but the point is well made. Measles-affected lymph nodes are usually large with florid follicular hyperplasia. The large germinal centres contain characteristic multinucleated forms of dendritic reticulum cells known as Warthin–Finkeldey cells. Such cells are also seen in other reactions, especially in HIV infections and in some lymphomas, but rarely are there as many as in measles (Fig 2.13).
Progressive transformation of germinal centres may occur as an isolated event in many different types of reactive follicular hyperplasia. However, the term is generally used as a diagnosis when they are plentiful and are scattered throughout nodes alongside typical reactive germinal centres. This tends to occur in children and young adults [23,24]. It is relatively frequent in association with nodular lymphocytepredominant Hodgkin lymphoma where it may occur before, during or after the diagnosis [25–27]. Progressive transformation of germinal centres describes a changed pattern in the relationship of the mantle zone and germinal centre in hyperplastic follicles. The name refers to the apparent progressive infiltration of the germinal centre with mantle zone cells, leading to a blurring of the two in an apparently jumbled manner (Fig 2.14). Aggregates of germinal centre cells are better seen after immunostaining. They are negative for bcl-2 and strongly positive for Ki-67.
29
CD31 In lymph node
In soft tissue
CNA42
Fig 2.12 Angiolymphoid hyperplasia occurs mostly in soft tissues and only rarely in lymph nodes. It differs from Kimura disease in not being associated with follicular hyperplasia, possessing thick-walled vessels and without large numbers of eosinophils.
Fig 2.13 Measles lymphadenopathy is characterised by follicular hyperplasia with giant syncytial follicular dendritic cells known as Warthin–Finkeldy cells. These can be definitely identified as such with antibodies against follicular dendritic cells such as CD21 or CNA42 (as illustrated here).
CHAPTER 2
Reactive and Infective Conditions
Fig 2.14 Two typical examples of lymph nodes involved by significant numbers of progressively transformed germinal centres. Note that they do not involve the whole node and have many different architectural patterns.
31
CHAPTER 2
Reactive and Infective Conditions
Expanded mantle zone lymphocytes are highlighted by their strong positive staining for IgD or DBA-44 (Fig 2.15). The process is benign and resolves of its own accord although it may recur. There has been much discussion of its relationship to nodular lymphocyte-predominant Hodgkin lymphoma with the current consensus being that, although associated, there is no relationship to the development or recurrence of nodular lymphocyte-predominant Hodgkin lymphoma. It is important to distinguish progressive transformation of germinal centres from definite nodular lymphocytepredominant Hodgkin lymphoma. This can be very challenging diagnostically. In general progressive transformation of germinal centres does not involve the whole node; involved follicles are intermixed with normal secondary follicles and tend not to be surrounded by small clusters of epithelioid macrophages and lack characteristic lymphocytepredominant (LP) cells. In contrast, the nodules of nodular lymphocyte-predominant Hodgkin lymphoma typically form a mass lesion within the node, often surrounded by a small rim of normal uninvolved lymph node which may contain one or more progressively transformed follicles. The larger blast cells seen in progressive transformation of germinal centres are usually not seen outside the nodules, are CD10 positive, and are neither rosetted by CD57-positive T cells nor epithelial membrane antigen (EMA) positive. That said, most experienced haematopathologists can relate one or two borderline cases where, by Murphy’s law, they jumped the wrong way and regretted it. In other words at times one should be brave enough to admit that a distinction is not possible and seek another opinion or write a suitably contrite report. Occasionally the transformed germinal centres may be so filled with bcl2-positive mantle cells and T cells that the possibility of follicular lymphoma is raised. Here the key to diagnosis is to assess the whole immunophenotypic picture that so characterizes follicular lymphoma which usually clearly enables a distinction to be made (see Chapter 12).
IgD CD20
IgD
bcl-2
CD21
CD3
HIV Many cases of lymphadenopathy occurring in relationship to HIV infection are caused by specific infections or malignancies. In the absence of any cause other than HIV there is a syndrome of reactive lymphadenopathy called persistent generalised lymphadenopathy [28]. This has a clinical definition as lymph node enlargement of more than 3 months’ duration at two or more sites other than inguinal regions with no demonstrable aetiology other than HIV [29]. The histological appearances are typically those of extremely florid follicular hyperplasia with many bizarrely shaped germinal centres. A common feature is the presence of follicle lysis where the germinal centre looks as though it has exploded out into the rest of the node (Fig 2.16).
32
Proliferation Fig 2.15 Immunophenotyping shows that progressively transformed germinal centres are large secondary B-cell follicles (CD20) with abundant follicular dendritic cell meshworks (CD21) and a great increase in the mantle zone (IgD, bcl-2). Their proliferation rate (Ki67) is high, reflecting their origin from reactive germinal centres.
CHAPTER 2
Reactive and Infective Conditions
Fig 2.16 A selection of bizarre follicles showing the appearances of follicle lysis in HIV-related lymphadenopathy.
33
CHAPTER 2
Reactive and Infective Conditions
CD79a
CD3
IgD
p24
CD21
Fig 2.17 The lysis of HIV-infected follicles is often best appreciated by immunostaining. The mantle zones (IgD) are profoundly disrupted with a prominent infiltration of T cells (CD3) into the germinal centre. Inside the germinal centre the HIV-related p24 antigen is prominently displayed on follicular dendritic cells (FDCs) and macrophages. Note how disrupted the FDC meshwork is (CD21). Contrast these appearances with those of progressively transformed germinal centres discussed previously and it is obvious how different they are.
This is often best appreciated by inspecting the FDC stains where the FDC meshwork is broken up into little packets apparently floating in a sea of small lymphocytes (Fig 2.17). Indeed at times this may be the first presentation of otherwise unsuspected HIV infection and other confirmatory investigations can then be undertaken. It should be noted that follicle lysis occurs in other reactive nodes too and is not specific for HIV lymphadenopathy [30]. Immunostaining for the HIV p24 antigen will confirm the diagnosis, although pathologists should take advice before undertaking what is in essence an HIV test because local ethical regulations on this will vary. As the disease progresses
34
into AIDS this lymphadenopathy is either complicated by infection or malignancy or starts to undergo involution, so that terminally the nodes are almost empty with atrophic involuted follicles which are often vascularised giving a Castleman disease-like appearance (Fig 2.18). Indeed as mentioned previously coinfection with HHV8 multicentric Castleman disease is a common condition in HIV infection (Fig 2.19). The most common infectious agents seen in association with HIV are the so-called opportunistic ones including Mycobacterium tuberculosis and M. avian-intracellulare (Fig 2.20), fungi especially Histoplasma, Cryptococcus, Toxoplasma
CHAPTER 2
"Burn out"
Involution Fig 2.18 Some complications of HIV associated lymphadenopathy.
and Pneumocystis spp. Coexisting malignancies in HIV-related lymphadenopathy are typically either Kaposi sarcoma (which may be focal and easily overlooked) and aggressive non-Hodgkin lymphomas (see Fig 2.18).
Paracortical expansion Viral lymphadenopathy especially Epstein–Barr virus infection Lymphadenopathy is a common feature in many viral illnesses but the diagnosis is so obvious clinically that biopsies are not commonly taken. This has two consequences: most haematopathologists have limited experience of these lesions and are often not expecting such a diagnosis. The biopsies typically come from young people with persistent lymphadenopathy being treated by experienced clinicians who feel that malignancy is a likely diagnosis. Occasionally tonsillectomy is performed because of asphyxia due to tonsillar swelling. The majority of viruses (measles being a major exception – see above) produce marked paracortical expansion in
Reactive and Infective Conditions
which many large blast cells (often described as immunoblasts) are scattered (Fig 2.21). Abnormal forms and in particular Reed–Sternberg-like cells may occur but they are not usually numerous. Follicles do occur but rarely is there an associated follicular hyperplasia [32]. Immunostains usually show that the blasts are a mixture of B and T cells – indeed in EBV infection most may be of B-cell type (Fig 2.22). Viral antigens such as LMP (latent membrane protein) for EBV or CMV associated can be detected in some of these cells. Some of the blasts may be CD30 positive but they are typically negative for CD15 and EMA [33](Fig 2.23). Note that, Reed-Sternberg-like cells in these lesions are LMP1+ and EBNA2+ whereas in EBVpositive Hodgkin lymphoma, Reed–Sternberg cells are LMP1+ but EBNA2− [34]. CMV infection also gives rise to a paracortical expansion very similar to that seen with EBV (Fig 2.24). However, it should be noted that with both EBV and CMV the earliest changes are in fact a follicular hyperplasia, with monocytoid B-cell hyperplasia similar to that seen with toxoplasmosis. Depending on local clinical thresholds for biopsy different haematopathology services will see more early or late cases. Often, if a hospital has a large transplant service, there is a low threshold for biopsy leading to more cases showing follicular rather than paracortical expansion.
Herpes lymphadenitis Herpetic lymphadenitis frequently involves inguinal lymph nodes [35,36]. Typical cutaneous lesions are usually found in the genital area either at diagnosis or after the lymph node biopsy [36]. Generalised lymphadenopathy may occur [37]. Rare cases of acute necrotising tonsillitis have also been reported [38]. Herpes lymphadenopathy may occur in patients with chronic lymphocytic leukaemia (CLL) or other low-grade lymphomas/leukaemias [39–41]. Indeed any area of necrosis in a lymph node involved by CLL should raise suspicion for herpes. The recognition of herpes simplex virus (HSV) lymphadenitis is important because of the availability of an effective anti-herpetic therapy (aciclovir). However, patients with CLL and associated herpes often do well without specific antiviral therapy. Nodal changes consist of necrotising lymphadenitis and proliferation of immunoblasts with plasma cells [35,36]. A large number of immunoblasts in the setting of CLL may raise concern for progression (the Richter transformation). Close inspection on high power examination shows diagnostic intranuclear inclusions associated with peripheral chromatin. Infected cells are easily detectable with immunostaining with an anti-HSV antibody that reacts with antigens common to HSV-1 and -2 (Fig 2.25). These cells appear to be restricted to the necrotic areas.
35
CHAPTER 2
Reactive and Infective Conditions
ZN
Tuberculosis
Kaposi sarcoma Fig 2.19 The number of tubercle bacilli seen in HIV-associated cases is variable. Sometimes they are plentiful and clumped and at other times single and scattered as shown. It is worth noting that opportunistic infections in lymph nodes may be associated with Kaposi sarcoma (shown here in the subcapsular sinus at three different powers) and/or Hodgkin lymphoma [31]. ZN, Ziehl–Neelsen stain.
36
CHAPTER 2
Reactive and Infective Conditions
As a result of the presence of neutrophils in necrotic areas, cat-scratch disease is a possible differential diagnosis but the palisading histiocytes surrounding these are missing in herpetic lymphadenitis. Herpetic lymphadenitis may also simulate the lymph node changes seen in systemic lupus erythematosus or Kikuchi disease. However, in contrast to these lesions, the necrotic areas in herpetic lymphadenitis are usually rich in neutrophils.
Kikuchi disease
ZN
Kikuchi disease is a benign self-limiting necrotising lymphadenitis typically seen in young Oriental individuals especially females [42,43]. Patients are typically unwell for some weeks or months with prominent unilateral cervical lymphadenopathy. The lymph nodes may be painful and are often accompanied by fever, leukopenia and sometimes skin rashes. A few cases have developed a haemophagocytic syndrome. Most patients recover without treatment although a few have relapses. Only one fatality has been recorded (from myocarditis) [44]. It is believed to be of viral origin although this is as yet unproven. The histology is typical with loose granulomatous nodules in the paracortex, composed of a mixture of macrophages some of which have crescent-shaped nuclei, a typical feature of this condition [45,46] (Fig 2.26). Other macrophages have a variety of cytological features, some of which may be quite blastic, causing concern about a lymphoma. Lymphocytes and granulocytes are rare within these lesions. Usually the centre of the nodule is necrotic but this is not invariable. All these features add up to one of the alternative names for this condition – ‘necrotising lymphadenitis without neutrophil polymorphs’. Immunostains are very helpful in confirming the histiocytic nature of the process with B and T cells being rare in the lesions, although there may be residual B-cell follicles surrounding them (Fig 2.27). Occasionally there is a surprising number of T cells, many of which are CD8+, which may cause concerns about a T-cell lymphoma (although CD8+ peripheral T-cell lymphomas are not so common). These are also not usually the large pleomorphic cells in the lesions but, in case of doubt, PCR for T-cell rearrangement should be requested. A proportion of the histiocytes is also myeloperoxidase positive which is very useful as a final confirmation of diagnosis [47].
Lupus lymphadenitis
CD68 Fig 2.20 In HIV infection the reaction of histiocytes to an overwhelming infection of atypical mycobacteria (ZN stain) can give rise to a sarcomatous reaction as illustrated. The histiocytic response is demonstrated by CD68 staining.
Lymphadenitis associated with SLE (systemic lupus erythematosus) is not common and usually occurs when the clinical syndrome is manifest and the diagnosis obvious. However, the histology of lupus lymphadenitis is very similar to that seen in Kikuchi disease (Fig 2.28). In fact it is so similar that many have speculated that they are at two ends of a clinical spectrum. The literature on the comparisons of these conditions is confusing but in general it seems that
37
Fig 2.21 This is an example of an HIV-related plasma cell variant of Castleman disease complicated by focal collections of Kaposi sarcoma. In the upper row both features can be seen in the low power view on the left, with higher power views of the Kaposi sarcoma in the middle and the plasma cell-rich Castleman disease on the right. The plasma cells are highlighted by antibody VS38 in the lower row left, with HHV8 staining of the Kaposi sarcoma and next to it adjacent ‘normal vessels’ (both shown in the middle lower panel), with the typical vascularisation of the follicles detailed by the antibody CD34 on the lower right.
Fig 2.22 Epstein–Barr virus infection typically causes a pure paracortical expansion, although a few large follicles may be present. The infiltrate consists of a mixture of blast cells and other reactive cell types. The blast cells are usually immunoblastic in cytology, although some may have a ‘Reed–Sternberglike’ appearance (black arrows).
EBV
CD20
CD30
CD3
CD8
LMP
EBER
Fig 2.23 Immunophenotype of Epstein–Barr virus (EBV) infection. The infiltrate is a mixture of B- and T-blast cells, the latter being predominantly CD8+. Some of the blasts are also CD30+ (any Reed–Sternberg-like cells are CD20+, CD30+ but CD15−). EBV can usually be demonstrated by immunostaining for LMP (latent membrane protein) or in situ for EBER (EBV RNA). Sometimes only the latter is positive.
Fig 2.24 Cytomegalovirus (CMV) infection is another less common infectious cause of paracortical expansion. The appearances may be similar to Epstein–Barr virus (EBV) infection but its nature can be confirmed by immunostaining for CMV antigens (far right figure). These lesions are almost always associated with a severe immunodeficiency.
CHAPTER 2
Reactive and Infective Conditions
Fig 2.25 Herpetic lymphadenitis is characterised by necrotic areas surrounded by plasma cells and immunoblasts. Within the necrotic areas are the infected cells seen in H&E with their inclusions and characteristic marginated nuclear chromatin (upper figures with high power insert). These cells are clearly highlighted by immunostaining with an anti-herpes antibody (lower figures).
40
CHAPTER 2
Reactive and Infective Conditions
Fig 2.26 The low-power views at the top of this figure show the loosely cohesive granulomatous lesions, some with and some without necrosis seen in Kikuchi disease lymphadenitis. At higher power in the lower row, the characteristic macrophages with crescentic nuclei and the admixture of other blastic cells are evident. Note the high amount of apoptotic debris that is characteristic of this disorder. Indeed such abundant apoptotic debris is seldom seen in lymphomas with which Kikuchi disease may be confused.
there are more neutrophil polymorphs and fewer CD8+ T cells in SLE, although estimating these in practice can be extremely subjective [48]. Plasma cells may be prominent in SLE and less conspicuous in Kikuchi disease. Occasionally, too clear evidence of vasculitis can be seen in affected lymph nodes which is rather rare in Kikuchi disease lymphadenitis. The presence of so-called haematoxylin bodies in the necrotic areas is also helpful because these at best are rare in Kikuchi disease lymphadenitis. These are small purple bodies seen both extracellularly and in macrophages in the necrotic areas.
Typhoid lymphadenitis Lymph nodes are rarely biopsied in this condition but, when they are, they show many features that remind one of Kikuchi disease lymphadenitis. In typhoid, however, the mononuclear phagocytes are even more prominent and may form well-circumscribed nodules (Fig 2.29). Within and around these infiltrates areas of necrosis are commonly seen. Further similarities with Kikuchi disease have been shown by J Chan (personal communication), in that these mononuclear macrophages are also positive for myeloperoxidase.
Dermatopathic lymphadenopathy Dermatopathic lymphadenopathy is a common cause of lymph node enlargement distal to chronic skin conditions which may be either inflammatory or neoplastic, especially mycosis fungoides. Lymph nodes show very characteristic focal areas of pale cells in the paracortex. The paleness is caused by an accumulation of dendritic cells of both Langerhans and interdigitating types. Admixed are variable numbers of lymphocytes and macrophages, some of which may contain melanin pigment, a characteristic feature of this lesion. Immunocytochemistry is helpful by showing that these pale cells are S100 protein, CD1a and CD207 (Langerin) positive [49] (Fig 2.30). In patients with mycosis fungoides it can be difficult to distinguish early infiltration from the reactive dendritic cells. T-cell gene rearrangement studies suggest that most patients with mycosis fungoides and dermatopathic lymphadenopathy do in fact have lymph node involvement that is just difficult to detect morphologically. As the mycosis progresses of course the lymph node involvement becomes increasingly obvious [50,51]. As neoplastic cells in mycosis fungoides have a tendency to lose the CD7 T-cell-associated antigen, the demonstration of a CD3+,
41
CHAPTER 2
Reactive and Infective Conditions
CD20
CD68
myeloperoxidase Fig 2.27 Immunostaining for B-cell antigens (CD20) shows the paracortical nature of this disorder. Macrophage markers such as CD68 highlight the nodules as histiocytic in nature. In Kikuchi disease these macrophages are characteristically positive for myeloperoxidase which can be very useful in identifying this disorder. Plasmacytoid dendritic cells are also increased and may be numerous in this disorder. These cells can be specifically labelled by newer markers such as CD123 or bcl11a.
42
CHAPTER 2
Reactive and Infective Conditions
Fig 2.28 This case came from a lymph node biopsy of a patient with severe systemic lupus erythematosus (SLE) taken to exclude associated malignancy. It shows significant areas of necrosis looking very similar to Kikuchi disease lymphadenitis (H&E at low power on top left). This similarity extends to the general lack of neutrophils and other lymphocytes, with the predominant cells being macrophages positive for CD68 (bottom left) and many crescentic and mononuclear forms being myeloperoxidase positive (bottom middle left). However, a careful search revealed evidence of vasculitis (top middle left) shown rather more clearly by CD31 immunostaining (left panel). The high-power haematoxylin and eosin (H&E)-stained image demonstrates the presence of haematoxylin bodies (right panel).
CD7− T-cell population is suggestive of neoplastic involvement of a lymph node.
Sinus hyperplasia
Drug-induced lymphadenopathy
Sinus histiocytosis
A long list of drugs can give rise to the syndrome of druginduced lymphadenopathy, of which phenytoin is the best known and most reported, although increasing numbers of cases are arising in patients treated with methotrexate for autoimmune disorders such as rheumatoid arthritis. The lymphadenopathy usually occurs within weeks of starting the drug, and typically is part of a constellation of systemic symptoms including fevers and skin rashes. Lymph node enlargement may occur in isolation, when it can be tricky to distinguish from lymphomas and as such has often acquired the label ‘pseudolymphoma’. A typical case shows marked paracortical expansion composed of a mixture of small-to-medium-sized reactive T cells admixed with polymorphic B-blast cells (Fig 2.31). The latter can be very abnormal and at times resemble Reed–Sternberg cells. The key to the diagnosis is that the proliferation does not destroy the underlying lymph node architecture and does not really look like any definite lymphoma subtype. When there is genuine doubt PCR for B- and T-cell gene rearrangements can be helpful. Excluding classic Hodgkin lymphoma is more testing because, although the blast cells express a full B-cell phenotype with CD30 and lack CD15, this can be seen on genuine cases of Hodgkin lymphoma too. Caution and careful clinicopathological discussions are needed.
This is a very common reaction pattern in lymph nodes draining a distant infection or tumour. The sinuses become dilated and filled with bland and unremarkable macrophages, few if any of which contain phagocytosed material (Fig 2.32). When examining such nodes draining cancers one needs to look carefully to ensure that small numbers of metastatic cells are not overlooked. Occasionally especially in children the sinuses can be filled with macrophages laden with red cells (and other cell types) as part of a presumed virally induced haemophagocytic syndrome [52] (Fig 2.33). This condition usually presents in the bone marrow and, by the time lymph nodes or spleen are involved, the prognosis is grave. There is now growing evidence implicating EBV in the pathogenesis of this condition [53].
Rosai–Dorfman disease This is also known as sinus histiocytosis with massive lymphadenopathy (SHML) [54]. It presents typically in children and adolescents with extensive painless bilateral cervical lymphadenopathy, often associated with other extranodal involvement in the skin, lung, gut, bone or brain. Systemic symptoms are common and include fever, anaemia, raised white cell counts and a polyclonal hypergammaglobulinaemia. Although generally benign, the course is often long and
43
CHAPTER 2
Reactive and Infective Conditions
CD68
Myeloperoxidase
Fig 2.29 In typhoid lymphadenitis there is a prominent infiltration of mononuclear macrophages forming nodular aggregates in areas. These may be associated with areas of necrosis. The immunophenotype of these macrophages is very similar to that seen in Kikuchi disease lymphadenitis being CD68 and myeloperoxidase positive. (Courtesy of Dr J Chan, Hong Kong.)
44
S100
CD1a
CD1a
Fig 2.30 Dermatopathic lymphadenopathy has a characteristic low-power appearance of paracortical expansion caused by the proliferation of interdigitating/Langerhans cells. These are clearly seen at higher powers, with elongated twisted nuclei interspersed with melanin-containing macrophages (black arrow). They are also visible in subcapsular sinuses (second row right), presumably coming in from the draining skin. Immunostaining shows the characteristic phenotype of S100 and CD1a positivity. CD207 (Langerin) gives very similar results to CD1a indicating that either can be used reliably for diagnosis [49].
45
Fig 2.31 Drug-induced lymphadenopathy associated with methotrexate treatment of rheumatoid arthritis. The HEs at different powers on the top row show the paracortical expansion of the node by a polymorphic collection of lymphoid cells. Immunostains for CD3 (bottom left at low and high power) show a proliferation of reactive T cells, with the larger blast cells being of B-cell (CD20+) origin (bottom right at low and high power).
H&E
CD68
Fig 2.32 Two examples of sinus histiocytosis with the macrophages highlighted in the sinuses by CD68 immunostaining
CHAPTER 2
Reactive and Infective Conditions
around these invaginated cells. The rest of the lymph node is usually unremarkable, although there are huge numbers of plasma cells and some areas of fibrosis as well as capsular fibrosis. Immunostains for histiocytic markers such as CD68 may be useful to identify the enlarged cells as macrophages [55,56]. These cells also stain for S100 protein but are CD1a negative. An S100 stain can be very helpful for highlighting the emperipolesis (Fig 2.34).
Lymphangiography effect and silicon deposition Insoluble oils and foreign materials such as silicon may cause significant and dramatic sinus histiocytosis when they leak into the tissues. This may be deliberate as in the injection of iodised oils for diagnostic lymphangiograms (Fig 2.35) or by accident when a silicon-based implant leaks (Fig 2.36). If the source of the material is removed these lesions usually remit on their own, although there has been considerable speculation about long-term toxicity, especially with regard to leaking implants. A number of other foreign materials may accumulate in lymph nodes including tattoo pigments, polyvinylpyrrolidone (PVP) (which is contained in a number of drugs) and products derived from surgical material such as cellulose from the degradation of gauze inadvertently left behind after an operation.
Tattoos
Fig 2.33 Haemophagocytic syndrome showing red cell-laden macrophages in the sinuses of lymph node (top left) and spleen (top right), with a higher power view in the top centre. Immunostaining for CD68 (bottom with insert) demonstrates the histiocytic nature of these phagocytes and shows that the red cells are within these cells.
Inks and pigments from tattoos always leak into the lymphatics and may cause confusion with the diagnosis when lymph nodes are biopsied for other reasons. Indeed the accumulation of pigment in histiocytes may itself give rise to lymphadenopathy. The trick when faced with apparent black carbon deposits in lymph nodes (other than pulmonary of course) is to look for evidence of coloured pigments usually green, blue or turquoise. These are practically diagnostic of tattoos (Fig 2.37).
Granulomatous conditions relapsing and many forms of therapy (mostly without success) have been tried to stop or ameliorate this. A small percentage of cases end in death usually by infection resulting from immunosuppression. Histologically the nodes are characterised by the sinuses being grossly dilated by huge numbers of large macrophages, often with foamy cytoplasm. The histiocytes typically have vesicular nuclei that have a thin nuclear membrane and prominent nucleoli. Their cytoplasm may be filled with lymphocytes and occasionally other cells such as polymorphs or plasma cells. These are not being phagocytosed but are just invaginated into the cytoplasm, a process called emperipolesis (often displayed by megakaryocytes in the bone marrow in a variety of reactive settings). There is often a clear space
Tuberculosis Mycobacterium tuberculosis is extremely widespread as an infectious agent throughout the world and is re-emerging as a cause of lymphadenopathy in western countries due to HIV infection, homelessness and intravenous drug use. Atypical forms, especially Mycobacterium avium-intracellulare, are also becoming more common in AIDS patients. Tuberculosis is characterised by multiple well-formed granulomas arising in the interfollicular areas but progressively crushing the rest of the node [57]. The granulomas are foci of epithelioid histiocytes with Langhans-type giant cells often surrounded by a collar of T cells. B-cell follicular remnants can usually be appreciated only by immunostaining. The centre of the granulomas may be necrotic (caseous
47
CHAPTER 2
Reactive and Infective Conditions
nodal
CD68
CD45 GI tract Fig 2.34 Two cases of nodal and one of extranodal Rosai–Dorfman disease. The masses of enlarged macrophages through which lymphoid cells are passing are clearly visible. They may be more dramatically illustrated by immunostaining for macrophages with CD68 or with lymphoid markers such as CD45, the leukocyte common antigen.
48
CHAPTER 2
Reactive and Infective Conditions
lymph node
CD68 Spleen
CD68 Fig 2.35 Oil-based contrast dyes used to be employed routinely for lymphangiography in the staging of Hodgkin lymphoma and gave rise to the florid sinus histiocytosis seen in this figure.
49
CHAPTER 2
Reactive and Infective Conditions
CD68 Fig 2.36 Similar appearances to those of a lymphangiogram are more commonly seen today in axillary lymph nodes draining a leaking breast implant.
necrosis) and the numbers of organisms are usually small and have to be searched for carefully. Atypical tuberculosis, on the other hand, may have few granulomatous areas with the lymph nodes often replaced by diffuse sheets of epithelioid histiocytes, with few giant cells and little or no necrosis [22]. In contrast to classic tuberculosis acid-fast bacilli are very numerous in the histiocytes and can often be appreciated on the routine stains alone (Fig 2.38).
Leprosy Although an important condition in developing countries, especially in rural parts of India, leprosy lymphadenitis is rarely encountered in the west. There are two forms of the disease, which each give a different picture in lymph nodes. Lepromatous leprosy causes lymphadenopathy by expanding the interstitial areas with large numbers of foamy mac-
50
rophages. in which acid-fast leprosy bacilli can often be identified (Fig 2.39). Tuberculoid leprosy simulates tuberculosis with large areas of epithelioid granulomas, although unlike tuberculosis necrosis is uncommon. Leprosy bacilli are rarely identified in this form of the disease.
Sarcoidosis Sarcoidosis is a relatively uncommon granulomatous disorder of mysterious origins, although there are marked differences of incidence in different geographical regions. In the USA, it is especially prevalent in young black women [58]. Any organ may be involved but lungs and lymph nodes (especially those in the mediastinum and pulmonary hilum) are the most common. The course of the disease is highly variable and, although most run a relatively benign course, some patients end up with progressive pulmonary fibrosis [59].
CHAPTER 2
Reactive and Infective Conditions
weeks, lymphadenopathy occurs in the draining area. This is often associated with systemic symptoms such as fever. The condition is usually self-limiting and resolves over a further period of weeks. It is a bacterial infection caused by Bartonella henselae [60] which can sometimes be detected by silver staining, although they are very small and indistinct and the number of organisms is generally low in most biopsied nodes. Serology and/or PCR is currently the most reliable method of confirming this diagnosis, although a recently described monoclonal antibody working well on paraffin sections looks very promising [61] (Fig 2.41). Lymph nodes are usually biopsied when the condition has been present for some time. In these cases the typical pathological features of large perifollicular or paracortical suppurative granulomas or stellate microabscesses are seen [62]. These contain purulent material rich in polymorphs and are surrounded by a so-called palisade of histiocytes. At this stage organisms are very rarely seen by silver staining. As a result of this, in those cases where the polymorphs are scarce, the appearances can closely mimic tuberculosis and great care is needed in establishing the correct diagnosis. If the lymph node is biopsied early on in the process, the features are purely those of a non-specific reactive follicular hyperplasia. Now the organisms are often numerous and readily detectable if the condition is considered in the differential diagnosis (Fig 2.42).
Fig 2.37 Typical appearances of a tattoo in a lymph node with the sinusoidal localisation of the pigments within macrophages. Note, at higher power in the insert and below, the different coloured pigments used.
Sarcoidosis typically replaces the tissue or lymph node with multiple interlocking granulomas usually without any evidence of true caseation, although foci of central necrosis (often showing fibrin-like structures) are reasonably frequent. Multinucleate giant cells are present and often contain characteristic inclusions that are star shaped (asteroid bodies) or round (Schaumann bodies), although these are not specific for this disease. These granulomas are almost always surrounded by dense fibrosis (hyaline sclerosis) (Fig 2.40). Sarcoidosis, except in areas with a high incidence, remains a diagnosis of exclusion. The full range of infective and neoplastic conditions that can give rise to granulomatous inflammation should be excluded alongside careful clinical liaison before the diagnosis is accepted.
Cat-scratch fever This disease is caused, just as its name says, by cat (or more often kitten) scratches. Some time later, which may be
Lymphogranuloma venereum Lymphogranuloma venereum is caused by the sexually transmitted bacterium Chlamydia trachomatis. The inguinal lymphadenopathy is normally preceded by genital cutaneous rashes and ulcers. Systemic symptoms such as fevers and myalgias are common. The lymph node pathology is indistinguishable from late cat-scratch fever so that, if the diagnosis is not obvious clinically, the distinction needs to be made by serology or PCR testing for the relevant organisms.
Whipple disease (intestinal lipodystrophy) This chronic disease is not restricted to the bowel. Mesenteric and even peripheral lymphadenopathy is common. The lymph nodes are enlarged due to distended sinuses which may simulate a lymphangiogram effect, in particular on frozen section examination. Characteristically there is an accumulation of macrophages that usually predominates in the lymph node pulp close to sinuses. These histiocytes show epithelioid features and epithelioid granulomas may be present. As seen in jejunal biopsy specimens, the cytoplasm of histiocytes contains large amounts of periodic acid– Schiff (PAS)-positive lipids (Fig 2.43). These bacilliform bodies are believed to belong to the bacterium Tropheryma whipplei, although this still needs to be to be formally confirmed.
51
CHAPTER 2
Reactive and Infective Conditions
caseous necrosis
ZN
CD68
CD20 ZN
AIDs related Fig 2.38 The top two rows show the appearances of tuberculosis in an immunocompetent individual. Granulomas are typically associated with multinucleate giant cells (black arrow) and caseous necrosis (white arrow). Staining for the B-cell marker CD20 shows the paracortical location and CD68 immunostaining confirms the histiocytic nature of the granulomas. Acid-fast bacilli are few in number (Ziehl–Neelsen stain). In immunodeficient individuals (bottom row) such as in those with AIDS the picture is different. Granulomas are less defined, lack necrosis and giant cells, and acid-fast bacilli are numerous.
52
CHAPTER 2
Reactive and Infective Conditions
Fig 2.39 Lepromatous leprosy showing the interstitial infiltration at low power (top left) of foamy eosinophilic macrophages (top right and bottom left). An acid-fast (Fite-Faraco) stain shows numerous intracellular bacteria. (Courtesy of Professor R. Dorfman, Stanford, USA.)
Fungal Lymphadenitis arising from fungal infection is usually associated with immunosuppression from HIV, malignancy or chemotherapy. The features seen depend somewhat on the severity of the immunodeficiency. If this is relatively mild (or in the rare normal host) a typical granulomatous inflammatory response with central necrosis and giant cells may be seen. In contrast, severely immunodeficient patients may just have a node replaced by diffuse sheets of macrophages and lymphocytes associated with huge numbers of fungi. The most common agents are histoplasma and cryptococci, both of which are readily demonstrable with silver or PAS stains in lymph nodes, both granulomatous and diffuse.
Lipidoses and other depositions These are all very rare conditions affecting lymph nodes and include Gaucher and Niemann–Pick diseases. When encoun-
tered the lymph node sinuses are filled with large lipidcontaining macrophages which may coalesce to give a granuloma-like reaction. The diagnosis is most likely to have been made clinically or on a bone marrow biopsy already. Other depositions that may give granuloma-like reactions include amyloidoisis and a variety of other proteins and foreign body materials.
Lymph node inclusions such as nevus cell inclusion Inclusions in the capsules of lymph nodes can be very disconcerting when other diagnoses are being considered. The two most common ones are accumulations of nevus cells and ectopic localisation of salivary (in neck) or mammary (axillary) glands. All of these can be misdiagnosed if one neglects to consider that malignant cells really do not localise exclusively in the capsule (Fig 2.44).
53
CHAPTER 2
CD68
Reactive and Infective Conditions
CD20
Fig 2.40 Many of the features of sarcoidosis are similar to tuberculosis but granulomas are usually smaller without necrosis. Once again the location is paracortical (white arrow and CD20). As the disease develops the lymph node may become progressively hyalinised (black arrow). CD68 defines the granulomas as histiocytic in origin.
54
CHAPTER 2
Reactive and Infective Conditions
Late form
CD68
CD15
Early form
CD15
CD20
CD68
Fig 2.41 The most common picture of cat-scratch disease encountered in practice is that seen in the late form on the left. Here the large stellate granulomas are composed of a rim of macrophages (CD68) surrounding a suppurative centre filled with necrotising macrophages and polymorphs (CD15). Below are the features seen in early stages of the disease, where the picture is largely that of non-specific follicular hyperplasia. Careful analysis with immunostains will often show the developing granulomas (CD15). In the bottom row monocytoid B cells are illustrated accumulating in the subcapsular sinuses. This feature is of course most commonly seen in toxoplasmosis.
55
CHAPTER 2
Reactive and Infective Conditions
Fig 2.42 It is now possible to immunostain for Bartonella henselae reliably in paraffin sections.
Fig 2.44 Benign glandular inclusions in an axillary lymph node that should not be mistaken for malignant deposits.
References
Fig 2.43 Case of Whipple disease in the lymph node showing the sinusoidal localisation of the granulomas (H&E above) which consist of periodic acid–Schiff (PAS)-positive histiocytes (bottom left) within which PAS-positive bacilliform figures can be seen (bottom right).
56
1. Dorfman RF, Warnke R. Lymphadenopathy simulating the malignant lymphomas. Hum Pathol 1974;5:519–50. 2. McCabe RE, Brooks RG, Dorfman RF, Remington JS. Clinical spectrum in 107 cases of toxoplasmic lymphadenopathy. Rev Infect Dis 1987;9:754–74. 3. Dorfman RF, Remington JS. Value of lymph-node biopsy in the diagnosis of acute acquired toxoplasmosis. N Engl J Med 1973;289:878–81. 4. Weiss LM, Chen YY, Berry GJ, Strickler JG, Dorfman RF, Warnke RA. Infrequent detection of Toxoplasma gondii genome in toxoplasmic lymphadenitis: a polymerase chain reaction study. Hum Pathol 1992;23:154–8. 5. Frizzera G. Castleman’s disease and related disorders. Semin Diagn Pathol 1988;5:346–64. 6. Castleman B, Iverson L, Pardo Menendez V. Localised mediastinal lymph node hyperplasia resembling thymoma. Cancer 1956;9:822–30. 7. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood 2008;111:3778–92. 8. Radaszkiewicz T, Hansmann ML, Lennert K. Monoclonality and polyclonality of plasma cells in Castleman’s disease of the plasma cell variant. Histopathology 1989;14:11–24. 9. Soulier J, Grollet L, Oksenhendler E, et al. Molecular analysis of clonality in Castleman’s disease. Blood 1995;86:1131–8. 10. Hall PA, Donaghy M, Cotter FE, Stansfeld AG, Levison DA. An immunohistological and genotypic study of the plasma cell form of Castleman’s disease. Histopathology 1989;14:333–46; discussion 429–32. 11. Cannon M, Cesarman E. Kaposi’s sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. Semin Oncol 2000;27:409–19. 12. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcomaassociated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995;86:1276–80.
CHAPTER 2
13. Brousset P, Cesarman E, Meggetto F, Lamant L, Delsol G. Colocalization of the viral interleukin-6 with latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells of Kaposi’s sarcoma and lymphoid cells of multicentric Castleman’s disease. Hum Pathol 2001;32:95–100. 14. O’Leary J, Kennedy M, Howells D, et al. Cellular localisation of HHV-8 in Castleman’s disease: is there a link with lymph node vascularity? Mol Pathol 2000;53:69–76. 15. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 1978;31:691–6. 16. Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26:794–804. 17. Kondratowicz GM, Symmons DP, Bacon PA, Mageed RA, Jones EL. Rheumatoid lymphadenopathy: a morphological and immunohistochemical study. J Clin Pathol 1990;43:106–13. 18. Hartsock RJ, Halling LW, King FM. Luetic lymphadenitis: a clinical and histologic study of 20 cases. Am J Clin Pathol 1970; 53:304–14. 19. Hui PK, Chan JK, Ng CS, Kung IT, Gwi E. Lymphadenopathy of Kimura’s disease. Am J Surg Pathol 1989;13:177–86. 20. Googe PB, Harris NL, Mihm MC. Kimura’s disease and angiolymphoid hyperplasia with eosinophilia: two distinct histopathological entities. J Cutan Pathol 1987;14:263–71. 21. Chan JK, Hui PK, Ng CS, Yuen NW, Kung IT, Gwi E. Epithelioid haemangioma (angiolymphoid hyperplasia with eosinophilia) and Kimura’s disease in Chinese. Histopathology 1989;15: 557–74. 22. Strauchen J. Diagnostic Histopathology of the Lymph Node. New York: Oxford University Press, 1998. 23. Ferry JA, Zukerberg LR, Harris NL. Florid progressive transformation of germinal centers. A syndrome affecting young men, without early progression to nodular lymphocyte predominance Hodgkin’s disease. Am J Surg Pathol 1992;16:252–8. 24. Osborne BM, Butler JJ, Gresik MV. Progressive transformation of germinal centers: comparison of 23 pediatric patients to the adult population. Mod Pathol 1992;5:135–40. 25. Burns B, Colby T, Dorfman R. Differential diagnostic features of nodular L&H Hodgkin’s disease, including progressive transformation of germinal centers. Am J Surg Pathol 1984;8: 253–61. 26. Poppema S, Kaiserling E, Lennert K. Hodgkin’s disease with lymphocytic predominance, nodular type (nodular paragranuloma) and progressively transformed germinal centres–a cytohistological study. Histopathology 1979;3:295–308. 27. Crossley B, Heryet A, Gatter KC. Does nodular lymphocyte predominant Hodgkin’s disease arise from progressively transformed germinal centres? A case report with an unusually prolonged history. Histopathology 1987;11:621–30. 28. Metroka CE, Cunningham-Rundles S, Pollack MS, et al. Generalized lymphadenopathy in homosexual men. Ann Intern Med 1983;99:585–91. 29. Center for Control of Diseases. Persistent generalised lymphadenopathy among homosexual males. MMWR 1982;31:249–51. 30. Guettier C, Gatter KC, Heryet A, Mason DY. Dendritic reticulum cells in reactive lymph nodes and tonsils: an immunohistological study. Histopathology 1986;10:15–24.
Reactive and Infective Conditions
31. Brousset P, Marchou B, Chittal SM, Delsol G. Concomitant Mycobacterium avium complex infection and Epstein–Barr virus associated Hodgkin’s disease in a lymph node from a patient with AIDS. Histopathology 1994;24:586–8. 32. Strickler JG, Fedeli F, Horwitz CA, Copenhaver CM, Frizzera G. Infectious mononucleosis in lymphoid tissue. Histopathology, in situ hybridization, and differential diagnosis. Arch Pathol Lab Med 1993;117:269–78. 33. Abbondanzo SL, Sato N, Straus SE, Jaffe ES. Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologic correlations. Am J Clin Pathol 1990;93:698–702. 34. Salvador AH, Harrison EG, Kyle RA. Lymphadenopathy due to infectious mononucleosis: its confusion with malignant lymphoma. Cancer 1971;27:1029–40. 35. Gaffey MJ, Ben-Ezra JM, Weiss LM. Herpes simplex lymphadenitis. Am J Clin Pathol 1991;95:709–14. 36. Miliauskas JR, Leong AS. Localized herpes simplex lymphadenitis: report of three cases and review of the literature. Histopathology 1991;19:355–60. 37. Tamaru J, Mikata A, Horie H, et al. Herpes simplex lymphadenitis. Report of two cases with review of the literature. Am J Surg Pathol 1990;14:571–7. 38. Wat PJ, Strickler JG, Myers JL, Nordstrom MR. Herpes simplex infection causing acute necrotizing tonsillitis. Mayo Clin Proc 1994;69:269–71. 39. Doody MM, Linet MS, Glass AG, et al. Leukemia, lymphoma, and multiple myeloma following selected medical conditions. Cancer Causes Control 1992;3:449–56. 40. Higgins JP, Warnke RA. Herpes lymphadenitis in association with chronic lymphocytic leukemia. Cancer 1999;86:1210–5. 41. Mariette X, Molina JM, Asli B, Brouet JC. A patient with chronic lymphoid leukemia and recurrent necrotic herpetic lymphadenitis. Am J Med 1999;107:403–4. 42. Kikuchi M. Lymphadenitis showing focal reticulum cell hyperplasia with nuclear debris and phagocytes. Acta Hematol Jpn 1972;35:379–80. 43. Pileri S, Kikuchi M, Helbron D, Lennert K. Histiocytic necrotizing lymphadenitis without granulocytic infiltration. Virchows Arch A Pathol Anat Histol 1982;395:257–71. 44. Chan JK, Wong KC, Ng CS. A fatal case of multicentric Kikuchi’s histiocytic necrotizing lymphadenitis. Cancer 1989; 63:1856–62. 45. Rivano MT, Falini B, Stein H, et al. Histiocytic necrotizing lymphadenitis without granulocytic infiltration (Kikuchi’s lymphadenitis). Morphological and immunohistochemical study of eight cases. Histopathology 1987;11:1013–27. 46. Tsang WY, Chan JK, Ng CS. Kikuchi’s lymphadenitis. A morphologic analysis of 75 cases with special reference to unusual features. Am J Surg Pathol 1994;18:219–31. 47. Pileri S, Facchetti F, Ascani S, et al. Myeloperoxidase expression by histiocytes in Kikuchi’s and Kikuchi-like lymphadenopathy. Am J Pathol 2001;159:915–24. 48. Hu S, Kuo TT, Hong HS. Lupus lymphadenitis simulating Kikuchi’s lymphadenitis in patients with systemic lupus erythematosus: a clinicopathological analysis of six cases and review of the literature. Pathol Int 2003;53:221–6 49. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol 2008;32:615–19.
57
CHAPTER 2
Reactive and Infective Conditions
50. Weiss LM, Hu E, Wood GS, et al. Clonal rearrangements of T-cell receptor genes in mycosis fungoides and dermatopathic lymphadenopathy. N Engl J Med 1985;313:539–44. 51. Weiss LM, Wood GS, Warnke RA. Immunophenotypic differences between dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides. Am J Pathol 1985; 120:179–85. 52. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979;44: 993–1002. 53. Gaffey MJ, Frierson HF Jr, Medeiros LJ, Weiss LM. The relationship of Epstein–Barr virus to infection-related (sporadic) and familial hemophagocytic syndrome and secondary (lymphomarelated) hemophagocytosis: an in situ hybridization study. Hum Pathol 1993;24:657–67. 54. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol 1969;87:63–70. 55. Sacchi S, Artusi T, Torelli U, Emilia G. Sinus histiocytosis with massive lymphadenopathy. Leuk Lymphoma 1992;7:189–94.
58
56. Eisen RN, Buckley PJ, Rosai J. Immunophenotypic characterization of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Semin Diagn Pathol 1990;7:74–82. 57. Dandapat MC, Mishra BM, Dash SP, Kar PK. Peripheral lymph node tuberculosis: a review of 80 cases. Br J Surg 1990; 77:911–2. 58. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224–34. 59. Barnard J, Newman LS. Sarcoidosis: immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol 2001; 13:84–91. 60. Adal KA, Cockerell CJ, Petri WA. Cat scratch disease, bacillary angiomatosis, and other infections due to Rochalimaea. N Engl J Med 1994;330:1509–15. 61. Cheuk W, Chan AK, Wong MC, Chan JK. Confirmation of diagnosis of cat scratch disease by immunohistochemistry. Am J Surg Pathol 2006;30:274–5. 62. Ferry J, Harris N. Atlas of Lymphoid Hyperplasia and lymphoma. Philadelphia: WB Saunders, 1997.
3
An Introduction to Lymphoma Diagnosis
In the last few decades lymphoma classification has been parodied mercilessly as captured in the wisecrack ‘only three things are certain in life: birth, death and changes in lymphoma classification’. That has now changed with the publication of the REAL classification [1] and its general acceptance into the current World Health Organization (WHO) classification of lymphoid neoplasms (Table 3.1) [2]. This puts lymphoma classification on a firm basis of diagnosing clinical entities using all of the available data as required, and this approach is taken throughout this book. Clinical studies to date show that this approach is helpful and reliable [3,4]. This text does not dwell further on the background to the so-called ‘lymphoma wars’ because there are several good references available for those interested [5–8]. The only aspect worth emphasising is that one of the major strengths of the REAL and WHO classifications is the flexibility to incorporate new data and to make changes, as most recently shown in the 2008 version of the WHO classification [9]. Pathologists should never again try to have almost biblical allegiances to one or other guru’s views but to judge issues on the facts or the ‘data set’ as it is now often called.
of different entities. Although there is variability around the world, the non-Hodgkin lymphoma classification project set up to evaluate the REAL classification in the mid-1990s enlisted eight centres from different areas [4]. This allowed one of the best bird’s-eye views of relative numbers of lymphomas available. Basically only eight entities made it above 2% with any of the others being extremely rare (Table 3.2). Subsequent analyses by different lymphoma groups have broadly agreed with this project; occasionally Burkitt and lymphoblastic lymphoma make it above the 2% waterline and are added below. This means that familiarity with 10 reasonably straightforward entities (peripheral T cell being a possible exception) will enable any pathologist to deal with the bulk of his or her work in lymphoid neoplasms. It would be quite reasonable to send the rest (±10% of the workload) for consultation to the most accessible and amenable expert. This, of course, depends on the conditions and requirements in different countries, which is a matter currently under debate in several. If money were no object there might be a specialist haematopathologist for every 1000 or so lymphoid biopsies per annum who would not need this book anyway! However, we are writing this for the real world so will dwell no longer with the fairies.
The relative frequency of the different lymphomas Some of the sting is taken out of the complexity of lymphoma diagnosis when one looks at the relative frequency
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
59
CHAPTER 3
An Introduction to Lymphoma Diagnosis
Table 3.1 The WHO classification of lymphoid and related malignancies Precursor lymphoid neoplasms B-lymphoblastic leukemia/lymphoma B-lymphoblastic leukemia/lymphoma, not otherwise specified B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities B-lymphoblastic leukemia/lymphoma with t(9;22)(q34;q11.2); BCR-ABL1 B-lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged B-lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-RUNX1) B-lymphoblastic leukemia/lymphoma with hyperdiploidy B-lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL) B-lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1; (TCF3-PBX1) T-lymphoblastic leukemia/lymphoma Mature B-cell neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma B-cell prolymphocytic leukemia Splenic marginal zone lymphoma Hairy cell leukemia Splenic lymphoma/leukemia, unclassifiable Splenic diffuse red pulp small B-cell lymphoma Hairy cell leukemia – variant Lymphoplasmacytic lymphoma Waldenström macroglobulinemia Heavy chain diseases α heavy chain disease γ heavy chain disease μ heavy chain disease Plasma cell myeloma Solitary plasmacytoma of bone Extraosseous plasmacytoma Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) Nodal marginal zone lymphoma Pediatric nodal marginal zone lymphoma Follicular lymphoma Pediatric follicular lymphoma Primary cutaneous follicle center lymphoma Mantle cell lymphoma Diffuse large B-cell lymphoma (DLBCL) and variants Diffuse large B-cell lymphoma (DLBCL), not otherwise specified T-cell/histiocyte-rich large B-cell lymphoma Primary DLBCL of the CNS Primary cutaneous DLBCL, leg type EBV-positive DLBCL of the elderly DLBCL associated with chronic inflammation Lymphomatoid granulomatosis Primary mediastinal (thymic) large B-cell lymphoma Intravascular large B-cell lymphoma ALK-positive DLBCL Plasmablastic lymphoma Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease Primary effusion lymphoma Burkitt lymphoma B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma
60
CHAPTER 3
An Introduction to Lymphoma Diagnosis
Table 3.1 (continued) Mature T-cell and NK cell neoplasms T-cell prolymphocytic leukemia T-cell large granular lymphocytic leukemia Chronic lymphoproliferative disorder of NK cells Aggressive NK cell leukemia Systemic EBV-positive T-cell lymphoproliferative disease of childhood Hydroa vaccineforme-like lymphoma Adult T-cell leukemia/lymphoma Extranodal NK/T-cell lymphoma, nasal type Enteropathy-associated T-cell lymphoma Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Mycosis fungoides Sézary syndrome Primary cutaneous CD30+ T-cell lymphoproliferative disorders Lymphomatoid papulosis Primary cutaneous anaplastic large cell lymphoma Primary cutaneous γ/δ T-cell lymphoma Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma Primary cutaneous CD4+ small/medium T-cell lymphoma Peripheral T-cell lymphoma, not otherwise specified Angio-immunoblastic T-cell lymphoma Anaplastic large cell lymphoma, ALK positive Anaplastic large cell lymphoma, ALK negative Hodgkin lymphoma Nodular lymphocyte-predominant Hodgkin lymphoma Classic Hodgkin lymphoma Nodular sclerosis classic Hodgkin lymphoma Lymphocyte-rich classic Hodgkin lymphoma Mixed cellularity classic Hodgkin lymphoma Lymphocyte-depleted classic Hodgkin lymphoma Histiocytic and dendritic cell neoplasms Histiocytic sarcoma Langerhans cell histiocytosis Langerhans cell sarcoma Interdigitating dendritic cell sarcoma Follicular dendritic cell sarcoma Fibroblastic reticular cell tumor Indeterminate dendritic cell tumor Disseminated juvenile xanthogranuloma Other blastic disorders Myeloid sarcoma Blastic plasmacytoid dendritic cell neoplasm Post-transplant lymphoproliferative disorders (PTLD) Early lesions Plasmacytic hyperplasia Infectious mononucleosis-like PTLD polymorphic PTLD monomorphic PTLD (B- and T/NK- cell types) Classic Hodgkin lymphoma type PTLD
61
CHAPTER 3
An Introduction to Lymphoma Diagnosis
Table 3.2 The frequency of different lymphoma subtypes seen in clinical practice Lymphoma type
Frequency (%)
Diffuse large B cell Follicular Marginal zone lymphoma Peripheral T cell Chronic lymphocytic leukaemia Mantle cell lymphoma Mediastinal B cell Anaplastic large cell Burkitt lymphoma Lymphoblastic lymphoma
31 22 8 7 7 6 2 2 2 2
References 1. Harris NL, Jaffe ES, Stein H, et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood 1994;84:1361–92.
62
2. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press, 2008. 3. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the Revised European–American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood 1997;89:4514–20. 4. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997;89:3909–18. 5. Mason DY, Gatter KC. Not another lymphoma classification! Br J Haematol 1995;90:493–7. 6. Mason D, Gatter K. The Pocket Guide to Lymphoma Classification. Oxford: Blackwells, 1998. 7. Isaacson PG. The current status of lymphoma classification. Br J Haematol 2000;109:258–66. 8. Mason D, Harris N, eds. Human Lymphoma: Clinical implications of the REAL classification. London: Springer, 1999. 9. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009: 523–31.
4
B-cell Lymphoblastic Leukaemia/Lymphoma
This is a blastic proliferation of precursor B cells that may produce a tissue infiltration (lymphoma), and involve blood and bone marrow (leukaemia–acute lymphoblastic leukaemia [ALL]) or both. A figure of 25% blasts in the bone marrow is often used as the clinical criterion for the definition of ALL.
Clinical features B-lymphoblastic neoplasms most commonly present in childhood as common acute lymphoblastic leukaemia. Presentations as lymphoma are infrequent but most often involve skin, bone or lymph node and may occur at any age.
Histology Lymphoblastic lymphoma/leukaemia consists of mediumsized cells with scanty cytoplasm, most of the cell being occupied by the nucleus (Fig 4.1). These have a primitive structure with very fine chromatin and several small nucleoli, often described as ‘salt and pepper like’ in appearance. Although typically thought of as a monotonous infiltration, it is often surprising how pleomorphic these nuclei can be. Typically, tissues are just overwhelmed by the infiltration, although sometimes a pattern of single cell infiltration is seen which is reminiscent of that seen in lobular carcinoma of the breast. Mitoses are common and areas of necrosis and starry sky macrophages may be seen.
Blood involvement Blasts cells in the blood and bone marrow are commonly seen in the course of most lymphoblastic lymphomas. In fact, the cut-off between lymphoma and leukaemia is quite arbitrary, with some paediatric oncology groups considering only neoplasms with more than 25% bone marrow infiltra-
tion as leukaemia whereas anything less than 10% blast cells in the blood of adults is a lymphoma [1,2].
Immunophenotype B lymphoblasts have a characteristic phenotype of positivity for TdT (terminal deoxynucleotidyl transferase), CD10, CD19, CD22, CD43, PAX5 and CD79a (Table 4.1 and Fig 4.2). About 50% of cases are also positive for CD34(3). CD45 is often weak or absent, especially in paraffin sections. Of note in paraffin section studies is that the commonly used B-cell marker, CD20, is absent in approximately 50% of cases. Proliferation markers such as Ki67 show a high growth fraction, but with rarely more than 70–80% of cells positive. Increasing numbers of bi- or multiphenotypic acute leukaemias are being described as larger series of cases are being immunotyped. Cases of acute leukaemia with both B-cell and myeloid markers, including myeloperoxidase and CD117 (cKIT), are not infrequent and lesions sharing B- and T-cell antigens have been described [4,5]. Some of these cases are probably better placed in the new World Health Organization (WHO) category of acute leukaemias of ambiguous lineage, although there continues to be too little information about these cases to know whether they are or are not genuinely distinct entities.
Cytogenetics Cytogenetic abnormalities can be detected in most cases though they are quite variable and cover a wide range of different chromosomes. As denoted in the 2008 WHO classification, a number of cases of B-lymphoblastic leukaemia/ lymphoma with recurrent genetic abnormalities are recognized as a distinct subcategory, mainly because they have distinct prognostic implications [6–9]. Briefly these can be described as follows.
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
63
CHAPTER 4
B-cell Lymphoblastic Leukaemia/Lymphoma
Low power
High power
Giemsa
Fig 4.1 Both Giemsa and haematoxylin and eosin (H&E) stains show the typical infiltrative pattern of small- to medium-sized blastic cells. The higher powers show the typical pleomorphism of the blasts on histology that sometimes surprises those used to seeing them in cytological preparations such as blood or bone marrow smears.
H&E
Table 4.1 Comparison of the immunophenotypes of B-lymphoblastic lymphoma with its main differential diagnoses
B lymphoblastic T lymphoblastic Mantle cell blastic Acute myeloid leukaemia
CD20
CD79a
PAX5
CD3
CD5
CD10
TdT
CD34
Cyclin D1
± − + ±
+ ± + ±
+ − + ±
− + − −
− + + −
+ + − −
+ + − ±
± ± − ±
− − + −
Poor prognosis • B-lymphoblastic leukemia/lymphoma with t(9;22) (q34;q11.2); BCR-ABL1 • B-lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged • B-lymphoblastic leukemia/lymphoma with hypodiploidy (hypodiploid ALL).
Good prognosis • B lymphoblastic leukemia/lymphoma with t(12;21) (p13;q22); TEL-AML1 (ETV6-RUNX1) • B lymphoblastic leukemia/lymphoma with hyperdiploidy.
These cases are usually identified by cytogeneticists using standard karyotyping or fluorescent in situ hybridisation (FISH) techniques. For the pathologist they look identical to other B-lymphoblastic leukemia/lymphoma cases and have the same immunophenotype. A possible clue to B-lymphoblastic leukemia/lymphoma with t(v;11q23); MLL rearranged is that, unlike the other cytogenetic variants and most other standard cases, it is generally CD10−. Most cases of lymphoblastic B-cell lymphoma show immunoglobulin heavy chain rearrangement and a significant number also show T-cell γ gene rearrangement [10,11].
Unchanged prognosis • B-lymphoblastic leukemia/lymphoma (q31;q32); IL3-IGH • B-lymphoblastic leukemia/lymphoma (q23;p13.3); E2A-PBX1; (TCF3-PBX1).
64
with
t(5;14)
Differential diagnosis
with
t(1;19)
On morphological grounds alone, a number of tumours may mimic lymphoblastic B-cell lymphoma.
CHAPTER 4
CD79a
B-cell Lymphoblastic Leukaemia/Lymphoma
CD20
CD10
CD34
TdT
Proliferation
Fig 4.2 The typical and characteristic immunophenotype of B-lymphoblastic lymphoma. All cases are CD79a, CD10 and TdT positive, but only half show staining for CD20 (a positive and a negative case are illustrated here) and/or CD34. Staining for proliferation-associated markers such as Ki67 is often surprisingly low for such an aggressive tumour. The example shown here is only about 50% positive.
T-cell lymphoblastic lymphoma (see Chapter 5) In common with B-cell lymphoblastic lymphoma, these neoplasms are almost always positive for TdT and express CD10 and CD43 antigens. Approximately 40–50% of these tumours also express the ‘B-cell’ antigen CD79a [12,13]. However, the expression of CD3, often in association with other T-cell antigens (CD1a, CD2, CD4, CD5, CD8), is indicative of the T-cell origin of the tumour because B-cell lymphoblastic lymphomas do not express CD3. These coexpressing tumours also show T-cell gene rearrangements rather than immunoglobulin gene rearrangements [14].
Blastoid variant of mantle cell lymphoma (see Chapter 13) Mantle cell lymphoma usually consists of small- to mediumsized cells with characteristic hyperchromatic cleaved nuclei. However, the lymphoblastoid variant of these tumours may be extremely difficult to recognise and is easily misdiagnosed as lymphoblastic lymphoma. In the blastoid variant of mantle cell lymphoma, the malignant cells express CD20, CD79a, CD43 and CD5 antigens, but are best identified by nuclear positivity for cyclin D1 [15]. In contrast to lymphoblastic lymphomas these tumours are negative for TdT, CD10 and CD34 antigens.
65
CHAPTER 4
B-cell Lymphoblastic Leukaemia/Lymphoma
Burkitt lymphoma (see Chapter 15)
Other lymphomas
These tumours express IgM (most easily demonstrated on frozen sections) and most B-cell-associated antigens such as CD20 and CD79a. The malignant cells are also positive for CD10 and often CD43, but negative for CD34, TdT, bcl-2 and T-cell-associated antigens. In addition these tumours are strongly positive for CD45 antigen and have a proliferation rate close to 100%.
Depending on the circumstances it is possible to confuse virtually any other lymphoma type with lymphoblastic type, but two others worth mentioning are CLL (chronic lymphocytic leukaemia/lymphoma) and diffuse large B-cell lymphoma. These suggestions may raise a few eyebrows compared to the more obvious ones above but it is surprising how CLL can seem ‘blastic’ and how often diffuse large B-cell lymphoma is composed of cells that really do not look so large (see discussion in Chapter 14). The key is to diagnose lymphoblastic lymphoma with caution in elderly people and to perform a complete immunophenotype if there is any element of doubt.
Blastic plasmacytoid dendritic cell neoplasm (see Chapter 29) This new entity in the 2008 WHO Classification primarily involves the skin and is easily confused with lymphoblastic lymphoma, especially as many cases are TdT+ [16–18]. In these neoplasms the blastic cells are negative for B- and T-cell antigens and express CD4, CD43, CD56, CD68 and plasmacytoid dendritic cell antigens such as CD123 and bcl11a [19].
Myeloblastic tumours/acute myeloid leukaemia (see Chapter 32) Distinguishing myeloblastic proliferations from lymphoblastic lymphomas can be difficult, particularly in the case of
HE
HE
HE
CD79a
CD7
bcl2
CD117 (cKIT)
CD117 (cKIT)
TdT
Fig 4.3 An example of a challenging lymph node biopsy in a 16-year-old girl. The node is replaced by relatively pleomorphic blast cells (H&E) that are CD45+, CD79a+, CD7+ and bcl2+. They also show focal positivity for CD117 (cKit) and patchy positivity for TdT. The blast cells were negative for all other relevant markers including CD10, CD20, CD4, myeloperoxidase, CD68, CD30 and all other T-cell markers. Comment: the positivity for CD117 is unusual but has been reported in a small number of cases of B- and T-cell ALL [23]. Our conclusion is that this is a case of B-ALL with a primitive or early phenotype.
66
CHAPTER 4
H&E
CD10
B-cell Lymphoblastic Leukaemia/Lymphoma
CD79a
TdT
Bone marrow
Fig 4.4 B-lymphoblastic lymphoma in the testis usually occurs as a relapse of ALL or lymphoblastic lymphoma in treated children so the diagnosis is expected. It may occur from anew in elderly people in whom it can be confused with other lymphomas, or indeed germ-cell tumours if an appropriate immunophenotype is not performed.
extramedullary involvement (also known as granulocytic sarcomas). Myeloblastic proliferations are positive for myeloperoxidase, CD43, CD68, elastase and lysozyme. In general, these tumours are negative for B- and T-cell antigens such as CD20 and CD3, although, as mentioned above, increasing numbers of primitive leukaemias are being reported to show so-called aberrant or overlapping phenotypes. Absence of TdT and CD34 is helpful, although about a third of myeloblastic tumours express these antigens [20]. Promyelocytic leukaemia has been reported to be positive for the CD79a B-cell-associated antigen [21]. This is not in fact CD79a but a cross-reaction with the antibody HM57 and does not occur with the most widely used anti-CD79a antibody JCB 117 [22].
Round cell tumours Particularly in children these may be responsible for diagnostic difficulties (Fig 4.3). The expression of the leukocyte common antigen CD45, together with other B-cell markers, may be of critical value in this context. The important rule for diagnosis is not to guess but to try to make a positive diagnosis by using a full range of antibodies against epithelial, neural, muscle and other non-lymphoid antigens.
Prognosis and treatment Lymphoblastic lymphoma/leukaemia is an aggressive disease but responds well to intensive chemotherapy. The current
long-term survival rate in children is over 70% although, for reasons that are unclear, this is much lower in adults. Possible explanations include more unfavourable cytogenetics as well as a lower tolerance to and increased side effects from aggressive chemotherapy in adults. Relapse frequently occurs in so-called ‘sanctuary’ sites such as the brain and testis (Fig 4.4). Treatment is continually being refined to improve survival rates while minimising the side effects of chemotherapy – especially the long-term ones such as second malignancies. The role of bone marrow transplantation remains unclear and is generally used only for recurrent or resistant disease.
References 1. Murphy SB. Childhood non-Hodgkin’s lymphoma. N Engl J Med 1978;299:1446–8. 2. Coleman CN, Picozzi VJ Jr, Cox RS, et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986;4:1628–37. 3. Hanson CA, Ross CW, Schnitzer B. Anti-CD34 immunoperoxidase staining in paraffin sections of acute leukemia: comparison with flow cytometric immunophenotyping. Hum Pathol 1992; 23:26–32. 4. Cohen PL, Hoyer JD, Kurtin PJ, Dewald GW, Hanson CA. Acute myeloid leukemia with minimal differentiation. A multiple parameter study [see comments]. Am J Clin Pathol 1998;109:32–8.
67
CHAPTER 4
B-cell Lymphoblastic Leukaemia/Lymphoma
5. Hanson CA, Abaza M, Sheldon S, Ross CW, Schnitzer B, Stoolman LM. Acute biphenotypic leukaemia: immunophenotypic and cytogenetic analysis. Br J Haematol 1993;84:49–60. 6. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342:998–1006 7. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/ Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109:3189–97. 8. Bungaro S, Dell’Orto MC, Zangrando A, et al. Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. Genes Chromosomes Cancer 2009;48:22–38. 9. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009;10:125–34 10. Tawa A, Hozumi N, Minden M, Mak TW, Gelfand EW. Rearrangement of the T-cell receptor beta-chain gene in nonT-cell, non-B-cell acute lymphoblastic leukemia of childhood. N Engl J Med 1985;313:1033–7. 11. van der Velden VH, Bruggemann M, Hoogeveen PG, et al. TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse. Leukemia 2004;18:1971–80. 12. Pilozzi E, Pulford K, Jones M, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol 1998;186:140–3. 13. Hashimoto M, Yamashita Y, Mori N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol 2002;197:341–7.
68
14. Pilozzi E, Muller-Hermelink HK, Falini B, et al. Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol 1999;188: 267–70. 15. Soslow RA, Zukerberg LR, Harris NL, Warnke RA. BCL-1 (PRAD-1/cyclin D-1) overexpression distinguishes the blastoid variant of mantle cell lymphoma from B-lineage lymphoblastic lymphoma. Mod Pathol 1997;10:810–17. 16. Petrella T, Dalac S, Maynadié M, et al. CD4+ CD56+ cutaneous neoplasms: A distinct hematological entity? Am J Surg Pathol 1999;23:137–46. 17. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001;97:3210–17. 18. Petrella T, Comeau MR, Maynadie M, et al. ‘Agranular CD4+ CD56+ hematodermic neoplasm’ (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002;26:852–62. 19. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood 2008;111:3778–92. 20. Orazi A, Cotton J, Cattoretti G, et al. Terminal deoxynucleotidyl transferase staining in acute leukemia and normal bone marrow in routinely processed paraffin sections. Am J Clin Pathol 1994;102:640–5. 21. Arber DA, Jenkins KA, Slovak ML. CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia. Am J Pathol 1996;149:1105–10. 22. Mason DY, Cordell JL, Brown MH, et al. Cd79a – a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood 1995;86:1453–9. 23. Uckan D, Hicsonmez G, Yetgin S, et al. CD34/CD117 coexpression in childhood acute leukemia. Leuk Res 2000;24: 201–6.
5
T-cell Lymphoblastic Lymphoma/Leukaemia
The morphology of this blastic lesion is identical to that of B-cell lymphoblastic lymphoma/leukaemia. It is said to represent about 80% of lymphoblastic lymphomas but this is often confused by trying to eliminate the predominantly B-cell leukaemic cases from the comparison [1]. If lymphoblastic lymphoma/leukaemia is considered as one entity then T-cell cases are much less common. Indeed it took the combined efforts of 9 specialist haematopathology units to provide 150 cases of T-lymphoblastic neoplasia for a study of its phenotype [2]. In our Oxford database, only 9 of 246 cases of lymphoblastic lymphoma/leukaemia are T cell in phenotype.
Clinical features Apart from the bone marrow the mediastinum is the most commonly involved organ. Its rapid growth may give rise to tracheal or superior venal caval compression, necessitating urgent admission to hospital. There is infiltration of bone marrow in virtually all cases. Whether or not these should be considered as leukaemic is arbitrary. Certainly, unlike B-cell cases, a frankly leukaemic picture in the peripheral blood is uncommon (less than 15% of cases). This is what accounts for many sources stating that T-cell lymphoblastic lymphoma is more common than B cell.
Immunophenotype All cases are CD3+ usually homogeneously, but a small number will demonstrate only focal staining on about half of the tumour cells. They are all positive for terminal deoxynucleotidyl transferase (TdT) and most cases will also express CD1a, CD2, CD5, CD7 and CD43 (Fig 5.2). Staining for CD4 and CD8 is variable but in a significant proportion of cases both antigens are coexpressed. Positivity for CD10, CD34 and/or CD99 is seen in a proportion of cases. Perhaps surprising is the observation that 40–50% of T-lymphoblastic lesions coexpress to some extent the B-cell marker CD79a, and in a quarter of these the expression is as complete as the T-cell staining (Fig 5.3) [2,3]. No other B-cell marker has been noted on these cases and all showed T-cell receptor (TCR) gene rearrangement but germline Ig genes [4]. The meaning of this staining pattern is not known but, as coexpression is not seen in B-cell cases, it is important for haematopathologists to be aware of this so as not to confuse these lesions. Some cases also express natural killer (NK) cell antigens (CD56 and -57) and, although these are usually easily separated from the extranodal NK/T lymphomas on clinical and morphological grounds, they can be very difficult to differentiate from aggressive NK cell leukaemias. CD117 (cKIT) is present in a small number of T-lymphoblastic lymphomas and has been associated with activating mutations of FLT3 [5].
Histology Cytogenetics Occasional cases of T-cell lymphoblastic lymphoma have markedly convoluted blastic nuclei but overall the cytology and architectural pattern is identical to that seen in B-cell cases (Fig 5.1). In some cases macrophages with tingible bodies may give a ‘starry-sky’ appearance.
About a third of cases have abnormalities, either translocations or deletions, in a variety of genes most commonly involving the various TCR loci on chromosomes 7 or 14 with genes such as HOX11 (chromosome 10), HOX11L2
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
69
CHAPTER 5
T-cell Lymphoblastic Lymphoma/Leukaemia
Case 1
Case 2
Case 3
Case 4
Case 5
Fig 5.1 The histology of five different cases of T-cell lymphoblastic lymphoma shows that there is considerable cytological heterogeneity in this entity which results partially from different fixation and staining protocols.
70
CHAPTER 5
T-cell Lymphoblastic Lymphoma/Leukaemia
CD3
CD1a
CD8
CD43
CD10
Proliferation
TdT Fig 5.2 The points to pick out here are that only a proportion of cases will be CD8+ and some will also express CD4. The proliferation index is high but not more than 90% (and usually lower) and nuclear staining is required before counting TdT staining as positive.
71
CHAPTER 5
T-cell Lymphoblastic Lymphoma/Leukaemia
CD79a expression in T-lymphoblastic lymphoma
CD3
Case 1:
Case 2:
CD79a
CD3
CD79a
(chromosome 5), MYC (chromosome 8) and TAL1 (chromosome 1). TAL1 encodes a transcription factor with a basic helix–loop–helix pattern that is involved in growth control of mammalian haematopoietic cells. Of interest is the fact that immunocytochemical studies show expression of TAL-1 protein in approximately 50% of T-lymphoblastic lesions, indicating that abnormalities of TAL-1 regulation occurring later than genetic translation are also associated with blastic T-cell neoplasia [6,7]. Deletions also occur, especially del(9p), involving loss of the tumour suppressor CDKN2A, as do activating mutations of the important T-cell development gene NOTCH1.
72
Fig 5.3 Two cases (1 and 4) that coexpress the B-cell antigen CD79a compared with a T-cell case (2) and a B-cell case (3) that do not coexpress.
Differential diagnosis The differential diagnosis on morphological grounds is the same as that previously discussed for B-lymphoblastic lymphomas (see Chapter 4 for details). Careful immunohistochemical study is usually the key to distinguishing T-lymphoblastic lymphoma from other lesions such as B-lymphoblastic lymphoma, the blastoid variant of mantle cell lymphoma, Burkitt and Burkitt-like lymphoma, myeloblastic proliferations, blastic plasmacytoid dendritic cell tumour and round cell tumours, especially in children.
CHAPTER 5
T-cell Lymphoblastic Lymphoma/Leukaemia
CD3
CD79a
Case 3: Another B&T antigen co-expressing lymphoblastic lymphoma
Fig 5.3 (continued)
Case 4: Typical B-cell lymphoblastic lymphoma
Although they do not consist of blastic cells some lymphocyte-rich thymomas may be responsible for diagnostic difficulties, especially on needle biopsy specimens. Indeed, the lymphoid cells in these tumours have the same set of antigens as seen in lymphoblastic lymphoma (i.e. CD1a, CD2, CD3, CD43) and, in addition, are strongly positive for TdT. Of diagnostic value is the demonstration of the meshwork of epithelial cells in thymoma with antibodies against epithelial membrane antigen (EMA) and cytokeratins (Fig 5.4). In difficult cases, the clinical presentation may be crucial because most patients with thymoma do not present with the rapidly progressive disease seen in lymphoblastic lymphoma.
Prognosis and treatment The prognosis and treatment are not known to be different from B-cell lymphoblastic lymphoma/leukaemias in agematched groups of patients. As patients present at later ages, they tend to have more tissue disease and a poorer prognosis. Treatment is with multidrug chemotherapy aimed at producing long remissions. Central nervous system prophylaxis is part of most protocols. Radiotherapy used to be a first-line therapy for mediastinal disease but its efficacy is now being questioned, although it remains extremely valuable for emergency presentations.
73
CHAPTER 5
T-cell Lymphoblastic Lymphoma/Leukaemia
HE high power CD4
HE low power
CD79a
Cytokeratin
CD117 (cKit)
CD3
CD8
TdT
CD10
Fig 5.4 This is an example of a mediastinal needle biopsy in a young adult showing a blastic lymphoid infiltration that is cytokeratin negative (note the small thymic remnant present in the CK stain (top left), which is CD3+ CD4− CD8− (top row), and CD79a+ CD117+ TdT focally+ CD10− (bottom row).
References 1. Warnke R, Weiss L, Chan J, Cleary M, Dorfman R. Tumors of the Lymph Nodes and Spleen. Washington: Armed Forces institute of Pathology, 1995. 2. Pilozzi E, Pulford K, Jones M, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol 1998; 186:140–3. 3. Hashimoto M, Yamashita Y, Mori N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol 2002;197:341–7. 4. Pilozzi E, Muller-Hermelink HK, Falini B, et al. Gene
74
rearrangements in T-cell lymphoblastic lymphoma. J Pathol 1999;188:267–70. 5. Paietta E, Ferrando AA, Neuberg D, et al. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 2004;104:558–60. 6. Chetty R, Pulford K, Jones M, et al. SCL/Tal-1 expression in T-acute lymphoblastic leukemia: an immunohistochemical and genotypic study. Hum Pathol 1995;26:994–8. 7. Chetty R, Pulford K, Jones M, et al. An immunohistochemical study of TAL-1 protein expression in leukaemias and lymphomas with a novel monoclonal antibody, 2TL 242. J Pathol 1996;178: 311–15.
6
B-cell Chronic Lymphocytic Leukaemia
This lymphoma is indistinguishable cytologically from the leukaemia of the same name. It is composed of small round lymphocytes variably admixed with larger cells known as prolymphocytes and paraimmunoblasts. The World Health Organization (WHO) recommends calling cases without peripheral blood involvement ‘small lymphocytic lymphoma’.
Clinical features Chronic lymphocytic leukaemia (CLL; also known as small lymphocytic lymphoma) is a disease of elderly people usually occurring after the age of 60 and is extremely rare in patients younger than 40 years. Its incidence depends on whether the frank leukaemias are included (15–20% of all NHLs) or excluded (<5% of all non-Hodgkin lymphomas or NHLs). There is no point engaging in a sterile argument with clinicians over the terminology of this disease, which is why the alternative name of ‘small lymphocytic lymphoma’ is available. The clinical course of CLL, whether or not it presents with leukaemia, is slowly progressive with all or virtually all cases developing blood and bone marrow involvement with time. Widespread tissue dissemination usually develops, although an alternative terminal course may occur from transformation to an aggressive large-cell lymphoma (Richter syndrome) [1].
Some cases show a marked plasmacytoid differentiation and were separately classified as lymphoplasmacytoid lymphoma in the Kiel classification. It is now generally agreed that these should be considered as CLL. Less than 10% of CLL cases usually transform into an aggressive diffuse largecell lymphoma (Richter transformation) that occasionally has an almost anaplastic morphology (Fig 6.2). Occasional cases have been reported to transform into Hodgkin lymphoma usually with Epstein–Barr virus (EBV)positive Reed–Sternberg cells (Fig 6.3) [2,3]. In the spleen, involvement is initially of the white pulp with later diffuse extension into the red pulp. Bone marrow infiltration commences with interstitial infiltration or central lymphoid nodules but may develop a number of different patterns (diffuse, paratrabecular and central) with progression. These extranodal manifestations are often difficult to distinguish from other low-grade B-cell neoplasms without clinical correlation or immunophenotyping.
Blood involvement Those cases not presenting with a leukaemic picture usually develop one with time. The definition of leukaemia in this entity is arbitrary but a lymphocytosis of more than 5 × 109/L is usually present. A number of healthy individuals have relatively small monoclonal B-cell lymphocytoses (always <5 × 109/L) with the characteristic phenotype of CLL [4]. These are of interest as potential precursors of CLL although as yet there is no evidence to substantiate this.
Histology Immunophenotype In lymph nodes CLL normally occurs as a diffuse infiltration. There is usually some vague nodularity caused by an accumulation of larger cells (prolymphocytes and paraimmunoblasts) in so-called ‘proliferation centres’ (Fig 6.1).
CLL cells express the B-cell markers CD20 (sometimes weakly) and CD79a but are negative for CDw76(DBA44) (Table 6.1 and Fig 6.4).
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
75
CHAPTER 6
B-cell Chronic Lymphocytic Leukaemia
In contrast to normal B lymphocytes, almost all cases coexpress CD43 and CD5 antigens (Fig 6.5). CD5 is usually more weakly expressed on CLL cells than on surrounding reactive T cells, and occasionally requires a careful search of the paraffin sections, sometimes requiring frozen sections
H&E low power
H&E high power
Proliferation centres
H&E high power
for certainty. CD23 is usually positive and useful for differentiating small lymphocytic lymphoma from mantle cell lymphoma (Table 6.1). In some examples the labelling for CD23 may be quite weak whereas in others only the prolymphocytes and paraimmunoblasts label. Cyclin D1 is negative, although occasional positive cells may be seen especially in proliferation centres [5]. This is becoming an increasing problem in immunodiagnosis as anti-cyclin D1 antibodies become more avid and staining machines more sensitive, but is not surprising because cyclin D1 is a protein active to a certain extent in virtually all metabolising cells. CD21 is also, perhaps surprisingly, frequently positive on CLL cells, although any underlying follicular dendritic cells in overrun follicles are usually easily identified by their more intense staining and characteristic morphology [6]. Surface immunoglobulins are only reliably demonstrated in frozen sections but in some cases with careful attention to technique κ and λ light chain restriction can be identified (Fig 6.6). The proliferation index (Ki67) is usually very low (<5%) in these tumours.
Genetics
Proliferation centres at high power Fig 6.1 A selection of low- and high-power views illustrating the architectural and cytological features of chronic lymphocytic leukaemia (CLL) including the characteristic feature of proliferation centres. This is often more dramatically seen in Giemsa sections (middle left and bottom left) though a high-power haematoxylin and eosin (H&E) is shown for comparison (bottom right).
The underlying immunoglobulin gene rearrangements in CLL are divided almost equally into cases with somatic mutations and those that are not mutated. Studies have shown that the mutated cases have a better prognosis than those that are not. Immunostaining for ZAP-70 and CD38 provides an approximate surrogate to recognise cases that have not mutated [7]. Deletions on chromosome 13q and trisomy 12 are relatively common, as are deletions and mutations affecting p53 on chromosome 17. The latter enables p53 immunostaining to be used as a marker of poor prognosis [8].
CLL variant
Lymphoplasmacytoid
Richter transformation
Large cell
Anaplastic
Fig 6.2 Examples of variant morphologies in chronic lymphocytic leukaemia (CLL) are the lymphoplasmacytoid variant and the Richter transformation to a high-grade large cell or anaplastic morphology.
76
CHAPTER 6
HE
B-cell Chronic Lymphocytic Leukaemia
CD3
CD30
CD5
EBV LMP1
Fig 6.3 Hodgkin lymphoma-like transformation of chronic lymphocytic leukaemia (CLL) showing the Reed–Sternberg cells (top left) which are CD30+ (bottom left) and EBV+ (bottom right). The surrounding lymphocytes are identified as CLL cells by their negativity for CD3 but positivity for CD5 (top right panel).
Table 6.1 The typical immunophenotype of chronic lymphocytic leukaemia compared with its main differential diagnoses IgM
IgD
CD5
CD10
CD23
CD43
bcl-6
Cyclin D1
Chronic lymphocytic leukaemia
(+)
(+)
+
-
+
+
−
−
Lymphoplasmacytic lymphoma Mantle cell lymphoma Follicular lymphoma Marginal zone lymphoma Splenic marginal zone lymphoma
+ + + + +
− ± ± − +
− + − − −
− − ± − −
± − ± ± −
± + ± −
− − + − −
− + − − −
B-cell prolymphocytic lymphoma In the REAL classification it was suggested that this rare entity was part of the clinical spectrum of CLL. Further discussion has brought agreement that true prolymphocytic leukaemia is distinctly different. Patients present with
splenomegaly and high white blood cell counts, with more than half of these being prolymphocytes (Fig 6.7). These patients have no previous history of CLL and the tumour cells are usually CD5− and CD23−. B-cell prolymphocytic lymphoma (PLL) is difficult to treat and generally has a poor prognosis [9,10].
77
CHAPTER 6
B-cell Chronic Lymphocytic Leukaemia
CD79a
λ
CD20
Fig 6.6 Demonstration of light chain restriction on most cases of chronic lymphocytic leukaemia (CLL) is not easy on paraffin sections and may need frozen sections if considered important for diagnosis.
Fig 6.4 Chronic lymphocytic leukaemia (CLL) expresses most B-cell markers such as CD79a or CD20 but sometimes surprisingly weakly compared with other B-cell lymphomas.
CD5
Cyclin D1
κ
CD43
CD23
CD21
Fig 6.5 The most useful current markers for chronic lymphocytic leukaemia (CLL) are CD5, CD43 and CD23 (which may be quite weak on paraffin sections and need careful inspection to appreciate). CD21 (frequently positive in CLL) shows only scattered dendritic reticulum cells in this case and cyclin D1 is negative (note that many endothelial cells are cyclin D1 positive and provide a useful internal control).
Differential diagnosis Mantle cell lymphoma The most frequent and important differential diagnosis is with mantle cell lymphoma. Positivity for CD23 but not cyclin D1 provides the two most helpful immunostains (Fig
78
6.8). Previous reports of small numbers of cases of mainly PLL being cyclin D1 positive and to possess the translocation t(11:14) are now considered to be leukaemic variants of mantle cell lymphoma [11,12]. The positivity for CD5 and CD23 is useful in differentiating it from other low-grade B-cell neoplasms, although these two markers can be troublesome to detect in paraffin sec-
CHAPTER 6
Fig 6.7 Prolymphocytic leukaemia is a clinicopathological correlation as much as a straightforward histological diagnosis. In the tissues, typically the spleen, the predominant cell is a little larger than a small lymphocyte with a single prominent nucleolus rather than the mottled chromatin of a lymphocyte. But one should remember that prolymphocytes can be abundant in otherwise unremarkable chronic lymphocytic leukaemia.
H&E
Giemsa
H&E low power
Frozen
CD5
Paraffin
B-cell Chronic Lymphocytic Leukaemia
H&E high power
Frozen
CD23
Paraffin
CD20
Fig 6.8 Distinguishing chronic lymphocytic leukaemia (CLL) from mantle cell lymphoma may be difficult on cytological and/or, as in this case, architectural grounds where there is a ‘mantle zone’ pattern. A good immunophenotype showing CD5 and CD23 positivity with cyclin D1 negativity (not shown here) will provide a clear diagnosis.
79
CHAPTER 6
B-cell Chronic Lymphocytic Leukaemia
tions and require careful attention to antigen retrieval and sensitive immunohistochemistry techniques. The demonstration of follicular dendritic cell networks (using CNA.42, CD21 or CD35 antibodies) is also helpful for differentiating CLL from mantle cell lymphoma, which usually shows hyperplastic follicular dendritic cell meshworks.
Follicular lymphoma Occasionally the nodularity caused by the proliferation centres in CLL may lead to confusion with follicular lymphoma. Usually the cytology of follicular lymphoma with its predominance of centrocytes allows a confident distinction. This can now be confirmed immunocytochemically by immunostaining for CD5, CD10 and bcl-6 protein (see Table 6.1) [13–15].
Prognosis and treatment The clinical course is usually described as indolent, although the 10-year survival is lower than for most other low-grade lymphomas. This may reflect the age of patients at presentation more than the biology of the lymphoma. Therapy is currently only palliative, although recent results using the therapeutic antibody CAMPATH-1 are encouraging [16]. In a recent report [17], histological characteristics of lymph nodes were correlated with prognosis. The size of proliferation centres and their proliferation activity (Ki-67 index) were important predictors of survival. Patients with “accelerated” CLL (defined as expanded and confluent proliferation centers broader than a 20x field) had a shorter survival than those with small or absent proliferation centers (“non-accelerated” CLL). A Ki-67 index greater than 40% per proliferation centres, had also a poorer outcome. Overall, median survival of patients with “non-accelerated” CLL was 76 months compared to 34 months for those with “accelerated’’ CLL. In that study, median survival of patients with CLL with transformation to diffuse large B-cell lymphoma was 4.3 months.
References 1. Ben-Ezra J, Burke J, Swartz W, et al. Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases. Blood 1989; 73:579–87. 2. Brecher M, Banks PM. Hodgkin’s disease variant of Richter’s syndrome. Report of eight cases. Am J Clin Pathol 1990;93: 333–9.
80
3. Fayad L, Robertson LE, O’Brien S, et al. Hodgkin’s disease variant of Richter’s syndrome: experience at a single institution. Leuk Lymphoma 1996;23:333–7. 4. Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of ‘indolent’ chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002;100:635–9. 5. O’Malley DP, Vance GH, Orazi A. Chronic lymphocytic leukemia/ small lymphocytic lymphoma with trisomy 12 and focal cyclin d1 expression: a potential diagnostic pitfall. Arch Pathol Lab Med 2005;129:92–5. 6. Echeverri C, Fisher S, King D, Craig FE. Immunophenotypic variability of B-cell non-Hodgkin lymphoma: a retrospective study of cases analyzed by flow cytometry. Am J Clin Pathol 2002;117:615–20. 7. Morilla A, Gonzalez de Castro D, Del Giudice I, et al. Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. Leuk Lymphoma 2008;49:2108–15. 8. Schlette EJ, Admirand J, Wierda W, et al. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma 2009;50: 1597–605. 9. Galton D, Goldman J, Wiltshaw E, Catovsky D. Prolymphocytic leukaemia. Br J Haematol 1974;27:7–23. 10. Melo J, Catovsky D, Galton D. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 1986;63: 377–87. 11. Kobayashi H, Kitano K, Saito H, et al. Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32). Cancer Genet Cytogenet 1995;84:69–72. 12. Ruchlemer R, Parry-Jones N, Brito-Babapulle V, et al. B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br J Haematol 2004;125:330–6. 13. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000;24:846–52. 14. Raible MD, Hsi ED, Alkan S. Bcl-6 protein expression by follicle center lymphomas. A marker for differentiating follicle center lymphomas from other low-grade lymphoproliferative disorders. Am J Clin Pathol 1999;112:101–7. 15. Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol 1997;8(suppl 2):101–4. 16. Keating MJ. Chronic lymphocytic leukemia. Semin Oncol 1999;26(5 suppl 14):107–14. 17. Giné E, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Hematologica 2010;95:1526–33.
7
Splenic B-cell Marginal Zone Lymphoma
Splenic B-cell marginal zone lymphoma (splenic lymphoma) has often been confused with other low-grade B-cell conditions including chronic lymphocytic leukaemia (CLL), immunocytoma and hairy cell leukaemia. It was only identified as a lymphoma in its own right in 1992 [1].
Blood involvement A frank lymphocytosis with characteristic villous lymphocytes occurs only in a minority of patients, at least at presentation.
Clinical features Patients are usually older adults who present with splenomegaly or associated conditions such as hypersplenism and autoimmune haemolytic anaemias or thrombocytopenias.
Histology There is a characteristic biphasic replacement of splenic white pulp (Fig 7.1). This consists of a central dark zone of small lymphocytes surrounded by a lighter area of medium-sized marginal zone-like cells with pale cytoplasm, and interspersed blast cells. It is this lighter zone that gives rise to the name splenic marginal zone lymphoma (SMZL) and that extends out to infiltrate the red pulp as well. There is now considerable doubt that this is a marginal zone lymphoma, one argument against this being the biphasic pattern of the lymphoma whereas true marginal zone lymphomas are more homogeneous. Further evidence against it comes from immunocytochemical studies [2–4]. Plasmacytic differentiation may be observed. Splenic hilar lymph nodes may be involved by a nodular infiltration of lymphocytes with admixed blasts. There is no marginal zone pattern as seen in nodal involvement by MALT (mucosaassociated lymphoid tissue) lymphomas. Other lymph nodes are rarely involved, although bone marrow is usually infiltrated both by lymphocytic nodules in the centre of the marrow spaces and by a more diffuse intrasinusoidal spread.
Immunophenotype Splenic lymphoma cells are of B phenotype (CD20+, CD79a+) (Table 7.1 and see Fig 7.1). A significant proportion of these tumours are positive for CDw76/DBA-44 antibody, but it is the pattern of immunostaining with anti-immunoglobulins that is distinctive in this condition. Splenic lymphoma occupies both the mantle and the marginal zones as shown by the absence of a residual IgDpositive mantle zone. Other low-grade B-cell lymphomas in the spleen typically either replace the white pulp or are restricted to one zone, usually the marginal zone. A combination of immunoglobulin and bcl-2 protein staining usually enables one to sort these out (Fig 7.2). Then a detailed immunophenotype will enable the lymphoma to be subtyped [4]. In particular splenic lymphoma cells are negative for CD5, CD10, CD43, cyclin D1, annexin A1 and also usually for CD23. Staining for Ki67 shows a characteristic jumbled or targetoid appearance with relatively brisk proliferative activity in both the marginal zone and overrun germinal centres.
Cytogenetics The only consistent cytogenetic abnormality reported is loss of chromosome 7q31-32 in up to 40% of cases (this is rare in other low-grade B-cell lymphomas) [5].
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
81
CHAPTER 7
Splenic B-cell Marginal Zone Lymphoma
CD79a
bcl-2
CD3
CD43
Mantle zone
Fig 7.1 The histology and immunophenotype of splenic lymphoma showing the expansion of the splenic marginal zones with a polymorphic collection of lymphocytes of varying cytologies around preserved germinal centres (bcl2−). The lymphoma cells are variably bcl-2+ B cells which are CD43−.
Table 7.1 Comparing the immunophenotypes of splenic marginal zone lymphoma with its main differential diagnoses
Splenic marginal zone lymphoma Marginal zone lymphoma Follicular lymphoma Mantle cell lymphoma Lymphoplasmacytic lymphoma Chronic lymphocytic leukaemia
82
IgM
IgD
CD5
CD10
CD23
CD43
bcl-6
Cyclin D1
+ + + + + (+)
+ − ± ± − (+)
− − − + − +
− − + − − −
± ± ± − ± +
− ± − + ± +
− − + − − −
− − − + − −
CHAPTER 7
Splenic B-cell Marginal Zone Lymphoma
HE
HE
HE
CD20
CD79a
CD10
CD21
bcl2
κ
IgM
IgD
λ
mib1
Fig 7.2 In this case the splenic marginal zone lymphoma has overrun the germinal centres. The tumour cells are CD20+ and CD79a+ but CD10−. The tumour cells in the marginal zone area are bcl2+ but lose this as they colonise the previous germinal centres, the framework of which is outlined by CD21. The tumour cells are positive for both IgM and IgD, show κ light chain restriction and have a broken up but relatively high proliferative index with Ki67.
83
CHAPTER 7
Splenic B-cell Marginal Zone Lymphoma
HE
HE
CD20
CD10
CD23
CD23
bcl2
CD3
CD5
Fig 7.3 Example of a typical splenic marginal zone lymphoma with unusual positivity for CD23.
84
CHAPTER 7
Differential diagnosis In the spleen the differential diagnosis is generally with the other ‘low-grade’ B-cell lymphomas (Fig 7.3). Attention to imunophenotyping, as described above, allied with a careful clinicopathological correlation is the best way to make a confident diagnosis. Cyclin D1 immunostaining is the crucial marker in distinguishing it from mantle cell lymphoma. Early reports of t(11;14) and cyclin D1 positivity in splenic lymphoma are now generally believed to be mistaken mantle cell lymphomas as more detailed studies show splenic lymphomas to be cyclin D1 negative [6]. A note of caution has been raised by a study of six cases of splenic lymphoma with increased numbers of blasts and an aggressive clinical picture, of which two expressed cyclin D1, although again these may be unusual examples of mantle cell lymphoma [7]. Although the distinction from hairy cell leukaemia is rarely problematic any doubts may be dispelled by showing negativity for annexin A1 [8].
Splenic diffuse red pulp small B-cell lymphoma This is a very rare B-cell lymphoma in which there is red pulp sinusoidal infiltration of the spleen by unremarkable, small, basophilic, lymphoid cells with little or no evidence of residual white pulp. A similar intrasinusoidal infiltration pattern is seen in the bone marrow. The immunophenotype is virtually identical to SMZL apart from usually being IgD negative; hence an alternative name for it has been SMZL diffuse variant [9].
Prognosis and treatment Survival studies available to date suggest that this condition has an excellent prognosis and that the treatment of choice is splenectomy alone without any chemotherapy. Some
Splenic B-cell Marginal Zone Lymphoma
cases of transformation into large cell lymphoma have been reported [10].
References 1. Schmid C, Kirkham N, Diss T, Isaacson P. Splenic marginal zone cell lymphoma. Am J Surg Pathol 1992;16:455–66. 2. Mollejo M, Menarguez J, Lloret E, et al. Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A clinicopathological study of 13 cases. Am J Surg Pathol 1995; 19:1146–57. 3. Mollejo M, Lloret E, Menarguez J, Piris MA, Isaacson PG. Lymph node involvement by splenic marginal zone lymphoma: morphological and immunohistochemical features. Am J Surg Pathol 1997;21:772–80. 4. Piris MA, Mollejo M, Campo E, Menarguez J, Flores T, Isaacson PG. A marginal zone pattern may be found in different varieties of non- Hodgkin’s lymphoma: the morphology and immunohistology of splenic involvement by B-cell lymphomas simulating splenic marginal zone lymphoma. Histopathology 1998;33: 230–9. 5. Mateo M, Mollejo M, Villuendas R, et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol. 1999;154:1583–9. 6. Savilo E, Campo E, Mollejo M, et al. Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Mod Pathol 1998;11:601–6. 7. Lloret E, Mollejo M, Mateo MS, et al. Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant? Hum Pathol 1999;30:1153–60. 8. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004;363:1869–70. 9. Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood 2008;111:2253–60. 10. Kuwayama M, Machii T, Yamaguchi M, Yamaguti K, Kitani T, Kanakura Y. Blastic transformation of splenic lymphoma with villous lymphocytes after a well-controlled chronic phase of more than 10 years. Int J Hematol 2000;71:167–71.
85
8
Hairy Cell Leukaemia
Hairy cell leukaemia (HCL) is characterised by circulating mononuclear cells with fine villous projections (‘hairy cells’) and splenomegaly without lymphadenopathy.
Blood involvement
Clinical features
Peripheral blood is usually involved although it is rare to find more than a few scattered hairy cells in the typical smear. Frank leukaemias are rare. Pancytopenia associated with monocytopenia is a common finding.
Patients are elderly, predominantly male and pancytopenic. Symptoms are usually related to the splenomegaly (abdominal pain or distension) or bone marrow infiltration (bruising, fatigue, infection).
Histology The spleen is typically very large (2 kg or more) with a deep burgundy red coloration and a friable soggy feel to it. It is extensively infiltrated throughout the red pulp, with little or no sign of remaining white pulp. The soggy feel is probably due to the pseudosinus formation of blood-filled spaces lined by hairy cells. Hairy cell leukaemia consists of an infiltrate of non-cohesive homogeneous cells, looking like a halfway house between monocytes and lymphocytes. They have a bean-shaped nucleus and relatively abundant clear cytoplasm (Fig 8.1). The picture is similar in bone marrow, which is usually inaspirable regardless of the extent of the infiltration (usually ascribed to an increase in reticulin occasioned by the infiltration) (Fig 8.2). The liver is also commonly involved (portal tracts and sinusoids) though to a lesser extent than the spleen. Lymph nodes at the splenic hilum frequently show involvement, although other lymph nodes are usually unaffected even with longstanding disease. Whether hairy cell leukaemia can ever be a primary lymph node disease remains unclear, but if it does it must be exceedingly rare (Fig 8.3).
Immunophenotype The immunophenotype is characteristic and reflects the appearance of the cell as a hybrid monocyte/lymphocyte [1–3] (Fig 8.4]. Hairy cells express a mixture of histiocytic and lymphocytic antigens unlike any other lymphoma. CD10 and CD23 were initially thought to be negative but detailed studies have shown that about 20% of cases may be positive for either [4]. The most specific marker is the recently described annexin A1 because this is positive on nearly all cases of hairy cell leukaemia but not on any other B-cell lymphomas [5]. The paraffin section immunophenotype is as shown in Table 8.1.
Cytogenetics No specific abnormalities have been described although a variety of abnormalities affecting chromosomes 5 and 7 has been reported [6,7].
Differential diagnosis Hairy cell leukaemia has such a characteristic cytology, histology and immunophenotype that it is not usually confused
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
86
CHAPTER 8
Hairy Cell Leukaemia
Fig 8.1 Typical appearances of hairy cell leukaemia in the spleen shown, at low and medium power to illustrate the diffuse infiltration with red cell lakes and at high power for the characteristic morphology.
87
CHAPTER 8
Hairy Cell Leukaemia
Hairy cell leukaemia in the bone marrow
Cytology
CD22
CD11c
Low power histology
High power histology Fig 8.2 showing the characteristic appearance of hairy cell leukaemia in the bone marrow. CD22 is a B-cell marker and CD11c a histiocytic marker working on cytological preparations or frozen sections but not paraffin.
88
Hairy cell leukaemia in lymph node
CD79a
CD68
DBA.44
Kappa
Cyclin D1
Lambda
Fig 8.3 A case of hairy cell leukaemia presenting as a solitary lymph node without involvement of spleen or bone marrow.
89
CHAPTER 8
Hairy Cell Leukaemia
Hairy cell leukaemia: immunophenotype
CD79a
DBA.44
CD79a
DBA.44
DBA.44
Cyclin D1
CD20
Annexin A1
Fig 8.4 The typical immunophenotype of hairy cell leukaemia in paraffin sections. Only a proportion of cases express cyclin D1.
90
CHAPTER 8
Table 8.1 Immunophenotype of paraffin sections B-cell antigens ‘Hairy cell antigen’ ‘Differentiation’ antigens
Histiocytic antigens Other antigens
CD19, CD20, CD22, CD79a CDw76 (DBA.44), annexin A1 CD5 CD10, CD23 Cyclin D1 CD68 CD25, CD103, CD123
+ + − ± ± Dot + +
with any other neoplasm. Occasionally immunocytochemical results may raise the possibility of splenic lymphoma expressing CDw76 (DBA.44) or mantle cell lymphoma because of cyclin D1 expression [8,9] but putting all of the features together should eliminate any doubts. For example, in the bone marrow, splenic lymphoma shows a predominantly sinusoidal infiltration whereas hairy cell leukaemia is interstitial (both being CDw76 [DBA.44] positive). A much more common problem faces the bone marrow diagnostician where hairy cell leukaemia can be a subtle infiltrate causing severe reactive, dysplastic or even aplastic changes leading to a false diagnosis [10].
Hairy cell leukaemia variant This rare entity has been provisionally recognised in the recent World Health Organization (WHO) classification. It is a low-grade B-cell lymphoproliferation somewhere between B-cell prolymphocytic leukaemia (B-PLL) and HCL in morphology and shows a similar pattern of infiltration of bone marrow and spleen. Its immunophenotype is clearly distinct from HCL by being CD25, annexin A1− and CD123−. Pathologists are usually directed towards it by clinicians who have been alerted to it by the easily aspirable marrow and unusual cytology (and also by the resistance to traditional HCL therapy if this has been undertaken) [11].
Prognosis and treatment Hairy cell leukaemia has an indolent course and is generally easily controllable. Indeed about 10% of patients will never require any specific therapy. Patients with symptoms from bone marrow infiltration or splenomegaly may be treated with purine analogues such as 2-chlorodeoxyadenosine
Hairy Cell Leukaemia
(Cladribine) or deoxycoformycin (Pentostatin), or with interferon-α or splenectomy [12,13]. Progressive HCL, postsplenectomy, is generally responsive to therapy with a good survival rate of >85% at 5 years. Rare cases of transformation to a diffuse large B-cell lymphoma have been reported.
References 1. Hounieu H, Shashikant C, Saati T, et al. Hairy cell leukemia: diagnosis of bone marrow involvement in paraffin-embedded sections with monoclonal antibody DBA.44. Am J Clin Pathol 1992;28:26–33. 2. Hsu S, Yank K, Jaffe E. Hairy cell leukemia: a B cell neoplasm with a unique antigenic phenotype. Am J Clin Pathol 1983; 80:421–8. 3. Visser L, Shaw A, Slupsky J, Vos H, Poppema S. Monoclonal antibodies reactive with hairy cell leukemia. Blood 1989; 74:320–5. 4. Chen YH, Tallman MS, Goolsby C, Peterson L. Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol 2006; 125:251–9. 5. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004;363:1869–70. 6. Wu X, Ivanova G, Merup M, et al. Molecular analysis of the human chromosome 5q13.3 region in patients with hairy cell leukemia and identification of tumor suppressor gene candidates. Genomics 1999;60:161–71. 7. Cawley JC. The pathophysiology of the hairy cell. Hematol Oncol Clin North Am 2006;20:1011–21. 8. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84: 2726–32. 9. de Boer CJ, van Krieken JH, Schuuring E, Kluin PM. Bcl-1/ cyclin D1 in malignant lymphoma. Ann Oncol 1997;8(suppl 2): 109–17. 10. Brown D, Gatter K, Natkunam Y, Warnke R. Bone Marrow diagnosis: An illustrated guide. Oxford: Blackwell’s Scientific, 2006. 11. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16:41–56. 12. Piro L, Carrera C, Carson D, Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2′-chlorodeoxyadenosine. Cancer 1990;332:1117–21. 13. Spiers A, Moore D, Cassileth P, et al. Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 1987;316:825–30.
91
9
Lymphoplasmacytic Lymphoma
This lymphoma is mainly composed of lymphocytes showing plasmacytic differentiation and plasma cells. Most cases have an associated serum IgM paraprotein [1].
Clinical features Lymphoplasmacytic lymphomas (LPLs) (also previously known as immunocytomas) have a similar age distribution to chronic lymphocytic leukaemia (CLL). Most patients have an IgM serum paraprotein, with about half of these also showing the clinical features of Waldenström macroglobulinaemia (hyperviscosity, autoimmunity, cryoglobulinaemia). Some cases have a leukaemic blood picture although this is not common and should alert one to a misdiagnosis of one of the other small B-cell lymphomas [2–4].
When Dutcher bodies are readily identified they are a reliable marker for a monoclonal proliferation (Fig 9.1). Some cases are associated with a marked granulomatous reaction [5]. The sinuses are occasionally preserved and are dilated by PAS-positive lymph. In extranodal sites, LPL is becoming a rare diagnosis because most of these cases are now considered to be marginal zone derived (i.e. extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue). In the spleen, clear-cut cases have a diffuse pattern of red pulp infiltration. Cases that appear to involve the white pulp heavily are often difficult to distinguish from splenic marginal zone lymphoma.
Blood involvement A variety of red cell abnormalities associated with the macroglobulinaemia are common whereas a lymphocytosis is rare.
Histology Many, if not most, cases of LPL/immunocytoma diagnosed before the first World Health Organization (WHO) classification in sites other than bone marrow have been reassigned on review to other categories of lymphoma. This means that much of the richness of histological description in the old literature is no longer applicable. Without a clear clinical picture of Waldenström macroglobulinaemia, it is almost a diagnosis of exclusion. In lymph nodes, LPL is a diffuse infiltration of lymphoplasmacytic cells and plasma cells, often with an intrasinusoidal pattern. There is no pseudofollicle formation as seen in CLL. Periodic acid–Schiff (PAS)positive intranuclear pseudoinclusions, known as ‘Dutcher bodies’, are helpful in establishing the diagnosis but are not restricted to this category of lymphoma because they may be seen in other lymphomas when accompanied by plasmacytic differentiation, e.g. marginal zone lymphoma and follicular lymphoma.
Immunophenotype In LPL, plasma cells and occasional immunoblasts stain for cytoplasmic monotypic IgM readily detectable on paraffin sections. In addition, most of the cells are positive for CD20 and CD79a and generally negative for CD5, CD10 and CD23 (Table 9.1). A careful analysis of LPL cases with Waldenström macroglobulinaemia by flow cytometry has shown a surprisingly high albeit often weak expression of CD5, CD10 and CD23 [6]. Pathologists need to be alert to this because, as new more avid antibodies become available, coupled to sensitive staining machines, we will start to see many more of these seeming anomalies. The expression of CD43 is variable. LPL cells are usually positive for the ‘plasma cell’ markers CD38 and VS38, although negative for CD138 which generally stains only associated mature plasma cells (Fig 9.2). The proliferation index is usually low (<5%).
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
92
CHAPTER 9
H&E low power
Lymphoplasmacytic Lymphoma
H&E Dutcher body
Cytogenetics There are no specific abnormalities recognised in LPL. Previous reports of PAX-5 gene rearrangements have now been shown not to be associated with LPL [7,8].
Differential diagnosis Strong cytoplasmic staining for immunoglobulin with light chain restriction alongside negativity for CD5 and cyclin D1 helps the distinction from CLL and mantle cell lymphoma (Fig 9.3). The monoclonal antibody VS38, recognising the rough endoplasmic reticulum protein p63, can also be useful in distinguishing LPL from other low-grade lymphomas that are usually negative [9,10]. Separation from marginal zone lymphoma is difficult and, it has to be said, is more a matter of personal opinion in our current state of knowledge.
PAS low power
PAS Dutcher body
Fig 9.1 Typical low and high power views of lymphoplasmacytic lymphoma with examples of both haematoxylin and eosin (H&E) and periodic acid–Schiff (PAS) stains. The latter can be helpful in highlighting the plasmacytoid differentiation and the intranuclear Dutcher bodies (arrowed in both H&E and PAS).
Heavy chain diseases These are a group of very rare lymphoplasmacytoid diseases in which the lymphoma cells only express a single heavy
IgM
p63 protein (VS38)
Lambda
Kappa
Fig 9.2 Immunostains showing the cytoplasmic reactivity in lymphoplasmacytic lymphoma for IgM with light chain restriction (λ in this case). Detection of the p63 protein with VS38 can also be helpful in differential diagnosis, but bear in mind that this antigen is present on all endoplasmic reticulum so other cells such as endocrine cells, osteoclasts and stromal cells are also positive.
93
CHAPTER 9
Lymphoplasmacytic Lymphoma
Table 9.1 Immunophenotypes of lymphoplasmacytic lymphoma compared with its main differential diagnoses
Lymphoplasmacytic lymphoma Chronic lymphocytic leukaemia Mantle cell lymphoma Follicular lymphoma Marginal zone lymphoma Splenic marginal zone lymphoma
IgM
IgD
CD5
CD10
CD23
CD43
bcl-6
Cyclin D1
+ (+) + + + +
− (+) ± ± − +
− + + − − −
− + −
± + ± ± ±
± + + − ± −
− − − + − −
− − + − − −
CD20
H&E
CD79a
Kappa Fig 9.3 Example of a case received in consultation with a differential diagnosis of reactive lymphocytosis versus non-specific non-Hodgkin lymphoma. Immunostaining identifies it as lymphoplasmacytic lymphoma secreting abundant κ-positive immunoglobulin. CD5, CD23 and cyclin D1 were negative.
94
CHAPTER 9
chain γ, μ or α without an accompanying light chain. They are easily confused with other low-grade lymphoproliferations and usually only come to light with an extended immunophenotype revealing the unusual heavy chain expression without any light chain expression. The α variant is slightly more common than the other two and involves the gastrointestinal tract in young adults. It is also known as immunoproliferative small intestinal disease and is generally believed to be a variant of extranodal marginal zone lymphoma (mucosa-associated lymphoid tissue or MALT).
Prognosis and treatment The clinical course is similar to CLL being slowly progressive and little affected by current therapy.
References 1. Harris N, Bhan A. B-cell neoplasms of the lymphocytic, lymphoplasmacytoid, and plasma cell types: immunohistologic analysis and clinical correlation. Hum Pathol 1985;16:829–37. 2. Pangalis G, Nathwani B, Rappaport H. Malignant lymphoma, well differentiated lymphocytic: its relationship with chronic lymphocytic leukemia and macroglobulinemia of Waldenstrom. Cancer 1977;39:999.
Lymphoplasmacytic Lymphoma
3. Gertz MA, Fonseca R, Rajkumar SV. Waldenström’s macroglobulinemia. Oncologist 2000;5:63–7. 4. Dimopoulos MA, Galani E, Matsouka C. Waldenström’s macroglobulinemia. Hematol Oncol Clin North Am 1999;13:1351–66. 5. Patsouris E, Noel H, Lennert K. Lymphoplasmacytic/ lymphoplasmacytoid LPL with a high content of epithelioid cells: histologic and immunohistochemical findings. Am J Surg Pathol 1990;14:660–70. 6. Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia. Am J Clin Pathol 2005;124: 414–20. 7. Cook JR, Aguilera NI, Reshmi-Skarja S, et al. Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). Hum Pathol 2004;35: 447–54. 8. George TI, Wrede JE, Bangs CD, Cherry AM, Warnke RA, Arber DA. Low-grade B-Cell lymphomas with plasmacytic differentiation lack PAX5 gene rearrangements. J Mol Diagn 2005; 7:346–51. 9. Turley H, Jones M, Erber W, Mayne K, de Waele M, Gatter K. VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections. J Clin Pathol 1994;47: 418–22. 10. Banham AH, Turley H, Pulford K, Gatter K, Mason DY. The plasma cell associated antigen detectable by antibody VS38 is the p63 rough endoplasmic reticulum protein. J Clin Pathol 1997;50:485–9.
95
10
Plasmacytoma/Myeloma
Introduction Multiple myeloma is a clinical entity caused by a malignant monoclonal proliferation of plasma cells within the bone marrow. It is characterised by: • increased numbers of clonal plasma cells within the bone marrow (>10% of the nucleated cell population) • end-organ damage: – hypercalcaemia – renal insufficiency – anaemia – lytic bone lesions • the presence of an M (or paraprotein) band identified electrophoretically in serum (usually >30 g/L) or urine. At least two of these three components must be present before a diagnosis of myeloma can be made.
Clinical features The most common clinical features associated with myeloma are bone pain and pathological fractures, fatigue caused by anaemia and renal failure. Hyperviscosity and hypercalcaemia may occasionally cause symptoms such as altered consciousness or blurred vision. Some patients may have additional complications from amyloidosis.
Histology Myeloma is characterised by a proliferation of clonal plasma cells in the marrow (Fig 10.1). Typically the neoplastic plasma cells have many abnormal features including binucleated and immunoblastic forms. The more blastic forms of myeloma are believed to signal a poorer prognosis. Myeloma cells are often patchily distributed around the marrow in clusters rather than the single cell layers around blood vessels, as seen with reactive plasma cells. Amyloid deposition is commonly found around vessels in many organs (kidney, gut, spleen, liver) which if extensive enough
may give rise to the clinical syndrome of amyloidosis (of AL type) (Figs 10.2 and 10.3). Myeloma cells are not usually involved with the amyloid and if plasma cells are present they are polyclonal with benign cytologies.
Blood involvement It is very uncommon to detect circulating myeloma cells in blood films. Clonal plasma cells constituting more than 20% of peripheral white cells are considered to represent plasma cell leukaemia. This is a very rare variant of myeloma and has a poor prognosis.
Immunophenotype For the pathologist the most useful markers are antibodies against heavy and light chains together with a plasma cell marker such as the VS38 (p63 antigen) [1], CD38 or CD138/ syndecan 1 [2]. In difficult to interpret or poorly fixed, badly staining cases in situ hybridisation for light chain RNA can be very useful. Although of B-cell lineage most B-cell antigens other than CD79a are absent, although some lightchain-secreting myeloma cells may be positive for both CD20 and CD45. CD56 is positive on 70–80% of cases [3,4]. Myeloma cells may on occasion express a number of ‘unexpected’ antigens such as cytokeratins, epithelial membrane antigen (EMA), CD117 or CD10 which can cause diagnostic errors if not appreciated. Myeloma also commonly expresses nuclear cyclin D1 staining although this is unlikely to lead to confusion with mantle cell lymphoma [5].
Cytogenetics A variety of translocations and cyclin D upregulations have been combined into an eight-group algorithm that gives an overview of good or bad prognosis [6]. At the moment pathologists can broadly mirror this as the 50% or
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
96
CHAPTER 10
Fig 10.1 Typical clonal myeloma in the bone marrow with an example of the plasmablastic variant at bottom right.
Plasmacytoma/Myeloma
Giemsa
H&E
Lambda
Kappa
p63 (VS38)
Plasmablastic variant
so of cyclin D1+ cases have a better survival than negative cases [7].
Differential diagnosis In bone marrow, the differential diagnosis is usually reactive plasmacytosis but this problem is generally solved by immunohistochemistry which shows polytypic Ig-secreting plasma cells. Another diagnostic difficulty is represented by a bone marrow trephine biopsy performed in patients with mild monoclonal gammopathy (so-called MGUS or monoclonal gammopathy of uncertain significance). In these patients one sees a moderate or minimal bone marrow involvement (<10%) by monotypic Ig-secreting plasma cells without clear morphological abnormalities. This diagnostic difficulty cannot usually be solved by immunomorphology alone and requires clinicopathological correlations (basically these patients do not meet the minimum clinical criteria for a diagnosis of myeloma).
Plasma cells tumours may also occur in extraskeletal sites and the term ‘plasmacytoma’ is commonly used after appropriate staging investigations to exclude myeloma. Plasmacytomas may arise in a lymph node, tonsil, skin, upper respiratory tract or gastrointestinal tract (Fig 10.4). In lymph node, plasmacytomas usually consist of almost normal appearing but monoclonal plasma cells associated with scattered atypical cells with large nuclei, but with the same chromatin pattern as typical plasma cells. A pseudoangiomatous pattern is frequently observed. Amyloid deposits with foreign-body giant cells have also been described. Patients with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes) syndrome, frequently seen in association with the plasma cell variant of Castleman disease, often have deposits of osteosclerotic plasmacytomas as single or multiple lesions in their bone marrows. The number of plasma cells in these may be relatively low but they are monotypic for immunoglobulins and virtually always restricted for λ light chains [8].
97
CHAPTER 10
Plasmacytoma/Myeloma
Fig 10.2 Amyloid deposition in the spleen (top) and in a localised plasmacytoma in the larynx (bottom) with a multinucleated cell reaction.
Solitary bone tumours have also been described. In this case the main difficulty is to rule out a bone tumour associated with multiple myeloma. The best criterion supporting the diagnosis of a solitary bone plasmacytoma is the lack of plasma cell infiltration on bone marrow biopsy distant from the bone tumour and the disappearance of the M component after treatment of the plasma cell bone tumour [9].
Prognosis and treatment The clinical course is one of remission after chemotherapy but with eventual relapse into more high-grade disease which is then less responsive to further chemotherapy. Poor prognostic features include plasmablastic forms of myeloma and high degrees of marrow infiltration. An indolent form, known as smouldering myeloma, has been described that meets the laboratory criteria for myeloma but does not display any end-organ damage. Patients may be symptom
98
Lambda
Kappa
Fig 10.3 AL amyloid in the small intestine associated with a λ-producing myeloma in the bone marrow. Note the presence of plasma cells of both light chain classes in the gut with soluble κ immunoglobulin in the vessel lumina (arrowed above).
free for many years although progression to frank myeloma is common with time [10]. Many new modalities of treatment are being actively researched in the search for a better outcome in myeloma, including various forms of bone marrow transplantation, biologic therapies such as velcade, thalidomide and lenalidomide, and monoclonal antibody therapies [11,12].
CHAPTER 10
Plasmacytoma/Myeloma
HE
VS38
κ
κ in situ
λ
λ in situ
Fig 10.4 Example of a solitary deposit of plasmacytoma in the skin with the morphology and plasma cell nature shown by H&E and antibody VS38 (top row). Light chain restriction for κ light chains is shown below with both immunostains (left column) and in situ for light chain RNA (right column).
References 7. 1. Turley H, Jones M, Erber W, Mayne K, de Waele M, Gatter K. VS38: a new monoclonal antibody for detecting plasma cell differentiation in routine sections. J Clin Pathol 1994;47:418–22. 2. Costes V, Magen V, Legouffe E, et al. The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol 1999;30:1405–11. 3. Van Camp B, Durie B, Spier C, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NHK-1; Leu-19). Blood 1990;76:377–82. 4 4, Harrington AM, Hari P, Kroft SH. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. Am J Clin Pathol 2009;132:60–6. 5. Hoechtlen-Vollmar W, Menzel G, Bartl R, Lamerz R, Wick M, Seidel D. Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol 2000;109:30–8. 6. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a conse-
8. 9.
10.
11. 12.
quent classification of multiple myeloma. J Clin Oncol 2005;23: 6333–8. Cook JR, Hsi ED, Worley S, Tubbs RR, Hussein M. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol 2006;125:615–24. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003;101:2496–506. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood 2000;96:2037–44. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–57. Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9:278–88. Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of total therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 200666 with VRD maintenance. Blood 2010;115:4168–73. 99
11
Marginal Zone B-cell Lymphoma (Extranodal Malt and Nodal Types) and Extranodal Malt Lymphoma
These lymphomas have a relatively heterogeneous population of lymphoid cells, including lymphocytes, centrocytelike cells and plasmacytoid cells. Their special characteristic is that they arise in mucosal sites such as the gut where they remain localised for long periods before disseminating to lymph nodes and bone marrow [1,2]. Hence the acronym MALT for lymphomas of mucosa-associated lymphoid tissue.
Clinical features MALT lymphomas typically arise in the gastrointestinal tract or other glandular epithelial tissues. Gastric MALT lymphoma is usually associated with helicobacter infection and may respond to appropriate antibiotic therapy [3,4]. In other sites there may be an association with autoimmune conditions such as Sjögren syndrome or Hashimoto thyroiditis. Borrelia burgdorferi has been proposed as a similar stimulating antigen in some cases of cutaneous marginal zone lymphoma [5,6].
Histology The diagnosis is made by clinicopathological correlation as well as microscopy. The cell population is a mixture of small lymphocytes, plasmacytoid cells and centrocyte-like lymphocytes and is easily confused with other low-grade lymphomas, especially lymphoplasmacytic lymphomas. In some cases the lymphoma cells have a monocytoid appearance. A characteristic feature is the presence of invasive epithelial lesions (the so-called lymphoepithelial lesions) (Figs 11.1 and 11.2). Epithelial cells derived from these, often with
acidophilic cytoplasm, are commonly found scattered among lymphoid cells. Within the mucosa there may be large prominent reactive lymphoid follicles that are progressively colonised and replaced by the lymphoma. Helicobacter pylori can be demonstrated in most cases of gastric MALT lymphoma (Fig 11.3). It should be emphasised that lymphoepithelial lesions are not seen in all cases of MALT lymphoma in any site. They are uncommon in large cell transformations and in MALTs in the eye, skin or breast. Furthermore they may be seen in benign inflammatory lesions such as gastritis. Large cell transformation does occur both with disease progression and at diagnosis and exhibits a more aggressive course, justifying a label of high-grade lymphoma [7]. This should be diagnosed only when there is prior or coexisting evidence of low-grade marginal zone lymphoma, although the 2008 WHO classification emphasises that this transformation should be called diffuse large B-cell lymphoma and that the term ‘high-grade MALT’ lymphoma should not be used to avoid confusion with what is in essence a low-grade lesion. It is important to note that scattered large B cells (centroblasts or immunoblasts) are commonly seen in MALT lymphomas and do not indicate a diagnosis of large cell lymphoma transformation which requires the presence of sheets of large cells. Secondary involvement of local lymph nodes is not uncommon. The tumour cells have a characteristic marginal zone and perisinusoidal pattern, which spreads with time to become more diffuse (Fig 11.4) [8].
Blood involvement Involvement of the peripheral blood or bone marrow is rare until late in the progression of the disease.
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
100
CHAPTER 11
Marginal Zone B-cell Lymphoma and Extranodal Malt Lymphoma
Lymphoepithelial lesions
Cytokeratin
CD20
Fig 11.1 Typical gastric MALT (mucosa-associated lymphoid tissue) lymphoma showing lymphoepithelial lesions highlighted by immunostaining.
101
CHAPTER 11
Marginal Zone B-cell Lymphoma and Extranodal Malt Lymphoma
H&E low power
H&E lymphoepithelial lesion
Fig 11.3 Helicobacter pylori can often be seen on H&E sections but are most easily demonstrated by immunostaining.
[9] and there have been two case reports of CD10 positivity [10]. Cytokeratin staining is useful for demonstrating lymphoepithelial lesions. In approximately 40% of cases the plasma cells secrete monotypic immunoglobulin (IgM > IgG or IgA).
Kappa
Lambda
Cytogenetics
Fig 11.2 MALT (mucosa-associated lymphoid tissue) lymphoma in the thyroid demonstrating monoclonal plasma cells and lymphoepithelial lesions.
Trisomy 3 and 18, although not specific, are common in MALT lymphomas [11]. A number of chromosomal translocations have been described, including t(1;14),t(3;14), t(11;18) and t(14;18). Their frequency varies considerably in different geographical and anatomical sites, suggesting that local and environmental factors play an aetiological role [12,13]. The translocation t(1;14) is associated with translocation of the bcl-10 gene which has further been shown to undergo mutations in 6–8% of MALT lymphomas, the higher figure being associated with large cell transformations [14]. The t(11;18) translocation occurs in about 25% of cases and results in the fusion of the API2 gene (an inhibitor of apoptosis) on chromosome 11 and the MALT1 gene on chromosome 18 [15]. Clinical studies have shown that its presence is related to a poor response to helicobacter treatment and chemotherapy but not to rituximab responsiveness [16].
Immunophenotype (Table 11.1) Tumour cells express several B-cell associated antigens (CD20, CD79a) and are typically negative for CD5, CD43, CD23 and CD10. As exceptions a few cases with a more aggressive clinical phenotype have been reported as CD5+
102
Differential diagnosis MALT gastric lymphoma can be difficult to differentiate from dense reactive lymphoid infiltrates. However, in
CHAPTER 11
Marginal Zone B-cell Lymphoma and Extranodal Malt Lymphoma
H&E low power
Early follicular colonisation
Late follicular colonisation
bcl-2 protein
Fig 11.4 Pattern of lymph node infiltration seen with both primary and secondary marginal zone lymphoma (MZL) (this case is secondary), showing both early and late colonisation of the lymphoid follicles. The early colonisation is highlighted by bcl-2 staining.
Table 11.1 The immunophenotypes of marginal zone lymphoma compared with its main differential diagnoses.
Marginal zone lymphoma Follicular lymphoma Mantle cell lymphoma Lymphoplasmacytic lymphoma Chronic lymphocytic leukaemia Splenic marginal zone lymphoma
IgM
IgD
CD5
CD10
CD23
CD43
bcl-6
Cyclin D1
+ + + + (+) +
− ± ± − (+) +
− − + − + −
− + − − − −
± ± − ± + ±
± − + ± + −
− + − − − −
− − + − − −
103
CHAPTER 11
Marginal Zone B-cell Lymphoma and Extranodal Malt Lymphoma
HE
HE
CD79a
CD23
bcl2
CD10
bcl6
mib1
Fig 11.5 An example of a nodular MALT (mucosa-associated lymphoid tissue) lymphoma in which the cytology within the nodules looks like a follicular lymphoma due to the admixture of residual germinal centre cells. The MALT lymphoma can be seen to reside both within and outwith the follicles by B-cell staining (CD79a). The residual follicular structure is outlined by CD23 staining. It can be seen that the colonised follicles are bcl2, CD10 and bcl6 negative and have a much higher proliferative rate than a typical follicular lymphoma.
non-neoplastic infiltrates, lymphocytes seen within gastric glands are mainly of T-cell phenotype and the glands are not usually destroyed as in MALT lymphoma (emphasising the diagnostic value of cytokeratin staining). One of the most difficult differential diagnoses is to differentiate MALT lymphoma from lymphoplasmacytic lymphoma. There is currently no easy way to do this. On clinicopathological grounds the current tendency is to consider that most, if not all, of these cases in extranodal sites are MALT lymphoma with plasmacytic differentiation, rather than lymphoplasmacytic lymphoma as thought in the past. Apart from lymphoplasmacytic lymphoma, MALT lymphoma is easily confused with other low-grade lymphomas, especially mantle cell lymphoma. MALT lymphoma cells are characteristically negative for CD5, CD43, CD23 and cyclin D1 (thus excluding B-cell chronic lymphocytic leukaemia [B-CLL] and mantle cell lymphoma). A prominent nodular pattern may suggest a diagnosis of follicular lymphoma especially if the marginal zone cells have colonized the residual follicles (Fig 11.5). Although these MALT lymphomas are usually identified by their negativity for CD10 they can be puzzling because the colonized cells often lose their bcl2 positivity and become more highly proliferative than the cells left outside in the interstitial tissue [17].
Prognosis and treatment The clinical course may be entirely benign even in the absence of treatment. Most cases are slowly progressive with local recurrences often in other mucosal sites. Dissemination to nodes and bone marrow occurs late and some cases will terminate as large-cell lymphomas.
104
In helicobacter-associated gastric maltomas, long remissions or even cures are being reported with appropriate antibiotic therapy [4,18]. Similar results are beginning to appear for Borrelia burgdorferi-associated cutaneous marginal zone lymphomas [19,20].
Nodal marginal zone B-cell lymphoma There had been controversy as to whether or not marginal zone lymphoma could arise primarily in a lymph node without a pre-existing extranodal component. On this basis it was categorised as a provisional entity in the REAL classification. Further studies are convincing that primary nodal cases, although rare, do exist without an associated MALT lymphoma. These cases have a similar if not identical architecture and morphology (including follicular colonisation) to that seen in secondary MALTs and to that previously described as a monocytoid B-cell lymphoma (Fig 11.6). A variety of patterns may be observed including diffuse, nodular, interfollicular, perifollicular and sinusoidal. A major differential diagnostic consideration in lymph nodes, particularly when the pattern is nodular, is follicular lymphoma with marginal zone differentiation [21]. The immunophenotype is identical to extranodal cases [22,23]. Nodal marginal zone lymphoma (MZL) can also undergo high-grade or large-cell transformation (Fig 11.7). A variant of nodal marginal zone lymphoma occurs in young boys, usually localised to their head and neck regions. It looks very similar except that the follicles usually show pronounced progressive transformation changes. This can cause considerable problems to distinguish the lymphoma from an atypical marginal zone hyperplasia, especially as this reactive condition can demonstrate monotypic Ig expression. Polymerase chain reaction for clonal rearrangements
CHAPTER 11
Marginal Zone B-cell Lymphoma and Extranodal Malt Lymphoma
Marginal zone pattern
Colonised follicle
bcl-2
CD79a
Kappa
Lambda
Fig 11.6 A primary involvement of lymph node by marginal zone lymphoma (MZL) showing the marginal zone pattern, colonisation of follicles and monoclonal light chain restriction.
105
CHAPTER 11
Marginal Zone B-cell Lymphoma and Extranodal Malt Lymphoma is recommended for this distinction though the prognosis of both conditions is excellent after surgical removal [24].
References
Marginal zone pattern
Large cell transformation
CD20 Fig 11.7 Large cell transformation of a primary marginal zone lymphoma in a lymph node.
106
1. Isaacson P, Wright D. Malignant lymphoma of mucosa associated lymphoid tissue. A distinctive B cell lymphoma. Cancer 1983;52:1410–16. 2. Isaacson P, Spencer J. Malignant lymphoma of mucosaassociated lymphoid tissue. Histopathology 1987;11:445–62. 3. Doglioni C, Wotherspoon AC, Moschini A, de Boni M, Isaacson PG. High incidence of primary gastric lymphoma in northeastern Italy [see comments]. Lancet 1992;339:834–5. 4. Wotherspoon A, Doglioni C, Diss T, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575–7. 5. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997;24:457–61. 6. Garbe C, Stein H, Dienemann D, Orfanos CE. Borrelia burgdorferiassociated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol 1991;24:584–90. 7. Chan J, Ng C, Isaacson P. Relationship between high-grade lymphoma and low-grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach. Am J Pathol 1990;136:1153–64. 8. Isaacson P, Spencer J. Monocytoid B-cell lymphomas. Am J Surg Pathol 1990;14:888–91. 9. Wenzel C, Dieckmann K, Fiebiger W, Mannhalter C, Chott A, Raderer M. CD5 expression in a lymphoma of the mucosaassociated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour. Leuk Lymphoma 2001;42:823–9. 10. Millar EK, Waldron S, Spencer A, Braye S. CD10 positive thyroid marginal zone non-Hodgkin lymphoma. J Clin Pathol 1999;52:849–50. 11. Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in lowgrade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood 1995;85:2000–4. 12. Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 2004;18: 1722–6. 13. Remstein ED, Dogan A, Einerson RR, et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol 2006;30:1546–53. 14. Du MQ, Peng H, Liu H, et al. BCL10 gene mutation in lymphoma [in process citation]. Blood 2000;95:3885–90. 15. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol 2000;156:1183–8.
CHAPTER 11
Marginal Zone B-cell Lymphoma and Extranodal Malt Lymphoma
16. Thieblemont C. Clinical presentation and management of marginal zone lymphomas. Hematology Am Soc Hematol Educ Program 2005:307–13. 17. Isaacson PG, Wotherspoon AC, Diss TC, Pan LX. Bcl-2 expression in lymphomas. Lancet 1991;337:175–6. 18. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997; 89:1350–5. 19. Kutting B, Bonsmann G, Metze D, Luger TA, Cerroni L. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 1997;36(2 Pt 2):311–14. 20. Roggero E, Zucca E, Mainetti C, et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000;31:263–8.
21. Salama ME, Lossos IS, Warnke RA, Natkunam Y. Immunoarchitectural patterns in nodal marginal zone B-cell lymphoma: a study of 51 cases. Am J Clin Pathol 2009;132: 39–49. 22. Piris M, Rivas C, Morente M, Cruz M, Rubio C, Oliva H. Monocytoid B-cell lymphoma, a tumour related to the marginal zone. Histopathology 1988;12:383–92. 23. Ngan B-Y, Warnke R, Wilson M, Takagi K, Cleary M, Dorfman R. Monocytoid B-cell lymphoma: a study of 36 cases. Hum Pathol 1991;22:409–21. 24. Taddesse-Heath L, Pittaluga S, Sorbara L, Bussey M, Raffeld M, Jaffe ES. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol 2003;27:522–31.
107
12
Follicular Lymphoma
Follicular lymphoma is the most common adult lymphoma in the USA and Europe, comprising 35–40% of all nonHodgkin lymphomas and 75–80% of low-grade B-cell lymphomas.
Clinical features Follicular lymphoma affects predominantly older adults, with an equal male : female incidence. Most patients have widespread disease at diagnosis, predominantly in lymph nodes, but also involving the spleen, bone marrow and occasionally peripheral blood or extranodal sites.
Histology Typically there is a nodular growth pattern, although this is more prominent in some cases than others and areas of diffuse growth may be seen (Fig 12.1). In contrast to reactive follicles, most follicular lymphomas lack mantle zones and macrophages containing phagocytosed cellular debris (the so-called tingible body macrophages of reactive germinal centres). Whether follicular lymphomas present with a completely diffuse infiltration pattern has been controversial. What one typically has to deal with is a lymphoma with the cytology of follicular lymphoma that looks diffuse, but usually has recognisable areas of nodularity after immunostaining (especially for follicular dendritic cells [FDCs]
with CD21 or CD23). Truly diffuse follicular lymphomas (negative for FDCs) were a provisional entity in the REAL classification [1] and have been accepted as a rare subtype in the 2008 WHO classification [2]. They are most commonly faced in needle biopsies where they may just represent a sampling problem. In practical terms there is no evidence that they behave any differently from regular follicular lymphomas. It is important to distinguish these rare diffuse cases from follicular lymphomas with diffuse areas of large cells. These are areas of large-cell transformation and should be identified as such as diffuse large B-cell lymphoma. Follicular lymphomas are composed of a mixture of centrocytes and centroblasts (also referred to respectively as ‘cleaved’ and ‘large non-cleaved’ follicle centre cells). Centrocytes usually predominate. Occasionally rare atypical cells (some may even be bi- or multinucleate) are observed in some follicles (Fig 12.2). Grading follicular lymphomas for clinical purposes has been controversial. The matter has been extensively discussed by the panels dealing with this tumour for both recent World Health Organization (WHO) classifications [2,3]. The current agreement is to continue to use the Mann and Berard counting method [4] of three grades as shown in Table 12.1. As a result of the poor interobserver reproducibility in this scheme and the lack of any clinical relevance, it is now acceptable to combine grades 1 and 2 and report a case as grade 1/2 follicular lymphoma. Grade 3 is split into grade 3A which has a mixture of centroblasts and
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
108
CHAPTER 12
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
Follicular Lymphoma
Fig 12.1 Follicular lymphoma can demonstrate a wide range of architectural patterns ranging from a typical abnormal nodular pattern (a,b) through a variety of reactive nodule look-a-likes (c–f) to a marginal zone pattern (g) and an almost diffuse replacement of the node (h).
109
CHAPTER 12
Follicular Lymphoma
Table 12.1 The Mann and Berard [4] counting method of three grades.
Fig 12.2 This figure illustrates the typical cytology of follicular lymphoma in which centrocytes (small cleaved cells) predominate over the larger centroblasts.
110
Follicular lymphoma grading
Large cells per high power field
Grade Grade Grade Grade
0–5 6–15 >15 100%
1 2 3A 3B
centrocytes and grade 3B which contains only nodules of centroblasts [5]. A high power field is that observed through ×10 eyepieces and a ×40 objective and it is recommended that at least 10 fields are counted (Fig 12.3). It is accepted that this will vary slightly between different models of microscope. For current practical purposes only grade 3 has an additional clinical significance requiring high-grade lymphoma chemotherapy. Any diffuse areas of large cells should be reported separately as diffuse large B-cell lymphoma. The 2008 WHO classification is quite explicit about this, stating that the diagnosis should be reported as: 1. Diffuse large B-cell lymphoma (state % involved) 2. Follicular lymphoma (report grade and state % involved). For staging purposes the pathologist’s role is mainly in reading the bone marrow trephine because involvement is rarely seen in bone marrow smears or peripheral blood (Fig 12.4). According to the WHO classification it is also recommended to classify follicular lymphomas into three growth patterns: follicular (>75% nodular), follicular and diffuse (25–75% nodular) and predominantly diffuse (or minimally follicular <25% nodular) (Fig 12.5). Note that the presence of lymphoma cells in the interfollicular areas is a common finding and does not define diffuse areas [2]. Occasional cases show plasmacytoid differentiation or foci of cells with the appearance of ‘marginal zone’ or ‘monocytoid’ B cells. Periodic acid–Schiff (PAS)-positive material derived from the lymphoma cell membranes (CD20+, IgM+, CD10+) may also occasionally be detected [6]. Primary cutaneous follicular lymphoma is now listed as a separate entity in the 2008 WHO classification. It occurs mainly on the head and trunk. The lymphomas usually consist of larger cells (both centrocytes and centroblasts) than those observed in nodal follicular lymphoma and are often bcl-2 negative. It is important to ensure that the lesion is confined to the skin and not a secondary spread from a systemic lesion because primary cutaneous follicular lymphomas have an excellent prognosis and require little more
CHAPTER 12
Grade 1
Grade 2
Follicular Lymphoma
Grade 3
Fig 12.3 Examples of grading follicular lymphoma. Examples of grades 1, 2 and 3 follicular lymphoma are shown on the top. The figures on the bottom show similar fields all from the same tissue section of a single follicular lymphoma, emphasising that multiple fields must be sampled and common sense used in selecting them. In this particular example the field counted as grade 3 was unique in this otherwise grade 1 follicular lymphoma.
than local treatment. A detailed discussion of this topic may be found in a companion volume to this text dealing with cutaneous lymphoma [7].
Immunophenotype Follicular lymphoma cells usually express surface immunoglobulin. This is often IgM and less commonly IgG. It is of a single light chain type, reflecting the monoclonal nature of the tumour. The tumour cells also express pan-B-cell associated antigens (CD20, CD79a) and most (more than 85%) are bcl-2 and bcl-6 positive [8–11]. Bcl2 negativity may be related to mutations that are not picked up by the most commonly used antibody bcl2/-124 but may be identified by alternative anti-bcl-2 antibodies. Negativity is also related to increased proliferation and is seen more commonly in grade 3 subtypes [12]. CD10 is an important marker, being present on 70–80% of cases and is especially useful when it is positive on interstitial B cells as well as on the nodules [13,14]. CD10 negativity tends to be more frequent on grade 3 cases [15]. In addition CD10 may be expressed only in the intrafollicular component in some cases and other germinal centre markers such as bcl-6, HGAL and LMO2 may be useful in labelling the interfollicular component to provide support for a diagnosis of follicular lymphoma in such difficult cases. None of these germinal centre markers is typically expressed in bone
marrow infiltrates of follicular lymphoma. CD23 may be present in up to a third of cases whereas CD5+ and CD43+ cases are rare [16–18]. Tightly organised meshworks of FDCs are present in follicular areas. These are responsible for the follicular pattern of these tumours. In follicular and diffuse cases, the FDCs are absent or scattered singly in the diffuse areas with FDC meshworks being seen only in follicular areas (Table 12.2 and Fig 12.6).
Cytogenetics and molecular biological features A translocation t(14;18), involving rearrangement of the bc1-2 gene, is present in at least two-thirds of all cases, the frequency being greatest in cases of grade I and II. This translocation occurs at an early stage of B-cell development, during immunoglobulin gene rearrangement [19,20] and is now readily detectable by fluorescence in situ hybridisation (FISH) on paraffin sections (Fig 12.7). This results in expression of the ‘anti-apoptosis’ bcl-2 gene, which is not expressed in normal germinal centre cells. Expression of the bcl-2 protein permits accumulation of long-lived centrocytes. Occasional cells with rearranged bcl-2 genes can be detected in lymphoid tissues and peripheral blood lymphocytes in some normal individuals. Thus, when a resting B cell that carries the bcl-2 translocation undergoes
111
CHAPTER 12
Follicular Lymphoma blast transformation in response to antigen, failure to switch off the bcl-2 gene may contribute to development of a lymphoma [21].
Variants and subtypes The 2008 WHO classification lists four of these.
1. Paediatric follicular lymphoma This is very rare but usually presents as localised head and neck lymphoid disease. Morphologically it looks identical to adult disease except that it is frequently of grade 3 cytology, lacks bcl-2 expression and t(14;18) (Fig 12.8). The prognosis after treatment is generally excellent apart from the minority of cases that are bcl-2+ and do badly [22].
Giemsa low-power
2. Primary intestinal follicular lymphoma These are typical follicular lymphomas that occur most commonly in the duodenum (Fig 12.9). The disease is localised and patients do very well even without treatment.
3. Other extranodal follicular lymphomas These are again typical follicular lymphomas and can occur in almost any other site. They are usually localized with an excellent prognosis.
4. Intrafollicular neoplasia/‘in situ’ follicular lymphoma
B cell CD79a low-power
This is an unusual event mostly found in reactive lymph nodes removed for other diagnostic reasons. A typical case is illustrated in Fig 12.10. Most of these patients are well and have no other evidence of follicular lymphoma. Clinical data on these is sparse; some have systemic disease, others have developed follicular lymphoma with time, but so far most reported cases have remained well over relatively long periods [23].
Differential diagnosis All lymphoproliferations with a follicular or nodular pattern may mimic follicular lymphoma.
Reactive follicular hyperplasia (see Chapter 2)
B cell CD79a high-power Fig 12.4 Bone marrow involvement by follicular lymphoma typically has a paratrabecular localisation, often best appreciated by B-cell staining (here shown by CD79a). Such immunostaining also allows at higher power an appreciation of the predominantly centrocytic cytology.
112
These lesions are frequently encountered in lymphoid pathology and are the most common differential diagnosis of follicular lymphoma. Usually, no aetiology is found and these lesions are diagnosed as non-specific follicular hyperplasia. In follicular lymphoma, in contrast to follicular hyperplasia, malignant follicles lack mantle zones and macrophages with tingible bodies. However, in occasional cases, malignant follicles are surrounded, at least partially, by mantle zones, making the lesion very difficult to distinguish from hyperplasia. An even more difficult scenario comes
CHAPTER 12
Follicular Lymphoma
Fig 12.5 In this example a patient presented with a typical nodular grade 1 follicular lymphoma (FL) (upper images) which responded to single agent chemotherapy but relapsed as a high-grade transformation 10 years later (lower images). In the same relapse specimen, areas of typical grade 1 FL could be identified. The diagnosis was therefore diffuse large B-cell lymphoma 90% with FL grade 1–10%.
Table 12.2 The immunophenotypes of follicular lymphoma compared with its main differential diagnoses.
Follicular lymphoma Mantle cell lymphoma Lymphoplasmacytic lymphoma Chronic lymphocytic leukaemia Marginal zone lymphoma Splenic marginal zone lymphoma
IgM
IgD
CD5
CD10
CD23
CD43
bcl-6
Cyclin D1
+ + + (+) + +
± ± − (+) − +
− + − + − −
+ − − − − −
± − ± + ± ±
− + ± + ± −
+ − − − − −
− + − − − −
with a follicular lymphoma partially involving a reactive lymph node, especially when follicular lymphoma cells colonise reactive follicles. Immunohistochemistry (sometimes supplemented by molecular techniques) is then required for differentiating these two lesions. Both reactive and neoplastic follicles consist of a predominant population of B cells expressing CD20 and CD79a and are surrounded by CD3+ small T-cell lymphocytes. However, in follicular lymphoma, even with preserved mantle zones, there is a clear increase of B cells (mostly neoplastic and often being CD10+) in the interfollicular area, a finding that is useful in diagnosis. For the histopathologist the most helpful reagent to distinguish reactive lymphoid hyperplasia from follicular lymphoma is the anti-bcl-2 antibody [24]. However, 15–20% of follicular
lymphomas are negative for bcl-2 (Fig 12.11). Another aid is given by the proliferation rate staining (Ki-67 or similar), the pattern of which is scattered or targetoid in follicular lymphomas, unlike the neatly zoned and usually much higher rate seen in reactive germinal centres (Fig 12.12) [25]. With careful attention to technique, light chain restriction can be demonstrated on follicular lymphomas, whereas of course hyperplastic follicles are polytypic (Fig 12.13). In some cases frozen sections may be required for the demonstration of such clonality.
Castleman tumour (see Chapter 2) This benign tumour is usually distinctive but may be confused with a sclerosed follicular lymphoma. A complete immunophenotype will normally clarify the diagnosis
113
CHAPTER 12
Follicular Lymphoma
CD20
bcl-2
CD3
Ki67
CD10
Fig 12.6 The typical immunophenotype of follicular lymphoma. Note the low proliferation rate (Ki67), significant numbers of CD10+ interfollicular B cells (CD20) and bcl2 positivity. It is always important to perform a CD3 stain to ensure bcl2 is on the neoplastic B cells as well as reactive T cells. These are key features distinguishing follicular lymphoma from reactive hyperplasia.
Bcl2 breakapart probes
Fig 12.7 Fluorescence in situ hybridisation (FISH) for the t(14;18) using break-apart probes (arrowed) on paraffin sections.
114
CHAPTER 12
Follicular Lymphoma
HE
HE
CD20
CD10
bcl6
bcl2
Fig 12.8 Typical paediatric follicular lymphoma with large follicles, some with an appearance reminiscent of progressive transformation of germinal centres. The nodules are composed of centrocytes and centroblasts with a grade 3A appearance. The nodules are CD20+, CD10+, bcl-6 +, but bcl-2−.
HE
CD20
CD10
Fig 12.9 Intestinal follicular lymphoma in duodenum showing a nodular and diffuse pattern which is CD20+ and CD10+.
because the nodules are polytypic in Castleman disease, which also characteristically contains clusters of CD68+ plasmacytoid monocytes/dendritic cells in the interfollicular areas.
In contrast to mantle cell lymphomas, follicular lymphomas are CD10+ and bcl-6+ in most cases and negative for CD5, cyclin D1 and usually CD43 as well.
Mantle cell lymphoma
Nodular lymphocyte-predominance Hodgkin lymphoma (see Chapter 27)
Mantle cell lymphoma showing a nodular pattern may on superficial examination simulate follicular lymphoma. Follicular dendritic meshworks are present in both tumours.
Nodular lymphocyte-predominance Hodgkin lymphoma (NLPHL) is sometimes misdiagnosed as either follicular lymphoma or atypical follicular hyperplasia because of the
115
CHAPTER 12
Follicular Lymphoma
Dermatopathic change
CD1a
Abnormal follicles
bcl-2 protein
Fig 12.10 An example of ‘in situ’ follicular lymphoma manifesting as follicular colonisation of a few follicles in an otherwise reactive node showing dermatopathic changes secondary to a skin rash. The bcl-2 positivity and the proliferation pattern are crucial for the diagnosis.
116
CHAPTER 12
CD10
Follicular Lymphoma
Proliferation (Ki-67)
Fig 12.10 (continued)
B cell
bcl-2
Kappa
Lambda
Fig 12.11 An example of an otherwise unremarkable FL being negative for bcl-2 protein. There is no strict relationship bewteen bcl-2 negativity and the t(14;18) translocation: some negative cases have the translocation and vice versa.
117
CHAPTER 12
Follicular Lymphoma
Fig 12.12 The pattern of proliferation (Ki67) is characteristic in follicular lymphomas. Here is an example at low power (left) of reactive follicles (upper part of the image) with a high, zoned pattern contrasting with the broken up targetoid pattern of a follicular lymphoma (lower part of the image). This is shown at higher power (middle) and even when the proliferation rate is high in a follicular lymphoma the pattern is still quite abnormal and distinctive (right).
presence of progressively transformed germinal centres. The pattern of nodularity may be more easily recognised after immunostaining for FDCs or with anti-B-cell antibodies. Anti-IgD staining will show the expanded mantle zones in NLPHL. Although occasional large atypical cells can be seen in follicular lymphoma, they are not as numerous as those usually seen in NLPHL. Although the LP cells of NLPHL are of B-cell phenotype they differ from follicular lymphoma cells by often being positive for epithelial membrane antigen (EMA) and Oct-2 (an immunoglobulin gene regulator) but negative for CD10. Characteristically, LP cells are surrounded by a wreath or rosette of CD57+ T cells. A most important distinguishing feature is that the background small B cells are clonal in follicular lymphoma whereas they are polytypic in NLPHL.
Prognosis and treatment There have been attempts in the past to divide follicular lymphoma into distinct subtypes, on the basis of the proportion of centroblasts and the size of the centrocytes. However, in reality there is a continuous gradation in the number of
118
large cells. So the terms ‘follicular lymphoma grades 1, 2 and 3’ represent an arbitrary division of a spectrum. Grading follicular lymphomas is poorly reproducible. The ‘cell counting’ method of Mann and Berard [4] has been shown to be more reproducible than other methods and it may offer some indication of prognosis [26,27]. For this reason it has been adopted as described above by the WHO classification. The proportions of follicular and diffuse areas vary from case to case. In follicular large-cell (grade 3A and 3B) lymphoma, diffuse areas occupying more than 25% of the tissue signify a poorer outcome. Many factors and markers have been postulated as conferring prognostic information, including biomarkers such as bcl-2, CD10 and MUM1, infiltration by lymphocytes or macrophages, vascular growth and pattern, and proliferative index. Each has its protagonists and unfortunately the literature is replete with conflicting results [28]. None has yet been included in the international prognostic index which is based on clinical features alone and is a strong predictor of outcome [29]. All of these studies may well become irrelevant because the introduction of antiCD20 therapy (rituximab) with conventional chemotherapy has so changed the outlook for follicular lymphoma that it can now be argued that it has become a curable disease [30].
CHAPTER 12
Follicular Lymphoma
References
HE low power
HE high power
CD3
bcl-2
CD10
Lambda
Kappa Fig 12.13 Careful immunocytochemistry will distinguish a reactive hyperplasia from a follicular lymphoma (FL). A point that should be emphasised is that it is worth staining for CD3 to ensure that the bcl-2+ cells in the nodules are FL cells and not infiltrating reactive T cells. In this case light chain staining has been successful in demonstrating κ restriction but it is important to look carefully at the sections to detect the cytoplasmic dot positivity. Otherwise it is easy to dismiss the staining as non-reactive.
1. Harris NL, Jaffe ES, Stein H, et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood 1994;84:1361–92. 2. Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press, 2008. 3. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001. 4. Mann R, Berard C. Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematological Oncology 1982;1:187–92. 5. Bosga-Bouwer AG, van den Berg A, et al. Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol 2006;37:528–33. 6. Chittal S, Caverivière P, Voigt J, et al. Follicular lymphoma with abundant PAS-positive extracellular material. immunohistochemical and ultrastructural observations. Am J Surg Pathol 1987;11:618–24. 7. Cerroni L, Gatter KC, Kerl H. Skin Lymphoma: The illustrated guide. Oxford: Wiley-Blackwell, 2009. 8. Gaulard P, d’Agay M, Peuchmaur M, et al. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 1992; 140:1089–95. 9. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990;137: 225–32. 10. Ree HJ, Kadin ME, Kikuchi M, Ko YH, Suzumiya J, Go JH. Bcl-6 expression in reactive follicular hyperplasia, follicular lymphoma, and angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers: heterogeneity of intrafollicular T-cells and their altered distribution in the pathogenesis of angioimmunoblastic T-cell lymphoma. Hum Pathol 1999;30:403–11. 11. Falini B, Fizzotti M, Pileri S, Liso A, Pasqualucci L, Flenghi L. Bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol 1997;8(suppl 2):101–4. 12. Masir N, Campbell LJ, Goff LK, et al. BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol 2009;144:716–25. 13. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000;24:846–52. 14. Barcus ME, Karageorge LS, Veloso YL, Kornstein MJ. CD10 expression in follicular lymphoma versus reactive follicular hyperplasia: evaluation in paraffin-embedded tissue. Appl Immunohistochem Mol Morphol 2000;8:263–6. 15. Eshoa C, Perkins S, Kampalath B, Shidham V, Juckett M, Chang CC. Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. Am J Clin Pathol 2001;115:862–7. 16. Lai R, Weiss LM, Chang KL, Arber DA. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases
119
CHAPTER 12
17.
18.
19.
20.
21.
22.
23.
Follicular Lymphoma
and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol 1999;111:488–94. Thorns C, Kalies K, Fischer U, et al. Significant high expression of CD23 in follicular lymphoma of the inguinal region. Histopathology 2007;50:716–19. Barry TS, Jaffe ES, Kingma DW, et al. CD5+ follicular lymphoma: a clinicopathologic study of three cases. Am J Clin Pathol 2002;118:589–98. Tsujimoto T, Cossman J, Jaffe E, Croce C. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;288: 1440–3. Pezzella F, Gatter KC, Mason DY. Detection of 14;18 chromosomal translocation in paraffin-embedded lymphoma tissue [letter]. Lancet 1989;i:779–80. de Jong D, Voetdijk B, van Ommen G, Kluin-Nelemans J, Beverstock G, Kluin P. Translocation t(14;18) in B cell lymphomas as a cause for defective immunoglobulin production. J Exp Med 1989;169:613. Lorsbach RB, Shay-Seymore D, Moore J, et al. Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 2002;99:1959–64. Cong P, Raffeld M, Teruya-Feldstein J, Sorbara L, Pittaluga S, Jaffe ES. In situ localization of follicular lymphoma: description
120
24. 25.
26.
27.
28.
29. 30.
and analysis by laser capture microdissection. Blood 2002;99: 3376–82. Pezzella F, Gatter K. What is the value of bcl-2 protein detection for histopathologists? Histopathology 1995;26:89–93. Bryant RJ, Banks PM, O’Malley DP. Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology 2006;48:505–15. The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997;89: 3909–18. Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995;85:3671–8. Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Prognostic factors in follicular lymphoma. J Clin Oncol 2010;28:2902–13. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–65. Horning SJ. Follicular lymphoma, survival, and rituximab: is it time to declare victory? J Clin Oncol 2008;26:4537–8.
13
Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is known as ‘centrocytic lymphoma’ in the Kiel classification. It was also given the name ‘intermediate lymphocytic lymphoma’ in the US literature. However, there is no evidence that the neoplastic cells derive from a germinal centre cell (as the term ‘centrocytic’ implied), and they have many of the features of mantle zone lymphocytes (although it remains to be formally proved that they derive from this cell type) [1].
Clinical features MCL accounts for about 5% of adult non-Hodgkin lymphomas in the USA and Europe. It is a tumour of older adults (median age close to 60), with a twofold excess of male : female patients. Patients usually have widespread disease at diagnosis; the sites involved are shown in Table 13.1.
Histology The pattern is usually diffuse or vaguely nodular, but welldefined follicles, resembling follicular lymphoma, are occasionally seen (Fig 13.1). In many cases the tumour involves the mantle zones of at least some reactive follicles; less commonly, a pure mantle zone pattern occurs.
The neoplastic cells are usually small to medium sized, with slightly irregular or ‘cleaved’ nuclei; however, the morphological spectrum includes lymphocyte-like and large cleaved or lymphoblast-like cells (Fig 13.2). Transformed cells (resembling ‘centroblasts’ or ‘immunoblasts’) are rare or absent. Many cases contain scattered epithelioid histiocytes, creating a ‘starry-sky’ appearance, although these cells do not contain apoptotic debris (as seen in Burkitt lymphoma). Occasionally this appearance is associated with a blastic change in mantle cell lymphoma which may occur at presentation as well as relapse (Fig 13.3). A helpful diagnostic feature pointed out by Lennert many years ago is the presence of prominent pink hyaline deposits around small capillaries in MCL (or centrocytic lymphoma as it was then) [2]. This is not specific for MCL but is useful in alerting one to think about the possibility of MCL, especially in small or needle biopsies where other architectural features may be missing or destroyed. If MCL involves the gastrointestinal tract, it is characteristically in the form of multiple small submucosal nodules, giving rise to the clinical syndrome of multiple lymphomatous polyposis. Any area of bowel can be involved although the large bowel is most common (Fig 13.4). The neoplastic cells frequently infiltrate the bone marrow either diffusely or in nodules, which may be both central or paratrabecular (Fig 13.5). When the spleen is involved the infiltration is predominantly in the white pulp and may be difficult to distinguish
The Diagnosis of Lymphoproliferative Diseases, Second Edition. Kevin C. Gatter, Georges Delsol, Roger A. Warnke, Francesco Pezzella. © 2012 Kevin C. Gatter, Georges Delsol, Roger A. Warnke and Francesco Pezzella. Published 2012 by Blackwell Publishing Ltd.
121
CHAPTER 13
Mantle Cell Lymphoma
from other low-grade B-cell lymphomas without immunophenotyping studies (Fig 13.6). Cases have been described in which the tumour is restricted to mantle zones in otherwise unremarkable lymph nodes. This has been called ‘in situ’ MCL and likened to the in situ disease seen in follicular lymphoma (Fig 13.7) [3].
Blood involvement Neoplastic cells are commonly found in the blood, although rarely in sufficient numbers to produce an overt ‘lymphoma cell leukaemia’.
Immunophenotype Table 13.1 Sites of involvement by mantle cell lymphoma. Sites
Percentage
Generalised lymphadenopathy Bone marrow positivity Splenomegaly Hepatomegaly Gastrointestinal involvement
71–90 53–93 35–81 18–35 15–28
Diffuse
Mantle zone
MCLs express the B-cell markers CD20 and CD79a in paraffin sections. They also express monotypic SIg (IgM + IgD) which is difficult to demonstrate on paraffin sections. MCLs usually coexpress CD43 and CD5 and are negative for CD23 and CD10 antigen. Exceptions and variations in all of these have been described although generally only one per aberrant case [4]. The neoplastic cells, in common with many B-cell neoplasms express bcl-2. The range of proliferation
Diffuse and nodular
Nodular
Mantle zone higher power
Fig 13.1 The different architectural patterns of mantle cell lymphoma ranging from a diffuse infiltration through to one that is predominantly nodular. Note the eosinophilic hyaline deposits around the capillaries in the diffuse lymphoma at top left, a characteristic feature of mantle cell lymphoma (MCL). A few cases have a so-called mantle zone pattern where they surround reactive germinal centres (ringed at bottom left and arrowed at higher power at bottom right).
122
CHAPTER 13
Aspiration cytology
Mantle Cell Lymphoma
Ultrastructure
Histological cytology Fig 13.2 The typical cytological and morphological appearances of mantle cell lymphoma. Usually no large cells of any type are present but on occasions these may be seen as shown at bottom right.
123
CHAPTER 13
Mantle Cell Lymphoma
Typical MCL
Blastic transformation
Fig 13.3 A case of typical mantle cell lymphoma (MCL) on the left which transformed into a blastic version (right) within a few months, heralding a more aggressive phase of the disease. It can be seen how easy it would be to confuse this blastic transformation with Burkitt lymphoma, on the grounds of the starry-sky appearance at low power and the blastic morphology of the cells.
124
CHAPTER 13
Mantle Cell Lymphoma
Fig 13.4 Mantle cell lymphoma (MCL) in lymphomatous polyposis of the gut is present as multiple submucosal nodules readily identified as MCL by immunostaining for cyclin D1. Note the negative endothelial cell nuclei indicating that not all are positive for cyclin D1.
H&E
CD20
CD3
Cyclin D1 on lymph node
CD20 on bone marrow
Cyclin D1 on bone marrow
Fig 13.5 A typical case of mantle cell lymphoma (MCL) presenting in the lymph node but revealing disseminated disease in the bone marrow on staging. Note the different patterns of infiltration that may be seen in bone marrow, and that cyclin D1 can be demonstrated in trephine sections as well as in lymph nodes.
125
CD23
CD5
Fig 13.6 Mantle cell lymphoma (MCL) in the spleen is a white pulp infiltration similar to several other B-cell lymphomas and requires immunophenotyping for a confident diagnosis.
Cyclin D1
HE
CD5
cyclinD1
cyclinD1
Fig 13.7 Two examples of ‘in situ’ mantle cell lymphoma (MCL) restricted to the mantle zones. The upper row shows a case in a lymph node (H&E and cyclin D1) and the lower a case in the colon (CD5 and cyclin D1).
CHAPTER 13
Mantle Cell Lymphoma
H&E
bcl-2
Cyclin D1
CD5
CD3
Cyclin D1
Fig 13.8 A case of mantle cell lymphoma (MCL) showing a mantle zone pattern. The surrounded reactive germinal centres are revealed clearly by bcl-2 protein and cyclin D1 staining. CD3 immunostaining is often helpful in ensuring that the CD5+ cells are MCL rather than reactive T cells.
rates as revealed by staining for Ki-67 is relatively wide, enabling cases to be assigned to different groups for prognostic studies (Fig 13.8 and Table 13.2) [5]. A prominent, irregular meshwork of follicular dendritic cells is found even in diffuse cases (CNA.42, CD21, CD23, CD35) (Fig 13.9). The product of the cyclin D1 gene can be reliably detected in the nuclei of neoplastic mantle cells in paraffin-embedded tissue sections which is useful in distinguishing MCL from
other low-grade B-cell lymphomas [6–8]. A proportion of endothelial cell and macrophage nuclei is usually positive, providing an inbuilt control in most cases. New antibodies [9] and improvements in immunostaining machines are now producing increasing numbers of anomalous findings of cyclin D1 positivity in other lymphomas (Fig 13.10). This is usually weak and scattered, unlike the strong and frequent staining seen in MCLs, but it emphasises the need not to rely on any one parameter for a diagnosis.
127
CHAPTER 13
Mantle Cell Lymphoma
Table 13.2 The immunophenotypes of mantle cell lymphoma compared with its main differential diagnoses.
Mantle cell lymphoma Lymphoplasmacytic lymphoma Chronic lymphocytic leukaemia Follicular lymphoma Marginal zone lymphoma Splenic marginal zone lymphoma
IgM
IgD
CD5
CD10
CD23
CD43
bcl-6
Cyclin D1
+ + (+) + + +
± − (+) ± − +
+ − + − − −
− − − + − −
− ± + ± − ±
+ ± + − ± −
− − − + − −
+ − − − − −
Fig 13.9 Patterns of abnormal follicular dendritic cell meshworks seen in three different cases of mantle cell lymphoma (MCL) (CD21 left and middle; CD23 right).
Cytogenetics In most cases reciprocal translocation between chromosomes 11 and 14 juxtaposes the Ig heavy chain gene on chromosome 14 to a gene known as cyclin D1 (other names are PRAD1, bcl-1) (Fig 13.11). This encodes a cell-cycleassociated protein that is not expressed normally in lymphoid cells, and its overexpression in MCL may explain the often high mitotic index and aggressive clinical course. Many other secondary chromosomal aberrations have been reported including MYC and TP53.
Differential diagnosis Fig 13.10 Example of a follicular lymphoma in a salivary gland showing scattered weak cyclin D1 positivity in some of the centroblasts (contrast this with the strong staining seen in the salivary glands). It is important not to confuse this with the positive staining typically seen in mantle cell lymphomas and to take heed of the rest of the immunophenotype.
128
MCL needs to be distinguished from other low grade B-cell lymphomas notably CLL and follicular lymphoma (Figs 13.12 and 13.13). This is best done on immunophenotyping, as described earlier with the key to MCL recognition being
CHAPTER 13
Mantle Cell Lymphoma
CCND1 BAP
Fig 13.11 Fluorescence in situ hybridisation (FISH) can used to detect the t(14;18) on paraffin sections using either fusion (left) or break-apart probes (right).
HE
bcl2
Ki67
cyclinD1
CD3
CD5
Fig 13.12 A nodular mantle cell lymphoma (MCL) that initially caused confusion with a follicular lymphoma. The MCL has expanded the mantle zone to almost engulf the residual germinal centres shown with bcl-2 and Ki67 (top row). The MCL is clearly outlined by positivity for cyclin D1 and CD5 but negativity for CD3 (bottom row).
strong clear cyclin D1 nuclear staining associated with CD5 positivity. The blastoid variant of MCL can easily be confused with lymphoblastic or Burkitt lymphoma and careful immunophenotyping will be needed to identify its true nature. Cyclin D1 is the best and most reliable marker for this purpose. Cyclin D1 has been reported to be negative in a
small number of cases of typical MCL where it is replaced by expression of either cyclin D2 or cyclin D3 [10], although great care should be taken before relying on these latter markers because they have been shown to be widely distributed in other lymphomas [11]. A recent study reports that SOX11 protein expression is positive in all MCLs, including the cyclin D1 negative cases, although it will need to be used
129
CHAPTER 13
Mantle Cell Lymphoma
HE
cyclinD1
CD3 in a panel of markers because a number of cases of lymphoblastic and Burkitt lymphoma were also positive [12]. Otherwise, a distinction from lymphoblastic lymphoma is usually made by the lack of staining for TdT (terminal deoxynucleotide transferase), CD10 and CD34. Burkitt lymphoma may be more difficult to separate if there has not been a preceding diagnosis of cyclin D1+ MCL, although lack of CD10, positivity for bcl-2 protein and a Ki67 index of <90% would indicate MCL. As a note of caution CD43 is not reliable in this differential because some typical Burkitt lym-
130
CD5
Fig 13.13 Another mimic of follicular lymphoma is a mantle cell lymphoma (MCL) that colonises germinal centres. Here the MCL is shown replacing the germinal centre as cyclin D1+, CD5+ B cells. The mantle zones are reactive.
phomas, as well as lymphoblastic B-cell lymphomas, are positive for this marker. Transformation to a large-cell lymphoma composed of centroblasts and/or immunoblast-like cells does not appear to occur, although a gradual increase in the size of the tumour cells accompanied by an increase in proliferation fraction often occurs at relapse. This more aggressive type is also known as the pleomorphic variant. These two variants are often lumped together as blastoid/pleomorphic mantle cell lymphoma (Fig 13.14).
Fig 13.14 The case illustrated here was an elderly man who presented with a lymphocytosis consistent with chronic lymphocytic leukaemia (CLL). (a) Bone marrow presentation – CLL like; (b) splenic relapse with blastic transformation. The bone marrow trephine morphology and proliferation index were interpreted as supportive of that diagnosis. However, he was refractory to CLL therapy and indeed high-grade non-Hodgkin lymphoma (NHL) therapy when instituted, and deteriorated remorselessly. He developed a high-grade lymphoma in the spleen that was shown to be a blastoid/pleomorphic transformation of mantle cell lymphoma (MCL). Interestingly, the areas of blast cells are surrounded by areas of ‘low-grade’ disease, which is also cyclin D1+. Retrospectively the original bone marrow specimen was shown to be cyclin D1+, emphasising the importance of thinking about MCL in the initial diagnosis of low-grade B-cell lymphomas.
Proliferation (a) Bone marrow presentation: CLL-like
Cyclin D1
Low power H&E
High power H&E
CD20
CD5
Cyclin D1 (b) Splenic relapse with blastic transformation
Proliferation
CHAPTER 13
Mantle Cell Lymphoma
Before treatment: CD20 immunostain
After treatment: CD20 immunostain
After treatment: CD79a immunostain Fig 13.15 Anti-CD20 antibody therapy (rituximab) has a dramatic effect on bone marrow infiltrates as shown in this case of mantle cell lymphoma (MCL). Normal marrow B cells recover because a population of precursor cells and plasma cells remains as highlighted by CD79a immunostaining.
Prognosis and treatment The course is moderately aggressive [13]. The median survival ranges from 3 years to 5 years; the blastoid/pleomorphic variant is reported in some studies to be more aggressive, with a median survival of 3 years. The proliferation rate is proving to be one of the most accurate prognostic factors [4]. The response rate to conventional chemotherapy is better than 80% and about half of all patients achieve complete remission. The median progression-free survival is 20 months and the median overall survival is 36 months. There is no evidence that any conventional chemotherapy regimen is curative. Patients with slowly progressive disease might be managed with chlorambucil, cyclophosphamide
132
or CVP (cisplatin–vinblastine–dacarbazine). Markedly symptomatic patients or rapidly progressive cases should probably be treated with CHOP (cyclophosphamide– hydroxydaunorubicin–vincristine [Oncovin]–prednisone). Trials with anti-CD20 (rituximab) and biologic agents such as Velcade have had encouraging results, although treatment of MCL remains a challenge (Fig 13.15) [14,15].
References 1. Banks P, Chan J, Cleary M, et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992;16:637–40. 2. Lennert K, Feller A. Histopathology of Non-Hodgkin’s Lymphomas, 2nd edn. New York: Springer-Verlag, 1992.
CHAPTER 13
3. Richard P, Vassallo J, Valmary S, Missoury R, Delsol G, Brousset P. ‘In situ-like’ mantle cell lymphoma: a report of two cases. J Clin Pathol 2006;59:995–6. 4. Gao J, Peterson L, Nelson B, Goolsby C, Chen YH. Immunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol 2009;132:699–706. 5. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385–7. 6. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84: 2726–32. 7. de Boer CJ, van Krieken JH, Schuuring E, Kluin PM. Bcl-1/ cyclin D1 in malignant lymphoma. Ann Oncol 1997;8(suppl 2):109–17. 8. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115–27. 9. Cheuk W, Wong KO, Wong CS, Chan JK. Consistent immunostaining for cyclin D1 can be achieved on a routine basis using
10.
11.
12.
13.
14. 15.
Mantle Cell Lymphoma
a newly available rabbit monoclonal antibody. Am J Surg Pathol 2004;28:801–7. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315–21. Metcalf RA, Zhao S, Anderson MW, et al. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Mod Pathol 2010;23:420–33. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555–62. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The NonHodgkin’s Lymphoma Classification Project. Blood 1997;89: 3909–18. Zelenetz AD. Mantle cell lymphoma: an update on management. Ann Oncol 2006;17(suppl 4):iv12–4. Ruan J, Coleman M, Leonard JP. Management of relapsed mantle cell lymphoma: still a treatment challenge. Oncology 2009;23:683–90.
133
14
Diffuse Large B-cell Lymphoma
The REAL classification created the category of ‘diffuse large B-cell lymphoma’ (DLBCL). It includes the categories of ‘diffuse large cell (cleaved or non-cleaved)’ and ‘immunoblastic’ lymphoma from the working formulation and ‘centroblastic’ (diffuse) and ‘immunoblastic (B-cell type)’ lymphoma in the Kiel classification. In doing this it was recognised that the category probably comprised more than one clinically relevant subtype, but at that time it was felt there were no criteria that allowed reproducible subdivision [1]. This was considered to be particularly true of the morphological subdivision of large B-cell lymphomas which had been consistently shown to be both poorly reproducible in practice and lacking in prognostic discrimination. This was not accepted by the Kiel group which felt that the subdivision could be made with adequate sections and training, and was very relevant to clinical outcome [2]. The World health Organization (WHO) classification has compromised between these two views by accepting the overall REAL viewpoint for a single entity, but gives the criteria necessary to allow subdivision if individual pathologists feel confident to do this [3]. This has been further developed into a number of variants and subtypes in the 2008 WHO classification [3] as detailed in Table 14.1.
Clinical features Large-cell lymphomas mostly occur in elderly people although they are not restricted to any age group. Usually patients present with rapidly growing lymph nodes or extranodal masses often confined to one area.
Histology Normal tissue architecture is usually replaced by a diffuse infiltrate of large lymphoid cells. Occasionally a dispersed
growth pattern is seen in which the neoplastic cells are intimately intermingled with normal tissue constituents. Infiltration of soft tissue outside the lymph node is common. In extranodal sites the lymphoma usually exhibits permeative growth at the edges and invasion of blood vessel walls is common. When a lymph node is not totally replaced by neoplastic cells, there may be selective involvement of sinusoidal or interfollicular areas. At times, the lymphoma forms discrete nodules, but these differ from follicular lymphoma in that they are focal and often of a large size. Furthermore the cytological composition does not correspond to tha